The Role of Bacteriocins in Mediating Interactions of Bacterial Isolates from Cystic Fibrosis Patients by Bakkal, Emine Suphan
University of Massachusetts Amherst
ScholarWorks@UMass Amherst
Open Access Dissertations
2-2011
The Role of Bacteriocins in Mediating Interactions
of Bacterial Isolates from Cystic Fibrosis Patients
Emine Suphan Bakkal
University of Massachusetts Amherst
Follow this and additional works at: https://scholarworks.umass.edu/open_access_dissertations
Part of the Cell and Developmental Biology Commons, and the Molecular Biology Commons
This Open Access Dissertation is brought to you for free and open access by ScholarWorks@UMass Amherst. It has been accepted for inclusion in
Open Access Dissertations by an authorized administrator of ScholarWorks@UMass Amherst. For more information, please contact
scholarworks@library.umass.edu.
Recommended Citation
Bakkal, Emine Suphan, "The Role of Bacteriocins in Mediating Interactions of Bacterial Isolates from Cystic Fibrosis Patients" (2011).
Open Access Dissertations. 328.
https://scholarworks.umass.edu/open_access_dissertations/328
  
 
 
 
 
 
 
 
 
 
THE ROLE OF BACTERIOCINS IN MEDIATING INTERACTIONS OF 
BACTERIAL ISOLATES FROM CYSTIC FIBROSIS PATIENTS 
 
 
 
 
 
 
 
 
A Dissertation Presented 
 
 
by 
 
E. SUPHAN BAKKAL 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate School of the 
University of Massachusetts Amherst in partial fulfillment 
of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
 
February 2011 
 
Molecular and Cellular Biology Program 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright by E. Suphan Bakkal 2011 
 
All Rights Reserved 
 
 
 
 
 
 
 
THE ROLE OF BACTERIOCINS IN MEDIATING INTERACTIONS OF 
BACTERIAL ISOLATES FROM CYSTIC FIBROSIS PATIENTS 
 
 
 
 
A Dissertation Presented 
 
By 
 
E. Suphan Bakkal 
 
Approved as to style and content by: 
 
 
_______________________________________ 
Margaret A. Riley, Chair 
 
 
_______________________________________ 
Michele Klingbeil, Member 
 
 
_______________________________________ 
Lynne A. McLandsborough, Member 
 
 
_______________________________________ 
Rob Dorit, Member 
 
 
____________________________________ 
Barbara Osborne, Director 
Program in Molecular and Cellular Biology 
 
 
 
 
 
 
 
 
 
DEDICATION 
 
This thesis is dedicated to my beloved family, who has always been supportive in my life.  
No words can express how grateful I am to my mother (Filiz Bakkal), my father (Macit 
Bakkal), and my lovely sisters (Handan Bakkal-Caglayan and Nurdan Bakkal).   
 
 
 
 v 
ACKNOWLEDGMENTS 
Foremost, I would like to thank my advisor Margaret A. Riley, who has 
encouraged, has supported, and most importantly has guided me throughout my study. 
She has always been a great model all the way and I cannot express enough my gratitude 
to her for her continuous motivation and enthusiasm in teaching and science.  
I would also thank to my committee members, Dr. Michelle Klingbeil, Dr. Rob 
Dorit, and Dr. Lynne McLandsborough for their help and suggestions during the process 
of my doctorate study. Further, I thank to all members of the MCB program and the MCB 
program manager Sarah Czerwonka for always being supportive, friendly and helpful.  
I am deeply grateful to former Riley lab members Dr. Michelle Lizotte-
Waniewkski and Dr. Chris Vriezen for their continuous moral support, suggestions, and 
critical review of my research. They are excellent scientists and provided me great help 
as well as supported me as friends. 
My special thanks to Sandra M. Robinson, who has helped me in the phenotypic 
bacteriocin screening, and has worked with me even at late hours. She also helped to edit 
my thesis. I am deeply appreciated to her for her continuous help and support. 
I would also thank to Shanika Collins for helping me in the molecular bacteriocin 
screening study and to Chris Roy for helping me in the genomic library study. I would 
like to thank all the former and current Riley lab members for their moral support and 
friendship during the past six years.  
I am also deeply grateful to my roommate Tuba Ozacar. We have been 
roommates and friends for five years. She is an excellent listener, cook, and one of the 
best roommates ever. She has always supported me and cheers me up anytime. I do not 
 vi 
know how I went through this process without her help and support. I also thank to Deniz 
Erturk-Hasdemir. She has been always a good friend and has provided her friendship and 
support at all times. 
I am deeply thankful to my friends Burcu Guner-Ataman and Bulent Ataman. I 
cannot thank enough for their support and help when I first came to Amherst. I never feel 
homesick because of them. I am very grateful to Burcu in particular; we have been 
friends for a very long time. She has always been there for me and always finds a way to 
cheer me up. 
Finally, I would like to thank to my mom (Filiz Bakkal), dad (Macit Bakkal), 
sisters (Handan Caglayan-Bakkal and Nurdan Bakkal), and brother in law (Levent 
Caglayan), and nephews (Onur Caglayan and Ali Emir Caglayan) for always loving me 
and supporting me. I am really grateful to them since they are always being very patient 
with me in particular during the process of thesis writing.  
 
 vii 
 
ABSTRACT 
THE ROLE OF BACTERIOCINS IN MEDIATING INTERACTIONS OF BACTERIAL 
ISOLATES FROM CYSTIC FIBROSIS PATIENTS 
 
February 2011 
 
E. SUPHAN BAKKAL, B.SC. MOLECULAR BIOLOGY AND GENETICS,  
BOGAZICI UNIVERSITY, TURKEY 
 
M.SC. BIOLOGICAL SCIENCE AND BIOENGINEERING PROGRAM 
SABANCI UNIVERSITY, TURKEY 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Margaret A. Riley 
 
 
Cystic Fibrosis (CF) is a common autosomal genetic disorder in Caucasian 
populations. CF is caused by mutations in the cftr gene, which encodes the CF 
transmembrane conductance regulator (CFTR). CFTR regulates chloride and sodium ion 
transport across the epithelial cells lining the exocrine organs. Mutations in the cftr result 
in a failure to mediate chloride transport, which leads to dehydration of the mucus layer 
surrounding the epithelial cells. The mucus coating in the lung epithelia provides a 
favorable environment for invasion and growth of several opportunistic bacterial 
pathogens resulting in life threatening respiratory infections in CF patients.  
Pseudomonas aeruginosa (Pa) and Burkholderia cepacia complex (Bcc) are 
associated with chronic lung infections and are responsible for much of the mortality in 
CF. Little is known about interactions between these two, often co-infecting, species. 
When in competition, it is not known whether Bcc replaces the resident Pa or if the two 
species co-exist in the CF lung.  
 viii 
Bacteriocins are potent toxins produced by bacteria. They have a quite narrow 
killing range in comparison to antibiotics and have been implicated in intra-specific and 
inter-specific bacterial competition brought on by limited nutrients or niche space. Both 
Pa and Bcc produce bacteriocins known as pyocins and cepaciacins, respectively. More 
than 90% of Pa strains examined to date produce one or more of three pyocin types: R, F, 
and S. A limited number of phenotypic surveys suggest that approximately 30% of Bcc 
also produce bacteriocins. 
The goals of my thesis study were to determine if clinical strains of Pa and Bcc 
produce bacteriocins and to determine whether these toxins play a role in mediating intra- 
and inter-specific bacterial interactions in the CF lung. The final goal was to identify 
novel bacteriocins from clinical Pa and Bcc strains.  
First, I designed a phenotypic bacteriocin survey to evaluate bacteriocin 
production in 66 clinical Pa (38) and Bcc (28) strains procured from CF patients. This 
study revealed that 97% of Pa strains and 68% of Bcc strains produce bacteriocin-like 
inhibitory activity. Further phenotypic and molecular based assays showed that the source 
of inhibition is different for Pa and Bcc. In Pa, much of the inhibitory activity is due to 
the well known S- and RF-type pyocins. S-and RF pyocins were the source of within 
species inhibitory activity while RF pyocins were primarily implicated in the between 
species inhibitory activity of Pa strains. In contrast, Bcc inhibition appeared to be due to 
novel inhibitory agents. Finally, I constructed genome libraries of B. multivorans, B. 
dolosa, and B. cenocepacia to screen for genes responsible for the inhibitory activity 
previously described in Bcc. ~10,000 clones/genome were screened, resulting in fifteen 
clones with the anticipated inhibition phenotype. Of these fifteen, only five clones had 
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stable inhibitory activity. These clones encoded proteins involved in various metabolic 
pathways including bacterial apoptosis, amino acid biosynthesis, sugar metabolism, and 
degradation of aromatic compounds. Surprisingly, none of Bcc clones possessed typical 
bacteriocin-like genes. These data suggest that, in contrast to all bacterial species 
examined in a similar fashion to date, Bcc may not produce bacteriocins. Instead, Bcc 
may be using novel molecular strategies to mediate intra- and inter-specific bacterial 
interactions. 
 
 
 
 
 
 x 
 
TABLE OF CONTENTS 
 
 Page 
 
ACKNOWLEDGMENTS ...............................................................................................v 
ABSTRACT..................................................................................................................vii 
LIST OF TABLES .......................................................................................................xiii 
LIST OF FIGURES......................................................................................................xiv 
CHAPTER 
1.        BACKGROUND AND SIGNIFICANCE .............................................................1 
1.1 The Genetics of Cystic Fibrosis...................................................................3 
1.1.1 The cftr gene ...............................................................................................3 
1.2 The CFTR Protein..........................................................................................3 
1.3 Mutations Resulting in Disease ......................................................................6 
1.4 Diagnosing CF ...............................................................................................7 
1.4.1 Early warning signs .........................................................................7 
1.4.2 Clinical Tests for CF........................................................................8 
1.4.2.1 The Sweat Test..................................................................8 
1.4.2.2 DNA Mutation Analysis....................................................9 
1.4.2.3 Nasal Potential Difference Testing ....................................9 
1.5 Pulmonary Symptoms of Cystic Fibrosis: A Vicious Cycle ..........................10 
1.6 Pulmonary Structure: Setting the Stage ........................................................10 
1.7 Mucociliary Clearance and Bacterial Colonization of the Lung ....................12 
1.7.1 Mucociliary Clearance (MC) .........................................................13 
1.7.2 Inhibiting MC Clearance................................................................13 
1.7.3 Resisting Bacterial Infection ..........................................................13 
1.8 The Bacteria of Cystic Fibrosis ....................................................................15 
1.9 Interaction of Pseudomonas aeruginosa (Pa) and Burkholderia 
cepacia complex (Bcc) ...........................................................................25 
1.10 Bacteriocins ...............................................................................................26 
1.10.1 Bacteriocins of Pseudomonas aeruginosa (Pa) and 
Burkholderia cepacia complex (Bcc) ..........................................27 
1.10.1.1 Pyocins: Bacteriocins of Pa ...........................................27 
1.10.1.2 Cepaciacins: Bacteriocins of Bcc...................................29 
1.11 CF Treatment Regimens.............................................................................29 
1.11.1 Physical therapy...........................................................................29 
1.11.2 Anti-inflammatory therapy...........................................................30 
1.11.3 Mucus thinning drugs ..................................................................30 
1.11.4 Antibiotic therapy ........................................................................30 
 xi 
1.11.5 Bronchodilator therapy ................................................................31 
1.11.6 Lung transplantation ....................................................................31 
1.12 Research Questions ....................................................................................31 
1.13 Problem Statement .....................................................................................31 
1.14 Purpose of this study ..................................................................................32 
1.15 Methodology..............................................................................................32 
1.16 Significance ...............................................................................................33 
 
2.         THE ROLE OF BACTERIOCINS IN MEDIATING INTERACTIONS OF     
            BACTERIAL ISOLATES TAKEN FROM CYSTIC FIBROSIS PATIENTS....42 
2.1 Abstract .......................................................................................................42 
2.2 Introduction .................................................................................................43 
2.3 Materials and Methods .................................................................................46 
2.3.1 Bacterial strains. ............................................................................46 
2.3.2 Bacteriocin production and sensitivity screen.................................47 
2.3.3 Phenotypic bacteriocin identification. ............................................48 
2.3.4 Molecular Screening......................................................................48 
2.4 Results .........................................................................................................49 
2.4.1 Inhibitory activity in Pa and Bcc strains.........................................49 
2.4.2 Bacteriocins of clinical Pa and Bcc strains are a source of 
inhibitory activity .......................................................................51 
2.4.3 Clinical strains have the potential to produce multiple 
bacteriocins.................................................................................52 
2.4.4 Clinical strains show sensitivity to multiple bacteriocins................53 
2.4.5 Source of the intra- and inter-specific inhibitory activity of 
clinical strains.............................................................................53 
2.4.6 Molecular Screening: Clinical Pa strains possess multiple 
pyocin genes ...............................................................................54 
2.5 Discussion....................................................................................................54 
2.6 Acknowledgements......................................................................................60 
 
3.        CONSTRUCTION OF GENOMIC LIBRARIES TO IDENTIFY PUTATIVE    
           GENES INVOLVED IN BACTERIOCIN-LIKE INHIBITORY ACTIVITY OF      
           B. CEPACIA COMPLEX...................................................................................69 
3.1 Abstract .......................................................................................................69 
3.2 Introduction .................................................................................................70 
3.2.1 B. cepacia complex (Bcc) ..............................................................70 
            3.2.2 B. cepacia complex: Friend or Foe?...............................................71 
3.2.3 Burkholderia and Pseudomonas interaction....................................75 
3.3 Materials and Methods .................................................................................77 
3.3.1 Bacterial strains .............................................................................77 
 xii 
3.3.2 Construction of genomic library.....................................................77 
3.3.3 Phenotypic screening of genomic clones........................................78 
3.3.4 Nucleotide sequencing...................................................................79 
3.4 Results .........................................................................................................79 
3.4.1 Genomic Library Construction.......................................................79 
3.4.2 Phenotypic screening of genomic clones........................................80 
3.4.3 Nucleotide sequencing...................................................................81 
3.5 Discussion....................................................................................................85 
3.5.1 Amino Acid and Sugar Metabolism ...............................................89 
3.5.2 Degradation of aromatic compounds..............................................90 
3.5.3 Bacterial apoptosis.........................................................................90 
3.5.4 Proteins with unknown functions ...................................................91 
3.6 Acknowledgements......................................................................................93 
 
4.         CONCLUSION ............................................................................................... 121 
4.1 The Life of a CF patient ............................................................................. 121 
4.2 The battle with bacterial infections: Pseudomonas aeruginosa and 
Burkholderia cepacia complex ............................................................. 122 
4.3 Do clinical strains of Pa and Bcc isolated from CF lungs produce 
bacteriocins? ........................................................................................ 127 
4.4 What types of bacteriocins are produced and how specific or broad are 
their killing activities? .......................................................................... 129 
4.5 What roles do these bacteriocins serve in mediating intra- and inter-
specific interactions of Pa and Bcc strains isolated from CF lung 
patients? ............................................................................................... 130 
4.6 Further characterization of Bcc inhibitory activity...................................... 131 
4.7 The lessons learned from phenotypic bacteriocin screening and 
genome library of Pa and Bcc............................................................... 132 
 
APPENDICES 
A.        CLINICAL PSEUDOMONAS AND BURKHOLDERIA STRAIN  
            COLLECTION................................................................................................ 138 
B.        RESULT OF PHENOTYPIC BACTERIOCIN ASSAY OF CLINICAL 
            PSEUDOMONAS AND BURKHOLDERIA STRAINS.................................. 141 
C.        PRIMER PAIRS USED TO SCREEN PYOCIN GENES................................. 145 
BIBLIOGRAPHY ....................................................................................................... 146 
 
 xiii 
 
LIST OF TABLES 
Table Page 
 
Table 2-1. Inhibitory activity of Pa and Bcc from the CF lung .................................61 
Table 2-2 Bacteriocin phenotypes of clinical Pa and Bcc strains ..............................62 
Table 2.3 S-pyocin sensitivity of clinical Pa and Bcc strains ....................................63 
Table 3-1 Chromosomes and genome size of members of B. cepacia complex.........94 
Table 3-2 Genomic library clones of B. multivorans (ATCC17616) and 
Pseudomonas aeruginosa (PAO1) ..........................................................95 
 
 
 xiv 
 
LIST OF FIGURES 
Figure Page 
 
Figure 1-1 Cystic Fibrosis Transmembrane Regulator (cftr) gene and its 
encoded protein presented on epithelial cells. .........................................34 
Figure 1-2 Models of ATP dependent gating of CFTR channel ................................35 
Figure 1-3 Worldwide incidence of CF ....................................................................36 
Figure 1-4 Functional classification of CFTR mutations ..........................................37 
Figure 1-5 Cystic Fibrosis: the vicious cycle............................................................38 
Figure 1-6 Human lung epithelium ..........................................................................39 
Figure 1-7 Airway surface liquid (ASL)...................................................................40 
Figure 1-8 Structures of R- and F- type pyocins.......................................................41 
Figure 2-1 Genetic organization of exemplar pyocin genes ......................................64 
Figure 2-2 Inhibition haplotypes of clinical Pa and Bcc strains ................................65 
Figure 2-3 Inhibition types produced by clinical Pa and Bcc strains .........................66 
Figure 2-4 Source of the intra- and inter-specific inhibitory activity of clinical 
Pa and Bcc strains ..................................................................................67 
Figure 2-5 Pyocin gene distribution in the genomes of clinical Pa and Bcc ..............68 
Figure 3-1 Genomic library construction..................................................................96 
Figure 3-2 Inhibition phenotypes of genomic clones of B. multivorans 
(ATCC17616) and Pseudomonas aeruginosa (PAO1) ............................97 
Figure 3-3 Blast result of the clone 2 of B. multivorans (ATCC17616) genome 
library ....................................................................................................98 
Figure 3-4 Blast result of the clone 4 of B. multivorans (ATCC17616) genome 
library ....................................................................................................99 
Figure 3-5 Blast result of clone 6 of B. multivorans (ATCC17616) genome 
library .................................................................................................. 104 
 xv 
Figure 3-6 Blast result of clone 7 of B. multivorans (ATCC17616) genome 
library .................................................................................................. 107 
Figure 3-7  Blast result of clone 9 of B. multivorans (ATCC17616) genome 
library .................................................................................................. 112 
Figure 3-8 Blast result of clone 1 of Pa PAO1 genome library ............................... 114 
Figure 3-9 Open reading frame organization of colicin E2, pyocin S3, and 
entericidinAB....................................................................................... 119 
Figure 3-10 Genome comparison of B. multivorans (Bm) ATCC17616 and 
Pseudomonas aeruginosa (Pa) PAO1 ................................................... 120 
 
 
 
 
 1 
 
CHAPTER 1 
 
BACKGROUND AND SIGNIFICANCE  
"Woe is the child who tastes salty from a kiss on the brow, for he is cursed, and soon 
must die.“ 
          Northern European Folklore 
Preface  
Cystic Fibrosis (CF) was defined as a fibrocystic disease of secretory organs in 
the 1930s. In 1938, Dorothy Anderson, MD published a comprehensive study, which 
categorized 49 CF patients between 0-14.5 years old based on the age of death and 
clinical manifestations (Andersen, 1938). The major conclusion of this case study was 
that the disease creates diverse effects on multiple body systems, in particular the 
digestive and respiratory systems. Further, the majority of patients (44) died due to 
respiratory infections (Andersen, 1938). During the past 60 years, a vast amount of data 
has provided support to the notion that the disease was the causative agent of the 
resulting clinical outcomes; these clinical observations included salty-tasting skin, 
vitamin-A deficiency, poor growth, greasy, bulky stools, persistent coughing, wheezing, 
shortness of breath, malformation of pancreatic ducts, fertility problems, and lung 
infections (Darling et al., 1953; Freedman et al., 2000a; Freedman et al., 2000b). One of 
the most important milestones in the history of CF was the discovery of the cystic fibrosis 
transmembrane regulatory receptor (cftr) gene, whose mutation is responsible for this 
disease (Kerem et al., 1989; Riordan et al., 1989; Rommens et al., 1989). 
Today, we define CF as an autosomal recessive genetic disorder, mainly affects 
Caucasian population with an average incidence of 1 in 3000 live births (Morrissey et al., 
2003). CF patients ultimately die in their mid-30s due to chronic lung infections that are 
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associated with high mortality (Govan & Deretic, 1996). Staphylococcus aureus, 
Heamophilius influenzae, Stenotrophomonas maltophilia, Pseudomonas aeruginosa, and 
Burkholderia cepacia complex are commonly isolated species from CF patients (Jones & 
Webb, 2003).  
This thesis is focused on two bacterial species: Pseudomonas aeruginosa and 
Burkholderia cepacia complex. Both species are multi-drug resistant and became the 
major concern for CF patients in the past 30 years (Govan & Deretic, 1996). 
Pseudomonas aeruginosa is the most common infectious agent involved, which is 
normally acquired shortly after birth. Approximately 80% of adult CF patients have 
chronic Pseudomonas infections, which result in high levels of mortality (CFF2008; 
Govan & Deretic, 1996). In contrast, the Burkholderia cepacia complex affects a smaller 
portion of CF patients (~3%). However, colonization by Burkholderia, usually leads to 
rapid lung failure (Jones et al., 2004; Kalish et al., 2006; Tablan et al., 1985).   
There are numerous bacterial proteins thought to be associated with the 
pathogenicity of bacteria in CF lungs (Govan & Deretic, 1996; Mahenthiralingam et al., 
2005). In this thesis, I will specifically focus on bacteriocins produced by clinical 
Pseudomonas aeruginosa and Burkholderia cepacia complex. These bacteriocins are 
narrow spectrum toxins used by bacteria to kill strains of related species (Riley & Wertz, 
2002a; Riley & Wertz, 2002b). I investigated (i) bacteriocin production of Pseudomonas 
aeruginosa and Burkholderia cepacia complex and their role in mediating both within 
and between species inhibitory activity; (ii) bacteriocin types produced by Pseudomonas 
aeruginosa and Burkholderia cepacia complex; (iii) putative bacteriocin genes of 
Burkholderia cepacia complex.  
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The following sections will provide general information about CF, CF symptoms, 
current treatment regiments, mechanism of the disease, bacteria colonizing CF lung (in 
particular Pseudomonas aeruginosa and Burkholderia cepacia complex), interaction 
between Pseudomonas aeruginosa and Burkholderia cepacia complex, bacteriocins of 
Pseudomonas aeruginosa and Burkholderia cepacia complex, and finally the significance 
of the project. 
1.1 The Genetics of Cystic Fibrosis 
1.1.1 The cftr gene 
Cystic Fibrosis is an autosomal recessive genetic disorder, which is caused by 
mutations on the Cystic Fibrosis Transmembrane Regulator (cftr) gene (Morrissey et al., 
2003). The cftr gene is located on the long arm of chromosome 7 (7q.31.2). It spans a 215 
kb region and consists of 27 exons and 26 introns (Figure 1-1a). The cftr gene encodes a 
transmembrane protein with two membrane-spanning domains (MSD), one regulatory 
domain (R), and two nucleotide-binding domains (NBD) (Figure 1-1b) (Riordan et al., 
1989). 
1.2 The CFTR Protein 
The CFTR protein is an apical membrane Cl- ion channel on epithelial cells. The 
pore size of the channel is ~5.3 A (Linsdell et al., 1997). It is selectively permeable to Cl- 
ions. Water, urea, and ATP may also permeate through the CFTR channel (Hasegawa et 
al., 1992).  
Site directed mutagenesis studies have revealed the functions of each domain of 
the CFTR: The MSD domains contribute to ion selectivity and formation of Cl- channels; 
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The R domain connects two halves of the protein, and also has multiple sites for 
phosphorylation by protein kinase A and C (Figure 1-1b) (Riordan et al., 1989).  
The R domain controls channel gating activity by phosphorylation and 
dephosphorylation, and the NBD domains hydrolyze ATP to regulate channel gating 
(Sheppard & Welsh, 1999).  
The two MSDs are composed of six transmembrane segments (M) (Figure 1-1b). 
There are six conserved residues K95 (M1), R134 (M2), R334 (M6), R335 (M6), R347 
(M6), and R1030 (M10). A mutation in either arginine residue (R334 and R347) is 
associated with the onset of disease symptoms (Riordan et al., 1989). These mutations 
lead to more than a 70% decrease in Cl- ion conductance (Tabcharani et al., 1993). 
Positively charged arginine residues are required to interact with the negative charge on 
Cl- during Cl- conductance. Further, mutations in two basic lysine residues (K95 and 
K335) to acidic aspartate (D) and glutamate (E) changed ion selectivity of CFTR channel 
from Br->Cl->I->F- to I->Br->Cl->F- (Anderson et al., 1991b). Finally. Cheung and 
Akabas used the substituted cysteine accessibility method to identify pore-lining residues 
in M1 and M6. They revealed 11 residues (I331, L333, R334, K335, F337, S341, I334, 
R347, T351, R352, and Q353) along M1 and M6, which contribute formation of Cl- 
channel (Akabas et al., 1994; Cheung & Akabas, 1996). 
The residues at intracellular and extracellular loops (ICL and ECL) of CFTR are 
important for membrane localization and functioning of the CFTR protein. Mutations in 
internal loops (ICL) altered gating behavior and channel regulation and no effect on pore 
formation. Mutations in ICL 1 and 2-increased mean closed time of the CFTR channel 
while ICL 3 and 4-decreased mean opened state of the channel (Seibert et al., 1996). 
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Further, mutations in extracellular loops (ECL) contribute CFTR pore functioning 
(Sheppard & Welsh, 1999).  
The NBDs of CFTR has three conserved domains (Walker A, Walker B, and 
LSGGQ) to interact with ATP (Walker et al., 1982). These domains are associated with 
many CF-related mutations. The CFTR channel is tightly regulated by kinase and 
phosphatase activity, and also presence of cellular ATP levels (Anderson et al., 1991a; 
Gadsby & Nairn, 1999). Activation of cAMP dependent protein kinase A (PKA) causes 
phosphorylation of serine residues on the R domain, which is followed by ATP 
hydrolysis at NBDs, opening the Cl- channel. Dephosphorylation of serine residues by 
protein phosphatases return the Cl- channel to a closed state (Gadsby & Nairn, 1999; 
Ostedgaard et al., 2001).  
There are two main models proposed for ATP-dependent gate opening of CFTR. 
In the first model (Figure 1-2a), there are three closed states (C1, C2, and C3) and two 
open states (O1 and O2). ATP binds NBDs in a closed state. At C1 state, both NBDs are 
empty. Then R domain phosphorylation results in ATP binding to the NBDs sequentially, 
first to NBD2 (C2 state) and then to NBD1 (C3 state). Hydrolysis of ATP at NBD1 opens 
the channel (O1 state). Then ATP at NBD2 hydrolyzed (O2 state) (Sheppard & Welsh, 
1999). In the second model (Figure 1-2b), there are two closed (C1 and C2) and two open 
states (O1 and O2). The ion gate opens after R domain phosphorylation followed by ATP 
binding at NBD2 (O1 state). ATP hydrolysis at NBD2 (O2 state) followed by R domain 
phoshorylation and ATP binding at NBD1 leads to channel closing (Sheppard & Welsh, 
1999).  
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1.3 Mutations Resulting in Disease 
According to a 2004 World Health Organization (WHO) report, the incidence of 
CF in newborns in specific regions is as follows: US (1/3500), Europe (1/2-3,000), Africa 
(1/7056). We also see ranges of disease occurrence in Asia and the Middle East of (1/10-
40,000) and (1/2-15,000), respectively (WHO 2004 CF Report) (Figure 1-3).  
The most common CF mutations are missense mutations, point mutations of one 
nucleotide, which account for 48.7% of all CF mutations (Lommatzsch & Aris, 2009). 
There have been 1720 point mutations detected from CF patients, all of which are 
documented in the CF Genetic consortium database.  
Mutations are classified into 5 classes (Class I-V) based on CFTR function 
(Figure 1-4). Class I mutations create premature stop codons due to frameshift or 
nonsense mutations, leading to truncated mRNA. Therefore, the CFTR protein is not 
expressed (Figure 1-4) (Gibson et al., 2003). Class II mutations are the most common 
mutation and cause misfolded CFTR proteins. CFTR proteins does not fold into proper 
tertiary structures and therefore are degraded in the endoplasmic reticulum instead of 
being trafficked to the epithelial membrane (Figure 1-4) (Gibson et al., 2003; 
Lommatzsch & Aris, 2009). The ΔF508 deletion (a 3 bp deletion in exon 10) is the most 
common mutation in class II mutations. Approximately 70% of CF patients have ΔF508 
deletion (Bobadilla et al., 2002). ΔF508 deletion affects the interaction between the N-
terminus NBD1 and C-terminus of transmembrane segment-4, which is involved in 
channel gating (Lommatzsch & Aris, 2009). Class I and II mutations are the most 
frequently observed in CF patients. Their clinical manifestations are severe since 
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functional CFTR protein is not presented on the surface of the epithelial cell (Zielenski, 
2000). 
Class III mutations affect ATP binding to NBD1, NBD2, and therefore ATP 
hydrolysis, which is involved in channel activation. CFTR channels are not activated 
(Gibson et al., 2003; Lommatzsch & Aris, 2009). Class IV mutations mostly occur in 
transmembrane domain 1, which is associated with pore forming. Therefore Class IV 
mutations affect chloride ion conductance (Akabas et al., 1994). The CFTR is fully 
translated and trafficked to the membrane in Class III and IV mutations so the effect of 
these mutations are milder than those of Classes I and II (Zielenski, 2000).   
Class V mutations affects the number of functional CFTRs on the membrane. 
Splice mutations are most common in this class. The disease phenotype may range from 
mild to severe since functional CFTR copying differs from patient to patient as well as in 
the epithelial cells of various organs (Nissim-Rafinia & Kerem, 2002; Nissim-Rafinia et 
al., 2004).  
1.4 Diagnosing CF 
1.4.1 Early warning signs 
CF patients are diagnosed with the disease in infancy and/or early childhood 
(Koch & Hoiby, 2000). The majority of patients are diagnosed in early childhood due to 
respiratory infections (50.5%), malnutrition (42.9%), or both (Rosenstein & Cutting, 
1998). Nineteen percent of CF patients are diagnosed at birth due to meconium ileus, an 
intestinal obstruction leading to a twisting of the bowel and abdominal infection 
(Rosenstein & Cutting, 1998). Vomiting a few hours after birth is the first sign of 
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meconium ileus (Donnison et al., 1966). Knowledge of family history accounts for 16.8% 
of CF diagnoses. Another symptom of the disease is steatorrhea (the presence of excess 
fat in stool), which occurs in 35% of CF patients (Rosenstein & Cutting, 1998). 
1.4.2 Clinical Tests for CF 
Sweat tests, DNA mutation analysis, and nasal potential difference test are 
diagnostic tests used to detect CF in patients (Koch & Hoiby, 2000; Rosenstein & 
Cutting, 1998). In most cases, more than one test is used since diagnostic tests may be 
inconclusive due to various clinical manifestations depending on the type of mutation 
(Koch & Hoiby, 2000; Rosenstein & Cutting, 1998).  
1.4.2.1 The Sweat Test 
Testing sodium and chloride concentration in sweat (Sweat test) is a noninvasive 
routine method used to diagnose CF (Koch & Hoiby, 2000). In this procedure, two 
electrodes are attached to the patient’s arm. One of the straps has a disk with pilocarpine, 
which induces sweat glands. An electrical pulse stimulates pilocarpine diffusion through 
skin. Then a special sweat collection device is attached the skin where sweat glands are 
stimulated. A minimum of 15 µl sweat must be collected during a 30-minute period 
(Naehrlich, 2007). A healthy person has 30-40 mM sodium and chloride concentration in 
their sweat while a CF patient has greater than 60-70 mM of sodium and chloride. This 
concentration difference is due to nonfunctional CFTR channels in the CF patient (Green 
et al., 1985; Hodson et al., 1983; Kirk & Westwood, 1989). However, this test is not 
100% accurate. Some CF patients have normal salt levels in their sweat, which are 
dependent on the type of mutation in the cftr gene. This test also does not take into 
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account the fluctuation of sweat chloride levels with age (Lyczak et al., 2002). Therefore, 
additional diagnostic tools are required to verify this test’s findings.  
1.4.2.2 DNA Mutation Analysis 
DNA mutation analysis is a genetic test, which identifies the mutation in the cftr 
gene.  DNA is isolated from either saliva or blood and is screened for the presence or 
absence of common CF mutations.  These DNA screening kits (ex Tag-It™ Cystic 
Fibrosis Kit) are commercially available to physicians. The USA CF foundation 
recommends that all newborns be screened with this test since more than 10 million 
American are asymptomatic carriers of CF (CFF, 2008). The downside of this test is that 
it only detects the 70 most prevalent CF mutations, yet there are 1720 mutations listed in 
CF Genetic consortium database (CFF Consortium). 
1.4.2.3 Nasal Potential Difference Testing 
Nasal potential difference testing is used as a complementary diagnostic tool 
where sweat and genetic tests are inconclusive (Delmarco et al., 1997). Sodium and 
chloride ion transport through CFTR on epithelial cells create transepithelial electrical 
potential (TEP). The nasal potential difference testing directly measures the 
transepithelial electrical potential through the ion channels.  In this test, an electrode is 
placed in the nose of a patient and a series of solutions are applied to the nose. The 
solutions are a Ringer’s saline solution (a salt solution used to obtain the baseline 
potential difference), amiloride solution that blocks sodium channels, a chloride-free 
solution, and finally isoproterenol solution that stimulates CFTR. A typical CF patient 
has a more negative baseline potential (-60 mV vs. -40 mV), a larger inhibition of TEP 
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after addition of amilorate, and a little or no change in TEP after addition of the chloride-
free and isoproterenol solutions (Rosenstein & Cutting, 1998). 
1.5 Pulmonary Symptoms of Cystic Fibrosis: A Vicious Cycle 
CF is a genetic disease affecting the epithelium surrounding secretory organs, in 
particular the lung epithelium (Davies & Bilton, 2009). While the other secretory organs 
are also affected, the predominantly life-threatening symptoms occur within the lungs 
(Gibson et al., 2003). Defective and/or deficient CFTR causes thick, viscous mucous 
secretions in the airways, which are associated with an abnormal airway surface 
environment (Figure 1-5). Abnormal airway epithelia cause airway obstruction, which is 
followed by infection, inflammation, and finally bronchiectasis. The presence of 
infection, inflammation, and bronchiectasis leads to more obstruction in the bronchi, 
which leads to more infection and inflammation, which are the major driving forces in 
this vicious cycle. 
1.6 Pulmonary Structure: Setting the Stage 
The lungs are organized as right and left lobes, connected through trachea. The 
trachea branches into two bronchi, which branch into tubular extensions- bronchioles. 
Finally, bronchioles branch into alveoli where oxygen is transported into capillaries 
through alveoli epithelia (Figure 1-6a).  
The lung epithelium serves as a continuous lining around the lungs and provides a 
selective surface where ions and oxygen are transported into and out of the lung tissue 
(Matthay et al., 2002). Airway portions of the lungs (bronchi and bronchioles) are 
covered with basal, ciliated and mucous secretory (Goblet) epithelia cells (Figure 1-6b). 
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Goblet cells are located distally and secrete mucin (MUC5AC, MUC5B) to form a mucus 
layer surrounding the epithelia (Figure 1-6b). Clara cells replace Goblet cells at the 
proximal portion of the airways. Finally, the alveoli are composed of type I and type II 
epithelial cells (Figure 1-6b and 1-6c) (Matthay et al., 2002).  
Type I cells are very large, thin, squamous epithelial cells with 50-100 µm in 
diameter and constitute 95% of the alveolar surface (Figure 1-6c). They provide 
structural support to alveoli. Type II cells are cuboidal epithelial cells, approximately 10 
µm in diameter (Figure 1-6c). Type II cells function to secrete surfactant (e.g. 
phospholipids) to reduce surface tension in the lungs during pressure changes (Matthay et 
al., 2002; Matthay et al., 2005). Both types of cells are involved in active ion transport 
(or vectorial ion transport) at the proximal portion of the alveoli to maintain osmotic 
balance, and keep the lungs free of pathogens (Saumon & Basset, 1993).  
 Osmotic balance is required to keep the thickness of airway surface liquid (ASL) 
at optimum height for the efficient mucociliary clearance. ASL is a thin water surface, 
which lines the airway portion of the epithelial cells (Figure 1-7). It consists of a mucus 
layer (7 to 70 µm thickness) and a periciliary liquid layer (PCL) (Gibson et al., 2003) 
(Figure 1-7). The mucus layer traps foreign particles while the PCL layer separates the 
mucus layer from the epithelial cells. The osmotic balance is important to keep the 
thickness of the PCL at optimum height (approximately 7 µm) so cilia can outbeat and 
clear the foreign particles trapped in the mucus (mucociliary clearance) (Figure 1-7) 
(Boucher, 2004). 
Osmotic balance in the lungs is maintained via sodium influx through apical 
amilorate-sensitive epithelial Na+ channels (ENaC) in response to an electrochemical 
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gradient generated by basolateral quabain-inhibitable Na+/K+/ATPase (Matthay et al., 
2002). Type II cells are easy to culture and they form monolayers with intact tight 
junctions in 3-4 days (Matthay et al., 2005). These cells express apical amilorate-
sensitive epithelial Na+ channels (ENaC), basolateral quabain-inhibitable Na+/K+/ATPase 
pump, apical Ca+2 activated Cl- channel, CFTR, and basolateral Na+/K-2Cl cotransporter 
to mediate Na+ absorption and to secrete Cl-, respectively. Protein expression and 
immunocytochemical studies revealed the presence and distribution of two subunits of 
Na+/K+-ATPAse (α1 and α2) in type I cell in rats (Ridge et al., 2003). However, the role 
of type I cells in the vectorial ion transport is not certain due to inability to culture 
polarized type I alveolar cells and perform electrophysiological studies (Matalon & 
Davis, 2003). 
1.7 Mucociliary Clearance and Bacterial Colonization of the Lung 
Most CF patients are born with a normal lung function, followed by bacterial 
colonization of the lung, leading to chronic infections in the lungs within just a few years 
of life (Boucher, 2004). More than 80% of CF patients die due to bacterial infections 
(Lyczak et al., 2002). Defective mucociliary clearance (MC) is the major cause of 
bacterial colonization in the lungs. MC is an important part of the body’s innate defense 
mechanism, which traps and clears inhaled pathogenic organisms from the airways in less 
than 6 h under normal conditions (Knowles & Boucher, 2002). This mechanism is 
arrested in CF patients, allowing bacteria to enter the lungs and begin the invasion. 
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1.7.1 Mucociliary Clearance (MC) 
 MC utilizes three components to clear foreign bodies: cilia, a mucus layer, and a 
PCL (Figure 1-7). The height of the PCL is important to maintain osmotic balance in 
order to maintain effective MC. The optimum thickness of PCL is approximately 7 um. 
This height is required for efficient ciliary beating. 
1.7.2 Inhibiting MC Clearance 
Both absorption of Na+ and Cl- secretion is important to keep periciliary layer 
(PCL) height (or volume) constant. In CF patients, nonfunctional CFTR leads to impaired 
Cl- secretion to the ASL, causing accelerated Na+ absorption via ENaC. Thus, water is 
transported into the epithelial cell due to reverse osmosis. Water diffusion leads to 
depletion of the PCL layer, which in turn causes the formation of mucus plaques since 
mucus secretion continues from goblet cells. The continuous supply of mucus thickens 
the mucus plaques to more than 100 µM in thickness, where oxygen is limited. 
Thickened mucus plaques reduce the mucociliary transport of the foreign molecules. 
Further, oxygen is depleted into the deep surface of the epithelial cells leading to mucus 
hypoxia, which is a favored environment for certain bacterial species, in particular 
Pseudomonas aeruginosa (Worlitzsch et al., 2002).  
1.7.3 Resisting Bacterial Infection 
Thick mucus blocks the airways (airway obstruction), which results in infection 
and inflammation. The presence of pathogens in the airways induces the secretory 
apparatus (Goblet and Clara cells) to secrete antibacterials (proteins lysozyme, 
lactoferrin, secretory phospholipase A2, and secretory leukocyte protease inhibitor 
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(SLPI) to kill pathogens. Neutrophils are the first immune cells to arrive at the site of 
infection. They recognize chemicals (chemoattractants) produced by pathogens and/or 
damaged tissue. Cytokines (IL-1, IL-8, tumor necrosis factor alpha (TNF-α)), leukotrines 
(LTB-4), anaphylatoxin C5a, and bacterial proteins (LPS, exotoxins) are the major 
chemoattactants for neutrophil to the infection site (Konstan & Berger, 1997).  
Oxidants and proteases like elastase released by neutrophils degrade bacterial 
proteins as well as host lung tissue. This leads to a release of host DNA, which thickens 
the mucus further and is associated with pulmonary exacerbations, worsening due to 
infection and inflammation. Further, elastase induces genaration of more 
chemoattractants, which induce attraction of more neutrophils to the area of infection, 
resulting in more tissue damage. Both inflammation and infection lead to structural 
damage of the lung, this is known as bronchiectasis (Boucher, 2004). 
The common belief is that inflammation occurs after infection. A massive amount 
of neutrophil attraction to the site of infection is the signature of a CF lung. Some studies 
performed with infants revealed that the lungs are at the proinflammatory state before 
bacterial colonization (Khan et al., 1995; Muhlebach et al., 1999; Rosenfeld et al., 2001). 
Studies show elevated levels of proinflammatory markers like adhesion molecules at 
which neutrophils recognize and bind (ICAM-1), chemoattactants (IL-6 and IL-8) and 
deficiency of IL-10, which inhibits production of chemoattactants-IL-6, IL-8, TNF 
(Elizur et al., 2008). There is no direct link between the cftr gene mutation and the 
proinflammatory reaction observed in CF patients. However, other studies suggest 
inflammation might precede infection (Khan et al., 1995; Muhlebach et al., 1999; 
Rosenfeld et al., 2001). 
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1.8 The Bacteria of Cystic Fibrosis 
“Understanding the genetic defect underlying cystic fibrosis is only half the battle. 
Identifying the specific bacterium infecting CF patients is just as important”.  
John E. Herst and Karen E. Elliot 
Bacterial infection is the main reason for high mortality in CF (Gibson et al., 
2003; Govan & Deretic, 1996). CF patients are born with a sterile lung, and then shortly 
after birth they start to develop bacterial infections (Boucher, 2004). It is believed that 
susceptibility of CF patients to certain bacterial species is age-related. CF patients 
become infected with Staphylococcus aureus and Haemophilus influenzae in early years 
and then Pseudomonas aeruginosa and Burkholderia cepacia complex replace these 
species during adolescence (Govan & Deretic, 1996). Stenotrophomonas maltophilia and 
Achromobacter xylosoxidans are the other species isolated from CF patients.   
Staphylococcus aureus: 
Staphylococcus aureus (Sa) is a gram positive, non-motile, non-spore forming 
bacteria that is part of human upper respiratory tract flora (Williams, 1961). Forty percent 
of CF patients have Sa colonization during their first year of their life (CFF, 2008). In 
fact, it is usually the first pathogen to cause infection in CF patients (McCaffery et al., 
1999). Most of these initial infections result from endogenous colonization with patients’ 
own organism (Govan, 2000). 
In the pre-antibiotic era, most CF patients died due to Staph infections (Govan & 
Deretic, 1996). Today, CF patients are either under prophylactic (preventive) or 
intermittent treatment with antibiotics until the Staphylococcus is eradicated from their 
sputum cultures (McCaffery et al., 1999). Penicillin, cephalosporins, macrolide, and 
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tetracycline antibiotics are among the commonly prescribed antibiotics (Beardsmore et 
al., 1994; Szaff & Hoiby, 1982; Weaver et al., 1994). It has been shown that prophylactic 
treatment of CF patients with floxacillin (penicillin-derivative) is beneficial and is 
associated with fewer hospital visits, reduced morbidity, and lower rates of infection, 
when compared to intermittent antibiotic treatment (Weaver et al., 1994). However, 
another study revealed that prophylactic antibiotic therapy of patients under age 6 leads 
to significantly higher rates of Pseudomonas aeruginosa acquisition (approximately 50% 
more) when compared to patients with intermittent antibiotic treatment (Ratjen et al., 
2001).  Further, aggressive antibiotic treatment is also associated with the emergence of 
resistant Staphylococcus, in particular methicillin resistant Sa (MRSA), one of the most 
vexing resistance challenges worldwide (Nordmann et al., 2007). A recent survey of CF 
patient registry data from the US recorded between January 1996 and December 2008 has 
shown that detection of MRSA in CF patients is associated with more rapid lung failure 
and a significant decrease in life expectancy (Dasenbrook et al., 2010). 
Haemophilus influenzae:  
Haemophilus influenzae (Ha) is among the most commonly isolated opportunistic 
pathogens from CF patients, in particular from newborns and children under the age of 10 
years (CFF, 2008). The prevalence of Ha infection is approximately 30% among patients 
between 0-5 years old (Razvi et al., 2009).  
Ha infections are treated after detection of asymptomatic colonization or after the 
development of an infection. Amoxicillin, ciprofloxacin, and azithromycin are the most 
commonly prescribed antibiotics to treat Ha infections (Doring & Hoiby, 2004). 
Ciprofloxacin resistance has been observed in 40% of Ha strains isolated from CF 
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patients (Perez-Vazquez et al., 2007). Further, vaccination of infants is used as a 
preventive approach. However, infections with uncapsulated and therefore non-typable 
Ha reduce the chance of success via vaccination (Bilton et al., 1995).  
The role of Ha infection in CF pathogenicity is unknown. It may form biofilms in 
lung epithelia and induce inflammatory reactions in the lower respiratory tract (Starner et 
al., 2006). Inflammation due to Ha colonization at an early age causes lung damage in CF 
patients, which in turn provides an ideal environment for further colonization, 
particularly by Pseudomonas(Govan & Deretic, 1996; Lyczak et al., 2002). 
Stenotrophomonas maltophilia: 
Stenotrophomonas maltophilia (Sa) is gram-negative, motile bacteria present in 
the natural environment (such as on plants and in soil) and the hospital environment. Sa is 
also present in approximately 13% of CF patients (CFF, 2008). Acquisition of Sa is 
mostly from the environment (Denton & Kerr, 1998). Doxycyclin, ceftazidime, 
tobramycin, and ciprofloxacin are the most frequently used antibiotics to treat these 
infections. The exact role of Sa infections in CF pathogenicity is unknown. The common 
belief among clinicians is that these infections are more harmful to patients with already 
damaged lungs (Gladman et al., 1992; Karpati et al., 1994).  
Pseudomonas aeruginosa: 
Pseudomonas aeruginosa (Pa) is a gram-negative, multi-drug resistant versatile 
bacterium grows in soil, water, on plant, and animal tissues (Govan & Deretic, 1996).  It 
is the most common infectious agent involved in the CF lung and it is often acquired 
shortly after birth (Li et al., 2005). The prevalence of Pa infection is 30% of infants, 60% 
of adolescents, and 80% of adults with CF (CFF, 2008).   
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The initial source of Pa infection is unknown. Natural environment is one 
potential source of a CF patient’s first acquisition (Barben et al., 2005; Regnath et al., 
2004). Indeed, a recent genotype study of clinical Pa strains from newly infected CF 
patients and Pa strains isolated from various surfaces of the patients’ houses revealed that 
5.9% of the environmental isolates share the same genotypes with clinical isolates 
(Schelstraete et al., 2008).  Further, samples from hospital settings, including sinks, soap, 
tables, and tap water, are also contaminated with Pa (Doring et al., 1996; Zimakoff et al., 
1983). The prevalence of Pa is 72% from patient’s toilets, 44% on sinks, and 1.5% on 
other hospital surfaces (Festini et al., 2007). The risk of potential Pa acquisition of a CF 
patient from clinical settings at each visit is 5.4% (Festini et al., 2007).  
Patient-to-patient contact is another route for Pa transmission. Speert et al., 1987 
showed that patients sharing the same hospital room are colonized with the same Pa 
strain (Speert & Campbell, 1987). Another study performed on patients attending the 
same CF holiday camp revealed that ¼ of the patients are infected with the same strain 
(Brimicombe et al., 2008). Further, a genome fingerprinting study performed on siblings 
from 13 families showed that one to three Pa strains are identical in all siblings in 8 
families (Grothues et al., 1988). 
During infancy, Pa is isolated intermittently from CF patients. Screening the 
presence of Pa in oropharyngeal (OP) and bronchoalveolar lavage (BAL) cultures are 
routine approaches.  Patients are (i) intermittently infected if 50% or less of the preceding 
12 months the patients are Pa culture positive, (ii) chronically infected if more than 50% 
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of the preceding 12 months they are culture positive, (iii) free if no Pa is detected (Lee et 
al., 2003).  
The first step in colonization is the attachment of Pa to the epithelial cell surface 
(Davies & Bilton, 2009). As described above, defective MC traps bacteria on the viscous 
mucus ASL where Pa is in close contact with the epithelial cell surface. Early Pa 
colonizers isolated from CF airways are motile (Gibson et al., 2003). Pa flagellar mutants 
cause milder disease phenotypes in a murine model, suggesting that motility is important 
for early bacterial attachment and colonization (Feldman et al., 1998). Further, recent 
studies suggested that Pa pili bind CFTR and epithelial cell receptor ganglioside asialo-
GM1, which have been proposed as Pa receptors (de Bentzmann et al., 1996; Pier et al., 
1996; Pier et al., 1997). Interaction of Pa with ganglioside asialo-GM1 receptor induces 
NFΚ-B mediated expression of pro-inflammatory cytokines, which are major neutrophil 
attractants (Davies & Bilton, 2009). Therefore, colonization directly induces 
inflammation, which is associated with tissue destruction and additional infection cycles, 
as described above.  
Attachment of Pa to the CFTR channel is followed by internalization into 
epithelial cells where the bacterium colonizes, forms a biofilm, and may secrete virulence 
factors to further invade lung tissue, all of which results in the development of chronic 
lung infections (Davies & Bilton, 2009). Pa employs a variety of exoproducts to invade 
lung tissue, such as elastase, protease, exotoxin A, siderophores, and antibiotic resistance 
proteins. Elastase and alkaline phospahates are proteases, which cleave host immune 
proteins including immunoglobulins, cytokines (Heck et al., 1990). Exotoxin A inhibits 
phagocytosis and siderophores (iron-binding proteins), like pyocyanin, slows down 
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ciliary beat frequency in the ASL and destroys tight junctions at epithelia, leading to lung 
tissue destruction (Haas et al., 1991).  
The most vexing feature of Pa lung invasion is the emergence of alginate forming 
mucoid variants over time (Hentzer et al., 2001). Levy et al, 2008 showed that nearly half 
of the patients in his study developed mucoidy Pa variants during the course of study. 
These data revealed that gender, presence/absence of the ΔF508 deletion, Forced 
Expiratory Volume (FEV), and sputum type are all indicators of the potential 
establishment of mucoid Pa (Levy et al., 2008).  
Mucoid Pa form dense biofilms, which are virtually impossible to eradicate once 
established (Hentzer et al., 2001). Biofilms are defined as polysaccharide matrix-
enclosed, differentiated micro-colonies of bacteria growing on solid surfaces. Many 
bacterial pathogens adapt to their hosts by shifting from a free living planktonic mode of 
growth to biofilm formation when exposed to host defenses, nutrient deprivation, and 
oxidative or osmotic stresses (Fuqua et al., 2001) (Jefferson, 2004). Biofilm formation in 
the lungs of CF patients creates a major health challenge. This is due in part to the fact 
that biofilms result in 10 to 1000-fold increase in antibiotic resistance and an increase in 
the ability to withstand host defense systems. Indeed, the formation of biofilms is the 
primary contributor to the mortality of CF patients (Giwercman et al., 1991; Hoyle et al., 
1992; Miller & Bassler, 2001). The elevated levels of antibiotic resistance and virulence 
are due primarily to the phenotypic heterogeneity within the biofilm structure, to reduced 
growth rate of cells in biofilm, to the limited access of antibiotics into the interior regions 
of the biofilm structure, and to the impact of quorum signaling based-induction of the 
virulence genes (Lewis, 2001; Stoodley et al., 2002). Quorum signaling (QS) is a cell-
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density dependent communication between bacteria that occurs via secreted signaling 
molecules (acylated homoserine lactones (AHLs)). Pa has two hierarchical quorum 
signaling systems: LasI/LasR and RhlI/RhlR (Van Delden & Iglewski, 1998). A recent 
study has shown that QS mutants of Pa possess higher susceptibility to antibiotic 
treatment compared to wild type Pa (Shih & Huang, 2002).  
 Despite high levels of antibiotic resistance in CF lung biofilms, antibiotic 
treatment remains the major therapeutic approach to treatment. The most promising drugs 
for treating Pseudomonal infections are TOBI®, which is a solution of the anti-
pseudomonal tobramycin designed for inhalation, and azithromycin, in either an oral 
suspension or capsules. These antibiotics differ in their modes of action. Tobramycin is 
an aminoglycoside, which inhibits protein synthesis and thus kills the target pathogen. 
Azithromycin is a macrolide, which improves the patients’ lung function by reducing 
inflammation and alginate production, which is the main component of a biofilm’s 
structure (Giamarellos-Bourboulis, 2008).  
Long-term exposure of Pa to antibiotics selects for multi-drug resistant strains. In 
fact, nearly half of adult CF patients are chronically infected with multi-drug resistant Pa, 
which is associated with a more rapid decline in lung function (Lechtzin et al., 2006). An 
antibiotic susceptibility study of Pa strains from sixty-seven CF centers revealed high 
levels of resistance, on average 75% of the strains were resistant to the 10 drugs 
examined, including tobramycin, gentamycin, ciprofloaxacin (Saiman et al., 1996). In 
addition, Pa strains are intrinsically multi-drug resistant. Genome sequencing studies 
revealed that the genome of at least one Pa strain (PAO1) genome has five different drug 
efflux pumps (Lomovskaya & Watkins, 2001). Finally, a recent study revealed a novel 
 22 
 
drug efflux mechanism in Pa, one that specifically mediates biofilm resistance to 
tobramycin, gentamycin, ciprofloxacin, which are among the most commonly prescribed 
antibiotics to treat CF lung infections (Zhang & Mah, 2008). 
Burkholderia cepacia complex: 
Members of the Burkholderia cepacia complex (Bcc) are gram-negative bacteria 
found in numerous environments including soil, water, as well as the roots of various 
plants (Mahenthiralingam et al., 2005). The Bcc comprises a group of genetically diverse, 
but phenotypically similar bacteria, including nine genomovars: Burkholderia ambifaria, 
Burkholderia anthina, Burkholderia cenocepacia, Burkholderia cepacia, Burkholderia 
dolosa, Burkholderia multivorans, Burkholderia pyrrocinia, Burkholderia stabilis, and 
Burkholderia vietnamiensis (Mahenthiralingam et al., 2000). In the 1930s, Burkholderia 
were classified as members of the Pseudomonas genus. Yabuuchi et al. 1992 proposed to 
re-classify these Pseudomonas species under the new genus Burkholderia, based on 16s 
rRNA sequences, phenotypic characteristics, and DNA-DNA hybridization (Yabuuchi et 
al., 1992).  
B. cepacia strains may be either pathogenic, beneficial or commensal, depending 
on the environment in which they are found. B. cepacia causes soft onion rot disease, 
which is a type of root tissue damage associated with yellow/brown coloring 
(Mahenthiralingam et al., 2005). Further, a type IV toxin from B. cenocepacia and B. 
vietnamiensis causes a type of plant tissue destruction called plant-tissue water soaking 
(Engledow et al., 2004). B. cepacia  degrades chlorinated aromatic substrates found in 
pesticides and herbicides. For example B. vietnamiensis degrades toluene and decreases 
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the concentration of toluene in the water present in a sand aquifer (Mahenthiralingam et 
al., 2005). 
In the 1970s, members of the Bcc were first identified in the airways of CF 
patients (Govan & Deretic, 1996). Although these species remain a relatively rare source 
of infection in the CF lung (roughly 3% of CF patients are colonized with B. cepacia), the 
clinical manifestations can be severe (2008).  Colonization may be asymptomatic or can 
result in progressive decline in lung function over a period of months. A smaller number 
of such infections (20%) result in cepacia syndrome, which is a fatal pneumonia that 
causes rapid death, within weeks to months (Jones et al., 2004; Kalish et al., 2006; 
Tablan et al., 1985). B. multivorans and B. cenocepacia are the species from the Bcc 
most frequently isolated from CF patients with a prevalence of 38% and 50%, 
respectively (LiPuma et al., 2001). However, all genomovars have been recovered from 
CF patients (Mahenthiralingam et al., 2000; Mahenthiralingam et al., 2005). 
Various disease outcomes are explained by host and strain dependent factors. 
Although the process of Bcc colonization is unclear, these species encode numerous 
virulence factors (Mahenthiralingam et al., 2005). A pathogenicity island is located in 
many of the Bcc genomes, which is absent in non-epidemic strains and rarely detected in 
environmental strains (Mahenthiralingam et al., 1997). Surveys reveal that the presence 
of this islands is various between geographic regions. For example, the strains of B. 
cepacia infecting CF patients in Canada are more likely (80%) to encode the 
pathogenicity island than are strains from US patients (23%) (LiPuma et al., 2001). The 
pathogenicity island contains quorum signaling factors, genes involved in fatty acid and 
amino acid metabolism, and several genes whose functions are unknown (Baldwin et al., 
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2004). Baldwin et al., 2004 also revealed that mutations in the amidase and quorum-
sensing genes result in lower levels of strain persistence and reduced levels of 
inflammation in the lungs of a CF rat model. Additional pathogenicity is conferred by 
cell surface lipopolysaccharides (LPS), which provide resistance to cationic antibiotics 
(Shimomura et al., 2003). Flagellar genes also contribute to strain virulence. Mutations in 
fliG gene, which encodes the ATPase subunit of the flagella, prevent attachment and 
invasion of the epithelial cells (Tomich et al., 2002). 
It is now becoming clear that both environment and clinical settings are potential 
reservoirs for Bcc infections. LiPuma et al., 2002 used DNA sequence data to determine 
that a B. cepacia strain found in an epidemic, was also isolated from an unrelated soil 
sample (LiPuma et al., 2002). However, frequently, patients are colonized with B. 
cepacia during a hospital visit or while at a CF camp (Gibson et al., 2003). It is clear that 
B. cepacia strains can be transmitted from person to person (contagious) (LiPuma et al., 
1990). In response, National CF organizations prepared an infection control consensus 
document, which recommends segregation of CF patients infected with Bcc from those 
not infected. Further, they urge that CF patients remain at least three feet away from one 
another, even if neither is infected with Bcc (Mahenthiralingam et al., 2005).  
Treatment of Bcc pulmonary infections is problematic due to the intrinsic 
antibiotic resistance of most strains. The Bcc genomes possess multi-drug efflux pumps, 
LPS, and chromosomally encoded beta-lactamases, which provide resistance to various 
classes of antibiotics including aminoglycosides, chloramphenicol, quinolones, and 
cationic peptides (Aronoff, 1988; Burns et al., 1989; Burns et al., 1996; LiPuma, 1998a; 
LiPuma, 1998b). Combinatorial application of multiple antibiotics is the current method 
 25 
 
of choice. These drug combinations usually include meropenem due to the low levels of 
meropenem resistance observed so far in Bcc (Aaron et al., 2000; Lewin et al., 1993). 
Minocyclin, amikacin, and ceftazidime are among the other antibiotics used in 
combination with meropenem (Gibson et al., 2003). 
1.9 Interaction of Pseudomonas aeruginosa (Pa) and Burkholderia cepacia complex 
(Bcc) 
Pa is the persistent species in CF lung infections. Bcc colonization is more rare, 
and, usually, follows an initial Pa colonization (Govan & Deretic, 1996). The outcome of 
these multiple rounds of colonization depends upon the patient and the bacterial species 
and strains involved. B. cenocepacia and B. multivorans are the most frequently isolated 
members of the Bcc (LiPuma et al., 2001). It is not known why some Bcc species and 
strains are effective lung colonizers while others are not. Certainly there are interactions 
between the Pa and Bcc species in CF lungs.  
The first evidence of communication between these two species comes from 
McKenney et al., 1995.  In this study, spent media, used to grow B. cepacia was 
supplemented with a cell free extract of Pa and the expression of siderophore, elastase, 
protease and lipase was monitored in B. cepacia. The levels of these virulence-related 
proteins were increased (McKenney et al., 1995).  
Weaver and Kolter (2004) investigated the effect of B. cepacia cell free extract on 
the expression of Pa genes. The genes upregulated in Burkholderia conditioned medium 
are the same as those induced under iron-limited conditions. These data reveal that 
Burkholderia conditioned medium has iron chelating activity (Weaver & Kolter, 2004).  
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Additionally Pa and Bcc strains interact through a process mediated by quorum 
signaling (QS). However, this communication is unidirectional, with Bcc strains capable 
of perceiving the QS molecules, acylated homoserine lactones (AHLs), released by Pa 
(Riedel et al., 2001). Geisenberger et al. (2000) analyzed the AHL profiles of Pa strains 
in CF patients co-infected with both species and revealed that during co-infection a 
dramatic reduction of AHL production occurs in the Pa (Geisenberger et al., 2000). Thus, 
the two species communicate, and the interaction results in an increased production of 
virulence factors. However, the final outcome, in terms of the patients’ health, is also 
dependent upon strain- and patient-specific factors, which might explain why a mixed 
infection results in such dramatic differences in infectivity, pathogenicity and host 
response. 
1.10 Bacteriocins 
Bacteriocins are narrow spectrum antibacterial proteins, which are produced by 
most bacterial species (Riley & Gordon, 1999; Riley & Wertz, 2002a; Riley & Wertz, 
2002b). They are classified based upon the producer species; such as colicins produced 
by E. coli, pyocins produced by Pa (formerly named pyocyania), and pesticins of Yersinia 
pestis. Colicins are one of the most thoroughly studied bacteriocin and are used as a 
model system to study bacteriocin structure, function, and evolution (Riley & Gordon, 
1999; Riley & Wertz, 2002a; Riley & Wertz, 2002b). 
Bacteriocins are high molecular weight proteins, produced by bacteria, usually 
under conditions of stress, such as then resources are limited (Riley & Gordon, 1999). 
They are encoded on both plasmids and chromosomes. The genes encoding bacteriocins 
are often found in clusters of genes, which include a toxin, immunity, and lysis genes. 
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The immunity gene encodes a protein, which confers immunity to that toxin, while the 
lysis gene encodes a protein that aids in the release of the toxin from the cell – often 
resulting in cell death. (Riley & Wertz, 2002a). 
1. 10.1 Bacteriocins of Pseudomonas aeruginosa (Pa) and Burkholderia cepacia 
complex (Bcc) 
1.10.1.1 Pyocins: Bacteriocins of Pa 
Francois Jacob was the first scientist to describe the production of bacteriocins 
(known as pyocins) in Pa (formerly P. pyocyanea). He detected a UV induced, protease 
resistant compound, which causes lysis of a susceptible bacterium (Jacob, 1952). Pa is 
one of the most prolific bacteriocin producing species. More than 90% of Pa isolates 
produce pyocins (Govan & Deretic, 1996).  
Pyocins fall into three types, known as R-, F-, and S pyocins. The R and F-type 
pyocins were the first pyocins described (Michel-Briand & Baysse, 2002). They share 
three key features: they can resist to proteases, resemble phage tails, and kill sensitive 
cells by depolarizing the cell membrane (Michel-Briand & Baysse, 2002). Two 
representative R and F-type pyocins, R2 and F2, are encoded in a large gene cluster, 
spans greater than 40 kb, located between the trpE and trpF genes in the genome of Pa 
strain PAO1 (Nakayama et al., 2000). There are 44 open reading frames associated with 
the R2/F2 phenotypes, which include regulatory, lysis and toxin genes. The R2 and F2 
pyocins show sequence similarity to the tail fiber genes of P2 and lambda phage, 
respectively (Nakayama et al., 2000).  
There are several R-type pyocins (R1, R2, R3, R4, and R5), which consist of 
extended sheets of 34 subunits, a base plate, tail fiber, and a core structure (Figure 1-8a). 
 28 
 
A single bacterium is capable of producing 200 R-pyocins (Shinomiya, 1972). R-pyocin 
binds to membrane lipopolysaccharide (LPS) via the tail fiber (Ikeda & Egami, 1969). 
Contraction of tail fiber penetrates the cell membrane and produces a channel, or pore. 
The sensitive cell is then lysed due to the resulting depolarization of the cytoplasmic 
membrane (Uratani & Hoshino, 1984). 
There are three F-type pyocins (F1, F2, and F3), which are flexible, non-
contractile rods, 106 nm in length and 10 nm in width (Figure 1-8b). The rod structure 
consists of 23 annuli and a fiber structure consisting of both long and short filaments 
(Michel-Briand & Baysse, 2002).  
The four known S-type pyocins (S1, S2, S3, and AP41) are protease sensitive 
bacteriocins, which resemble colicins in terms of their genetic structure and modes of 
action. They kill cells via DNAse activity located at the C-terminal end of the toxin 
protein. Different S-pyocins may recognize different receptors; S2 and S3 recognize type 
I and II ferripyoverdine receptors, respectively (de Chial et al., 2003).  
The typical S-pyocin operon spans an approximately 2 kb region of DNA and 
includes two genes: the toxin gene which provides the killing activity and the immunity 
gene which provides immunity to that pyocin. There are four domains in the toxin 
protein: domain I produces receptor binding activity; the function of domain II is 
unknown; domain III enables translocation of the toxin through the plasma membrane; 
and domain IV provides killing activity (Michel-Briand & Baysse, 2002). 
Two proteins regulate the synthesis of R, F and S pyocins: ptrN and ptrR, both of 
which are located upstream of the R2F2 gene cluster. PtrN is a transcriptional activator, 
which bind the regulatory sequence P-box located approximately 60-100 bp upstream of 
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the ribosome-binding site.  The P-box consists of a10-12 nt consensus sequence - 
ATTGnn(n)GT-nn(n). PtrR is a transcriptional repressor protein, which binds to PtrN, 
preventing its binding to the P-box. Under conditions of stress, such as DNA damage 
RecA cleaves PtrR, releasing PtrN. The binding of PtrN to the P box induces 
transcription of pyocin genes (Matsui et al., 1993; Michel-Briand & Baysse, 2002; 
Nakayama et al., 2000).  
1.10.1.2 Cepaciacins: Bacteriocins of Bcc 
The bacteriocin produced by B. cepacia (known as Pseudomonas cepacia at that 
time) are called cepaciacins (Govan & Harris, 1985). Govan et al, 1985 has assayed a 
collection of Pseudomonas cepacia, as they were known then, using pyocin producer and 
sensitive strains as indicator strains to phenotypically identify bacteriocins produced by 
B. cepacia. This study revealed that 30% of P. cepacia strains possess bacteriocin-like 
killing activity. Further, the cepaciacins looked like phage-tails when viewed under an 
electron microscope. Unfortunately, Govan’s study is the only publication on 
cepaciacins. No further molecular characterizations have been published. 
1.11 CF Treatment Regimens 
1.11.1 Physical therapy 
Physical therapy is applied to CF patients to clear mucus from their airways. 
Chest physical therapy, oscillating positive expiratory pressure, high frequency chest wall 
oscillation therapy, active cycle of breathing technique, autogenic drainage are all 
commonly employed approaches in treating CF patients (George et al., 2009). These 
methods are noninvasive and aim to dislodge and clear mucus from lungs. 
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1.11.2 Anti-inflammatory therapy 
The goal of anti-inflammatory therapy is to suppress inflammation in the lungs, 
which causes tissue destruction and results in further infection. Ibuprofen and 
azithromycin are the most frequently used anti-inflammatory drugs (George et al., 2009).  
1.11.3 Mucus thinning drugs 
 Mucus thinning therapy reduces the mucus, which clogs the airways of CF 
patients. This also results in a reduction of the bacterial load in the CF lungs. Pulmozyme 
is the most frequently prescribed mucus-thinning drug. Pulmozyme is a DNAse, inhaled 
via a nebulizor, which degrades the patients own DNA that was released during 
inflammation (Frederiksen et al., 2006).  
1.11.4 Antibiotic therapy 
Antibiotics are used to treat pulmonary bacterial infections. Pa and Bcc infections 
are the most problematic to treat since both species are intrinsically multi-drug resistant. 
Antibiotics can be administrated orally, intravenously, and are inhaled. The most 
common therapeutic approach involves application of a cocktail of antibiotics, usually a 
combination of beta-lactamases and aminoglycosides to treat chronic Pa infections. A 
combination of meropenem and another class of antibiotic (tetracycline, aminoglycoside 
and/or cephalosporins) is used to treat Bcc, based on the sensitivity phenotype of the 
strains isolated from the lung (Gibson et al., 2003). 
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1.11.5 Bronchodilator therapy 
A bronchodilator is a medicine that dilates bronchi and bronchioles. This therapy is 
administrated during airway obstruction when mucus clogs the airways, and the patient 
having difficulty breathing (Eggleston et al., 1991). 
1.11.6 Lung transplantation 
Lung transplantation is the therapy applied to CF patients, which are at the end-
stage of the disease. The lifespan of CF patients might increase up to 10 years. However, 
post transplantation infections in particular Pa infections are common and observed up to 
90% of patients (Morton & Glanville, 2009).  
1. 12 Research Questions 
The following research questions were the focus of my doctoral research: 
1. Do clinical strains of Pa and Bcc isolated from CF lungs produce bacteriocins? 
2. If so, what types of bacteriocins are produced and how specific or broad are their 
killing activity? 
3. What roles do these bacteriocins serve in mediating intra- and inter-specific 
interactions of bacterial isolates from cystic fibrosis patients? 
1.13 Problem Statement 
Over the past 60 years, a vast literature has focused on the bacteriocins produced 
by Pa and Bcc. Within the CF research community, most of this research has focused on 
phenotypic screens of pyocin and cepaciacin production of the two species (Edmonds et 
al., 1972b; Farmer & Herman, 1969; Farmer & Herman, 1974; Fyfe et al., 1984; Govan 
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& Harris, 1985; Jones et al., 1973; Jones et al., 1974a; Jones et al., 1974b; Kageyama et 
al., 1979; Moroz et al., 1984; Pitt, 1988; Richardson et al., 1991; Shriniwas, 1975; 
Zabransky & Day, 1969). However, none of this research has explored the potential role 
of bacteriocins in mediating within and between species killing of clinical Pa and Bcc 
strains. Given the high levels of bacteriocin production by both species, and the clear 
necessity that they interact during co-infections of the CF lung, this absence of research is 
striking. 
1.14 Purpose of this study 
The major goals of this study are to:  
1. Determine if clinical strains of Pa and Bcc isolated from the CF lung produce 
bacteriocins. 
2. Determine whether these toxins play a role in mediating intra- and inter-specific 
interactions of bacterial isolates from cystic fibrosis patients.  
3. Identify bacteriocins produced by the two species. 
1.15 Methodology 
1. Employ phenotypic screens of bacteriocin production to determine which isolates 
from CF lungs produce bacteriocin-like inhibition phenotypes. 
2. Employ phenotypic assays (protease digestion, freezing, and filtration) to assess. 
whether the phenotypes observed are due to bacteriocins, phage or some unknown 
mechanism. 
3. Employ multilocus pyocin sequence typing to determine the bacteriocin genes present 
in this strain collection. 
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4. Screen genomic libraries to identify bacteriocin genes that failed to amplify in the 
sequence typing characterization. 
1.16 Significance 
Pa and Bcc infections are the cause of significant mortality in patients with cystic 
fibrosis. Pa is the primary, persistent species found in CF lung infections. This species is 
hard to treat due to its intrinsic resistance to many antibiotics. Bcc causes secondary lung 
infections, usually colonizing the CF lung after initial Pa colonization. Little is known 
about how these two species interact during the strain invasion and establishment 
process. This study seeks to contribute to our understanding of the role bacteriocins serve 
in mediating the bacterial strain and species interactions in the CF lung. First, an 
extensive strain by strain survey reveals the inhibition potential of both species. Second, 
the same survey provides insight into the role these toxins play in mediating intra- and 
inter-species interactions in the CF lung. Finally, the molecular characterization reveals 
which bacteriocins are produced by CF strains. The data produced in this study are the 
first step in understanding the role of bacteriocins in mediating bacterial strain 
interactions in the CF lung.  
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Figure 1-1 Cystic Fibrosis Transmembrane Regulator (cftr) gene and its encoded 
protein presented on epithelial cells. 
a. The cftr gene spans 215 kb region and consists of 27 exons and 26 introns; b-The cftr 
gene encodes a transmembrane protein with two membrane spanning domains (MSD), 
regulatory domain (R ), and two nucleotide binding domains (NBD) (Zielenski et al., 
2000; Sheperd et al., 1999).  
 
 
a. cftr gene and CFTR protein 
 
 
 
 
 
 
 
 
 
 
 
 
b. CFTR protein topology 
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Figure 1-2 Models of ATP dependent gating of CFTR channel 
a. Model 1 has three closed states (C1, C2, and C3), and two open states (O1 and O2). 
Sequential hydrolysis of ATP at NBDs opens the channels; b. Model 2 has two closed 
(C1 and C2) and two open states (O1 and O2). ATP hydrolysis at NBD2 (O2 state) 
followed by R domain phosphorylation, which leads to channel closing (Sheperd et al., 
1999).  
 
 
a.   Model 1                                                         b. Model 2 
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Figure 1-3 Worldwide incidence of CF 
Cystic Fibrosis affects mostly Caucasian population in North America, Europe, and 
Australia (WHO 2004 CF Report). 
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Figure 1-4 Functional classification of CFTR mutations 
Mutations causing unfunctional or defective CFTR protein is classified into five classes 
(Class 1-5) (Gibson et al., 2003).  
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Figure 1-5 Cystic Fibrosis: the vicious cycle 
Pathogenesis of lung disease in CF is described as vicious cycle, in which abnormal 
airway surface cause airway obstruction, which is followed by infection, inflammation, 
and bronchiectasis (Konstan, 1997) 
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Figure 1-6 Human lung epithelium 
a-Pulmonary structure of the lungs. Bronchus branches into bronchioles, which branch 
into alveoli; b- Pulmonary cells. Type I, type II epithelial cells, mucous secretory cells 
(Clara and Goblet) are epithelial cell types in lungs; c- Type I cells are large squamous 
epithelial cells and type II cells are cuboidal epithelial cells in lungs (Matthay et al., 
2002; Livraghi et al., 2007) 
 
 
 
a. b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c. 
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Figure 1-7 Airway surface liquid (ASL) 
ASL is a thin water surface, which lines the airway portion of the epithelial cells. ASL 
composed of mucous layer and periciliary liquid (PCL) (Boucher, 2004).  
 
 
 
 
 
 
 
 
 
           ASL 
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Figure 1-8 Structures of R- and F- type pyocins 
a. R-type pyocin. R-type pyocins consist of extended sheets (ES), a base plate (BP), tail 
fiber (TF), and a core structure (CS); b-F-type pyocin. F-type pyocins consist of 23 annuli 
and a fiber (Fi) structure consists of both short and long filaments (Michael-Briand, 
2002). 
 
 
 
 
 
a. R-type pyocin                                           b. F-pyocin 
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CHAPTER 2 
 
THE ROLE OF BACTERIOCINS IN MEDIATING INTERACTIONS OF 
BACTERIAL ISOLATES TAKEN FROM CYSTIC FIBROSIS PATIENTS  
2.1 Abstract   
Pseudomonas aeruginosa (Pa) and Burkholderia cepacia complex (Bcc) lung 
infections are responsible for much of the mortality in cystic fibrosis (CF). However, 
little is known about the ecological interactions between these two, often co-infecting, 
species. This study provides the first report of the intra- and inter-species bacteriocin-like 
inhibition potential of Pa and Bcc strains recovered from CF patients. A total of 66 strains 
were screened and shown to possess bacteriocin-like inhibitory activity (Pa - 97% and 
Bcc - 68%), much of which acts across species boundaries. Further phenotypic and 
molecular based assays reveal that the source of this inhibition differs for the two species. 
In Pa, much of the inhibitory activity is due to the well known S and RF pyocins. In 
contrast, Bcc inhibition is due to unknown mechanisms, although RF-like toxins are 
implicated in some strains. These data suggest that bacteriocin-based inhibition may play 
a role in governing Pa and Bcc interactions in the CF lung and may, therefore, offer a 
novel approach to mediating these often-fatal infections.  
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2.2 Introduction 
Individuals with cystic fibrosis (CF) face a lifelong battle with chronic bacterial 
lung infections. Pseudomonas aeruginosa (Pa) is the predominant infectious agent in the 
lungs of adult CF patients and most individuals are infected shortly after birth (CFF, 
2008). Alginate-producing mucoid variants emerge over the course of several years and 
form dense bacterial biofilms in the CF lung. Once established, eradication of these 
infections is generally not possible (Govan & Deretic, 1996; Hentzer et al., 2001).   
In the 1970s, members of the Burkholderia cepacia complex (Bcc) of species 
were first identified in the airways of CF patients (Govan & Deretic, 1996). Although few 
patients colonized with Bcc (~3%), the clinical manifestations of these infections can be 
severe (CFF, 2008; Kalish et al., 2006). Colonization by Bcc may be asymptomatic or 
result in progressive decline in lung function. A smaller number of infections result in 
“cepacia syndrome”, a fatal pneumonia that results in death (Jones et al., 2004; Kalish et 
al., 2006; Tablan et al., 1985).                                                                                                                                                              
 Given that CF patients are initially infected with Pa, Bcc strains must either 
compete with or act in synergy with established Pa biofilms (Al-Bakri et al., 2004). How 
such interactions occur is unknown. In fact, little is known about the process of Bcc 
invasion and its outcomes. Do the strains from the two species peacefully co-exist? Do 
Bcc strains out-compete and displace pre-existing Pa strains? Few studies have sought to 
address how these two bacterial species interact in the CF lung (Al-Bakri et al., 2004; 
McKenney et al., 1995; Weaver & Kolter, 2004). 
One factor known to mediate bacterial interactions is the production of potent 
toxins known as bacteriocins (Riley & Gordon, 1999). Unlike traditional antibiotics, 
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many bacteriocins have a relatively narrow killing range. They have been implicated in 
intra-specific competition brought on by limited nutrients (Riley & Wertz, 2002a). In 
some cases, however, bacteriocins are also able to kill more broadly and have been 
implicated as a primary mechanism for mediating microbial diversity (Kerr et al., 2002).  
Much is already known about pyocins, the bacteriocins produced by 
Pseudomonas. In fact, more than 90% of all Pa strains examined to date produce one or 
more of three pyocin types: S, R, and F (Fyfe et al., 1984). S pyocins are high molecular 
weight proteins, which resemble the well-known colicins produced by Escherichia coli. 
They are protease sensitive and most kill by DNA degradation (Michel-Briand & Baysse, 
2002). Four S-pyocins (S1, S2, S3, and AP41) have been studied extensively (Duport et 
al., 1995; Sano & Kageyama, 1981; Sano et al., 1993a; Sano et al., 1993b; Sano, 1990) 
(Figure 2-1a). All S-pyocin operons share the presence of two genes: the larger (toxin 
gene) provides the killing activity, while the smaller (immunity gene) provides immunity 
against killing by that pyocin. The toxin gene is comprised of four domains: Domain I - 
produces receptor binding activity, which enables a pyocin to recognize a specific target, 
Domain II - has an unknown function, Domain III - enables translocation of the toxin 
through the plasma membrane, and Domain IV - produces the killing (DNAse) activity 
(Michel-Briand & Baysse, 2002). 
The R and F pyocins, which resemble bacteriophage tails, are resistant to both 
nuclease and protease digestion and kill by depolarizing the cell membrane. The genes 
encoding these pyocins are found in a cluster (which is why they are often referred to as 
RF pyocins), and are located between trpE (anthranilate synthase component I) and trpG 
(anthranilate synthase component II) genes (Nakayama et al., 2000; Shinomiya et al., 
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1983). Figure 2.1(b) shows the genetic organization of pyocin R2F2 genes. The open 
reading frames (PRF3-PRF43) include regulatory, lysis, and R and F pyocin genes. The 
lysis genes (PRF9, PRF24, PRF25, and PRF26) are similar in sequence to the lysis 
cassettes of P2 and lambda phages (Nakayama et al., 2000). There are 16 R and F pyocin 
genes (PRF10-23 and PRF28-43) (Nakayama et al., 2000). The encoded proteins show 
high levels of sequence similarity to tail genes of P2 and lambda phage, respectively 
(Nakayama et al., 2000). The function of PRF5-8 is unknown.  
The S, R, and F pyocins are controlled by the same ptrN and ptrR regulatory 
genes (Figure 2-1b) (Michel-Briand & Baysse, 2002; Nakayama et al., 2000). PtrN is a 
transcriptional activator, which is repressed by PtrR (Matsui et al., 1993). Under DNA 
damage, RecA protein cleaves the PtrR repressor protein, which leads to expression of 
ptrN. PtrN binds to the regulatory sequence (P-box), thus inducing transcription of pyocin 
genes (Matsui et al., 1993).  
Stress conditions, such as might be encountered in a CF lung, may induce pyocin 
production. Microarray analysis of Pa genomes revealed that pyocin transcription is up-
regulated by hydrogen peroxide and ciprofloxacin (Brazas & Hancock, 2005; Chang et 
al., 2005). White & Curtis (2009) investigated the effect of pyocins in mixed-culture 
biofilms under aerobic and anaerobic conditions and revealed that pyocins sensitivity 
increased under anaerobic conditions. Further, Heo et al., 2007 revealed that R pyocins 
provide a competitive advantage during growth in planktonic conditions.  
 Far less is known about cepaciacins, the bacteriocins produced by Burkholderia.  
Approximately 30% of Burkholderia cepacia (formerly Pseudomonas cepacia) strains 
produce cepaciacins (Govan & Harris, 1985). The few characterized cepaciacins 
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resemble R-type pyocins, as they are resistant to trypsin digestion and appear phage-tail-
like when viewed under the electron microscope (Govan & Harris, 1985). Nothing further 
is known about the abundance, diversity or molecular biology of these toxins.  
The goal of the present study is to determine if clinical strains of Pa and Bcc 
isolated from the CF lung produce bacteriocins and, if so, whether these play a role in 
mediating intra- and inter-specific bacterial interactions in the CF lung. To this end, a 
collection of clinical Pa and Bcc strains from CF patients was screened for bacteriocin 
production and sensitivity. This collection consists of strains isolated either as pairs (one 
strain of Pa and one of Bcc isolated from the same lung) or unpaired. Phenotypic screens 
for bacteriocin production coupled with typing methods to identify individual 
bacteriocins reveal a diversity of inhibitory mechanisms. Further, the patterns of within 
and between species inhibition suggests a role for these toxins in mediating bacterial 
interactions in the CF lung.  
2.3 Materials and Methods 
2.3.1 Bacterial strains 
The bacterial strains used in this study include a total of 66 clinical strains of Pa 
(38) and Bcc (28) obtained from Children’s Hospital, Boston MA. The study protocol 
was approved by the Committee on Human Research at Children’s Hospital Boston and 
written informed consent was obtained. The clinical collection can be divided into two 
groups. The first is composed of 14 Pa and 7 Bcc paired isolates procured from 7 patients 
with CF. Each pair of Pa and Bcc strains was isolated from the same CF patient. The 
second group is composed of 24 Pa and 21 Bcc unpaired isolates, which were isolated 
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from 31 patients. The Bcc strains include 4 genomovars (1 Burkholderia vietnamiensis, 
12 Burkholderia multivorans, 11 Burkholderia dolosa, and 4 Burkholderia cenocepacia). 
The reference strain collection includes bacteriocin producer strains which are Pa strains 
known to produce the following pyocins: S1, R4 (PML28), AP41 and F3 (PAF41), S2, R, 
F (NIH18), S2, R2, F2 (PAO1) (Ito, 1970; Kuroda & Kageyama, 1981; Nakayama et al., 
2000; Sano, 1990; Seo & Galloway, 1990). The reference collection also includes 
indicator strains sensitive to various combinations of pyocins:  PML1516d 
(S1SS2SAP41S), NIH3 (S1SS2SAP41S), NIH3S1R (S1RS2SAP41S), NIH3S2R 
(S1SS2RAP41S), NIH3AP41R (S1SS2SAP41R), 3295 (AP41S), 3012 (AP41SF3S), 7NSK2 
(S1SS3S), 7NSK2-fpvA (S1SS3R), PML14 (S1SR1SR2SR3SR4SR5S), 13s 
(S1SR1SR2SR3SR4SR5S), NIH5 (ATCC 25317) (F1SF2SF3S) (de Chial et al., 2003; 
Kageyama et al., 1979; Kuroda & Kageyama, 1981; Sano & Kageyama, 1981; Sano et 
al., 1993a; Williams et al., 2008). Additionally, four cloned S-pyocins (S1, S2, S3, and 
AP41) were employed to detect S-pyocin sensitivity of clinical Pa and Bcc strains 
(Duport et al., 1995; Sano & Kageyama, 1993; Sano et al., 1993b). There is no 
corresponding set of Bcc reference strains. 
2.3.2 Bacteriocin production and sensitivity screen.  
The patch assay was used to identify bacteriocin-like inhibition, which involves 
overnight growth in 10 ml Luria Broth (LB) at 37 0C, shaken at 250 rpm. Six ml. of LB 
top agar (0.6%, w/v) mixed with 3 µl of Mitomycin C (0.5 µg ml-1; Sigma) and 100 µl of 
indicator cells (108 cells) were plated as a lawn on an LB plate (Pugsley & Oudega, 
1987). The producer strain (~106 cells) was spotted on the indicator overlay by toothpick. 
Two spots per strain were applied. After overnight incubation at 37 0C the plates were 
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scored. If a strain produces an inhibition factor, such as a bacteriocin, active against the 
lawn, a zone of inhibition appears. The clinical collection was screened in an all-by-all 
assay, i.e. each strain was used as a potential inhibitor producer and indicator. The all-by-
all patch assay was done in duplicate. All positive results were tested a third time.  
The one-tailed Mann-Whitney U test was used for nonparametric comparison of 
inhibitory activities in order to identify significant differences in inhibition frequencies 
(Zar, 1999).  
2.3.3 Phenotypic bacteriocin identification.  
The clinical collection was screened against the indicator strains using the patch 
assay. In addition, a cell-free extract of each putative bacteriocin-producing strain was 
subjected to trypsin digestion, filtration, and freezing to distinguish between protease 
sensitive and phage-like bacteriocins (Pugsley & Oudega, 1987; Riley et al., 2003). Cell 
free extracts of putative producer strains were digested with trypsin (5mg ml-1) for 30 min 
at 25 0C, which inactivates protease-sensitive bacteriocins, frozen at -70 0C, which tends 
to fracture phage tail type bacteriocins, and filtered in a 100 kDa Microcon YM-100 
Centrifugal Filter Device (Millipore) using centrifugation at 14000 rpm for 12 min, 
which tends to retain phage tail-like bacteriocins. The treated cell free extracts were 
tested on the lawns of pyocin sensitive reference and clinical strains.  
2.3.4 Molecular Screening 
Genomic DNA was isolated using the DNeasy Tissue kit (QIAGEN). The Gram-
negative protocol was applied to 2X109 cells from an overnight culture. A standard PCR 
protocol was used to screen genomes for the presence of all previously characterized S-
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type pyocin genes (encoding S1, S2, S3, and AP41) and their corresponding immunity 
genes (Duport et al., 1995; Sano & Kageyama, 1993; Sano et al., 1993b). Multiple primer 
sets were designed based on existing pyocin sequences to amplify different regions of 
each S-pyocin and corresponding immunity genes (Appendix III). Further, primer sets 
specific to the regulatory region (P-box) of pyocins S1, S2, and AP41were employed. 
Primers designed to amplify the RF-type pyocins targeted PRF-10, PRF-31, and PRF-38 
genes were taken from the literature (Nakayama et al., 2000). NCBI accession numbers 
of the sequenced pyocins, primer positions, primer sequences, amplicon sizes, and 
identities are given in Appendix III.  
2.4 Results 
2.4.1 Inhibitory activity in Pa and Bcc strains 
A phenotypic screen for inhibitory activity and sensitivity was conducted on a 
collection of 66 clinical strains of Pa (38) and Bcc (28) isolated from CF patients. The 
collection consists of strains isolated as pairs, i.e. one Pa and one Bcc isolated from the 
same patient (taken from 7 patients, and resulting in 14 pairs; 14 Pa paired with 7 Bcc 
strains), and unpaired (24 Pa and 21 Bcc). Bacteriocin production and sensitivity was 
assayed in an all-by-all comparison, i.e. each strain was used as a putative producer and 
sensitive strain.  
In this screen, Pa and Bcc strains showed different levels of inhibitory activity. 
The majority of the Pa strains (97%) were inhibitory (Table 2-1). Most (76%) inhibit both 
Pa and Bcc species, resulting in similar levels of intra- (92%) versus inter- (81%) specific 
inhibition. Only 3% of Pa strains show no inhibitory activity.  
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The Bcc strains showed lower levels of overall inhibitory activity (68 %) (Table 
2-1). The one-tailed Mann-Whitney U test confirms significantly higher levels of total 
inhibition by Pa versus Bcc strains (P<0.0005). Similar to Pa, most Bcc strains (43%) 
inhibit both species, again resulting in similar levels of intra- (54%) versus inter- (57%) 
specific inhibition.  A much larger fraction of Bcc strains (32%) display no inhibitory 
activity. 
When the CF strain collection is divided into strains isolated as pairs or unpaired, 
the paired and unpaired Pa showed similar levels of total inhibition (Table 2-1). All 
paired and most unpaired (96%) Pa isolates possess inhibitory activity. Most of the paired 
Pa strains (86%; 12/14 strains) inhibit both species, while the remainder inhibit either Bcc 
(7%; 1/14 strains) or Pa (7%; 1/14 strains). Two of the paired Pa strains inhibit their Bcc 
pair mates. The inhibitory unpaired Pa show similar patterns of inhibition, 71%  (17/24 
strains) inhibit both species and the remainder inhibit either Bcc (4%; 1/24 strains) or Pa 
(21%; 5/24 strains).  
The paired Bcc strains show significantly different inhibition patterns than their 
Pa pair mates (Table 2-1). Only 43% of paired Bcc isolates (3 strains) possess inhibitory 
activity, significantly lower levels than paired Pa (0.025<P<0.05), and all of these strains 
inhibit both species, but not their pair mates (Table 2-1). The inhibition patterns of 
unpaired Bcc isolates are quite similar to those of unpaired Pa strains. Most of the 
unpaired Bcc are inhibitory (76%; 16/21 strains) and most of these (43%; 9/21 strains) 
inhibit both species. The remainder inhibit only Bcc (14%; 3/21 strains) or only Pa strains 
(19%; 4/21 strains) (Table 2-1).  
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Inhibition haplotypes (Pa and Bcc strains inhibited by a putative producer strain) 
were determined for each producer. The 37 Pa and 19 Bcc producers displayed 36 and 18 
haplotypes, respectively (Figure 2-2). Further, all Pa isolates inhibit multiple Pa and Bcc; 
12 Pa inhibit 1-10 strains (11 inhibition haplotypes), 8 inhibit 11-20 strains (8 inhibition 
haplotypes), 11 inhibit 21-30 strains (11 inhibition haplotypes), and 3 inhibit 31-40 
strains (3 inhibition haplotypes). Three of the paired Pa isolates were able to inhibit most 
of the strains in the collection (41-50 strains). The Bcc isolates have a more limited 
inhibition range. The majority (17 strains) inhibit 1-10 strains (16 inhibition haplotypes). 
Two Bcc strains are more broadly inhibitory, acting against 13 or 24 strains.  
2.4.2 Bacteriocins of clinical Pa and Bcc strains are a source of inhibitory activity 
A series of phenotypic assays were employed to assess whether the observed 
inhibitory activities were due to bacteriocin or bacteriophage production. Cell free 
extracts of each producer were subjected to filtration (to retain phage-like bacteriocins), 
protease digestion (to digest protein moieties), and freezing (to fracture phage-like 
bacteriocins). These assays revealed that 13% of Pa produce substances that appear to be 
protease sensitive bacteriocins, 11% produce phage-like bacteriocins, and 63% produce 
both (Figure 2-3). Finally, eleven percent of the Pa could not be further characterized due 
to the loss of inhibitory activity in the cell-free extract.  
Surprisingly, all of the Bcc producers lost inhibitory activity in their cell-free 
extracts. This result was further explored by concentrating the extracts 20 fold. One strain 
(4%) showed phage-like bacteriocin activity (Figure 2-3). None showed only protease-
sensitive bacteriocin activity. Eleven percent showed both. One Bcc strain (4%) produced 
phage plaques indicating that the inhibitory activity is due to lytic activity of a 
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bacteriophage. Finally, fifty percent could not be characterized due to the complete loss 
of inhibitory activity even after 20-fold concentration of the extract (Figure 2-3).  
2.4.3 Clinical strains have the potential to produce multiple bacteriocins 
A set of Pa reference strains enabled us to identify the source of some or all of the 
inhibition identified above. These reference strains are either producers of or are sensitive 
to specific S, R and F pyocins (de Chial et al., 2003; Ito, 1970; Kageyama et al., 1979; 
Kuroda & Kageyama, 1981; Nakayama et al., 2000; Sano, 1990; Seo & Galloway, 1990; 
Williams et al., 2008). Additionally, cloned pyocins (S1, S2, S3, and AP41) were also 
employed as references to identify S-pyocin sensitivity of clinical Pa and Bcc strains 
(Duport et al., 1995; Sano & Kageyama, 1981; Sano et al., 1993b). There are no 
corresponding reference strains for Bcc bacteriocins. 
All strains were assayed for bacteriocin-like inhibitory activity against the Pa 
reference collection. The bacteriocin phenotypes predicted from these inhibition 
haplotypes are given in Table 2-2. Among the 37 Pa producer strains, 76% inhibit one or 
more of the reference strains. Strains predicted to possess the most bacteriocins (Pa I: S1, 
S2, S3, AP41, R2, R4, F2, F3 and Pa II: S1, S2, AP41, R2, R4, F2, F3) are the most 
common phenotypes encountered in the clinical Pa strains. These two phenotypes inhibit 
an average of 31 and 23 strains, respectively. Pa II strains possessing all but the S3 
phenotype (PaIIS3-) experience a 42% decrease in Bcc inhibition in comparison to Pa I. 
The Pa III (S1, R2, R4, F2) phenotype is found in only one strain, however it inhibits the 
greatest number of clinical strains, an average of 44 strains. Pa strains with Pa IV (S1, 
R2, R4, F2, F3) and Pa V (S1, S3, AP41, R2, R4, F2, F3) phenotypes inhibit the least 
number of clinical strains, an average of 6.5 and 9, respectively. Strains with the Pa VI 
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(S1, S2, AP41) phenotype kill an average of 17 clinical strains. Nine Pa producers (Pa 
VII) do not inhibit any of the reference strain and have the lowest level of inhibition, an 
average of 2.4 clinical strains inhibited. Among the 19 Bcc producer strains, only 16% 
inhibit any of the Pa reference strains. These three possess the Bcc I (S1, S2, AP41, F3), 
Bcc II (F3) and Bcc III (R2, F2) phenotypes (Table 2-2). Fifteen Bcc producers (Bcc IV) 
do not inhibit any of the reference strains and inhibit an average of 5.8 clinical strains. 
2.4.4 Clinical strains show sensitivity to multiple bacteriocins. 
The clinical strains were exposed to cloned S-pyocins (Duport et al., 1995; Sano 
& Kageyama, 1981; Sano et al., 1993b) and 89% were sensitive (Table 2-3). Sixty-two 
percent were sensitive to a single pyocins and 38% to multiple pyocins. Finally, none of 
the Bcc are sensitive to the cloned S-pyocins (Table 2-3).   
2.4.5 Source of the intra- and inter-specific inhibitory activity of clinical strains 
Based on inhibition haplotypes, 28 Pa are predicted to produce combinations of S 
and RF type pyocins, which kill within and between species (Figure 2-4). Two inhibit 
intra-specifically with S-pyocins, 24 with RF-type pyocins, and 25 with S and/or RF 
pyocins. Twenty-five act inter-specifically, all with RF-type pyocins. Finally, 14 produce 
novel bacteriocins that act intra-specifically (50%) or inter-specifically (50%). 
In contrast, the majority of Bcc strains produce novel bacteriocin-like activity 
(Figure 2-4). Three produce RF-like factors and 12 produce novel bacteriocins, all of 
which act intra-specifically. Further, three produce RF-like, one produces S- and/or RF-
like pyocins, and the remainder (13) produce novel inhibitors to inhibit inter-specifically 
(Figure 2-4).  
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2.4.6 Molecular Screening: Clinical Pa strains possess multiple pyocin genes 
PCR primers specific to S-type (S1, S2, S3, and AP41) (Duport et al., 1995; Sano 
& Kageyama, 1981; Sano et al., 1993b) and RF-type (PRF-10, 31, and 38) pyocin genes 
were employed to screen for the presence of known pyocin-encoding genes (Appendix 
III). All Pa strains were amplification positive for one or more of the pyocin genes 
(Figure 2-5). Ninety-five percent possess one or more S-pyocin genes; 71% amplify the 
S1 gene, 71% S2 gene, 42% S3 gene, and 63% AP41 gene. A further 16% amplified from 
the pyocin AP41 immunity gene, but not the corresponding toxin gene. Ninety-five 
percent of the strains were amplification positive for one or more RF pyocin genes; 68% 
for PRF-10, 45% for PRF-31, and 24% for PRF38 (Figure 2-5). Finally, none of the Bcc 
strains were amplification positive for any of the pyocin genes (data not shown). 
2.5 Discussion 
Individuals with cystic fibrosis (CF) face a lifelong battle with chronic bacterial 
lung infections (Govan & Deretic, 1996). Pseudomonas aeruginosa is the most prevalent 
species in the CF lung and is associated with high mortality (Emerson et al., 2002). CF 
patients are first colonized with nonmucoid Pa in childhood, which is replaced by mucoid 
variants in adulthood (Gibson et al., 2003). Mucoid Pa form biofilms, which are virtually 
impossible to eradicate even with aggressive antibiotic therapy (Hentzer et al., 2001). 
Secondary bacterial infections, such as with Burkholderia cepacia, although less 
common, are of particular concern because they are often associated with faster decline in 
lung function and may result in cepacia syndrome, which is a rapidly progressing and 
fatal pneumonia (Huang et al., 2001; Lambiase et al., 2006). What is remarkable about 
these secondary infections is that they require a strain to compete with, and perhaps even 
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displace, the established Pseudomonas strain (Lambiase et al., 2006; Ledson et al., 1998; 
Ledson et al., 2002; McManus et al., 2004). Further, the time interval between exposure 
and invasion may be as short as days to weeks (Ledson et al., 1998; Tablan et al., 1985; 
Whiteford et al., 1995). This ability of Bcc strains to compete with, or even displace, the 
resident Pa strains stands in sharp contrast with our seeming inability to significantly 
impact long standing Pseudomonas lung infections with even the most aggressive use of 
broad spectrum antibiotics.  
Bacteriocins, narrow spectrum antimicrobials, are recognized as one of the most 
common mechanisms by which bacteria mediate population and community level 
interactions (Kerr et al., 2002; Riley & Gordon, 1999; Riley & Wertz, 2002a). Pa is a 
well-characterized and prolific bacteriocin producer. Indeed, studies indicate that nearly 
all clinical and only slightly fewer environmental (~70%) Pa strains produce pyocins 
(B.Bouhaddioui, 2002; Farmer & Herman, 1969; Jones et al., 1974b; Zabransky & Day, 
1969). Typing of a much smaller number of Burkholderia cepacia strains from clinical 
sources (previously known as Pseudomonas cepacia) revealed far fewer producers (30%) 
of putative bacteriocin-like toxins (labeled cepaciacins) (Govan & Harris, 1985). What 
little we know about cepaciacins suggests that some may be similar to the phage-tail like 
R-pyocins (Govan & Harris, 1985).  
In an attempt to understand how Pa and Bcc strains interact in the CF lung, 
isolates of both species were surveyed for the production of bacteriocins. Not 
surprisingly, both species are prolific producers of bacteriocin-like toxins, with 97% of 
Pa and 68% of Bcc capable of inhibition (Table 2-1). For Pseudomonas, most of the 
inhibitory activity detected (76%) is due to S and RF pyocins (Table 2-2). In contrast, for 
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Burkholderia, most of the inhibition could not be characterized (Table 2-2). Only a small 
fraction (16%) was attributable to bacteriocin-like proteins (Table 2-2). 
More surprisingly, the levels of between species inhibition is high, 81% of the Pa 
and 57% of the Bcc producers inhibit the other species (Table 2-1). Previous studies of 
Gram-negative bacteriocins have described bacteriocins as narrow spectrum toxins, 
referring to the observation that they are active against members of the same species and 
generally display restricted levels of inhibition outside of the producing species (Riley & 
Wertz, 2002a; Riley & Wertz, 2002b). A similar survey in closely related Klebsiella 
species revealed that only 20% of strains show inter-specific inhibitory activity (Riley et 
al., 2003).  
The high levels of inter-specific inhibition detected for Pa and Bcc may reflect the 
competitive interactions that occur between these species in the CF lung. Prior studies 
have suggested that these two species actively inhibit each other’s growth. McKenney et 
al. (1995) revealed that the addition of cell free Pa exo-products to the growth medium 
used to cultivate Bcc enhances the production of siderophores, lipases and proteases. 
Further, Weaver & Kolter (2004) examined the impact of cell free extracts of Bcc on Pa 
gene expression and revealed that most of the up-regulated genes of Pa are normally 
induced under iron-limited conditions. The authors concluded that iron-limited conditions 
might be created in these pairwise growth conditions due to the iron chelator-ornibactin 
produced by Bcc. Indeed, iron-siderophores and S-pyocins (S2, S3) share the same 
receptors (type I and II ferripyoverdines, respectively) (Denayer et al., 2007). Thus, S-
pyocins are better absorbed by sensitive strains under iron-limited conditions (Ohkawa et 
al., 1980). Given these facts, Bcc colonization in the CF lung may induce intra-specific 
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Pa inhibitory activity. Clearly, the effect of iron on inter-specific inhibitory activity of 
pyocins and cepaciacins bears further investigation. For these purposes, identification of 
cepaciacins and the corresponding cell surface receptors is required.  
The majority of Pa inter-specific inhibitory activity is due to RF type pyocins 
(Figure 2-4). In fact, R pyocins inhibit a variety of Gram-negative bacteria (Blackwell et 
al., 1979; Filiatrault et al., 2001). This study provides the first substantial report of the 
potential role of RF pyocins in clinical Bcc inhibition. The remainder of the Pa inter-
specific inhibitory activity is due to novel virulence factors. The majority of Bcc inter-
specific inhibitory activity is due to novel factors, which require further investigation 
(Figure 2-4).  
Another intriguing observation reported here is that most isolates of Pa from the 
CF lung produce multiple bacteriocins (Table 2-2 and Figure 2-5). In fact, the most 
frequently encountered bacteriocin types (Pa I-II) include essentially all characterized S 
and RF-pyocins. The observation of such high levels of Pa bacteriocin diversity is good 
news for those interested in the potential use of bacteriocins as narrow spectrum 
antimicrobials. Although the bacteriocin-like production patterns are complex, they offer 
a wide range of inhibition specificities.  
Given the lack of effective antibiotic therapies for adult patients with CF, it is 
intriguing that these strains are inhibited by a diversity of Pa and Bcc bacteriocins 
(characterized and putative). Bacteriocins may be an effective alternative for mediating 
some of these long-standing infections in the CF lung. One requirement would be the 
production of bacteriocin sensitivity profiles to permit identification of the appropriate 
therapeutic bacteriocins. Of course, such treatment will select for bacteriocin resistance 
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(e.g. protease sensitivity, lipopolysaccharide (LPS) receptor modification) (Loutet et al., 
2006). However, given the plethora of potential bacteriocins, cocktails of toxins could be 
created, which would result in far lower rates of resistance evolution (Riley, personal 
communication). Bacteriocins are now frequently being considered for such therapeutic 
use (Gillor et al., 2005). For example, they are employed as antibiotics for use in mastitis 
in dairy cows (Diez-Gonzalez, 2007), and to inhibit growth of pathogenic Escherichia 
coli in newborn piglets and foals (Gillor et al., 2005). 
The most striking difference between Pa and Bcc inhibition patterns involves their 
breadth of activity. Almost all Pa isolates are able to inhibit a wide range of Pa and Bcc 
strains (Figure 2-2). In contrast, Bcc strains, on average, inhibit a much more limited 
number of strains. Further, the Bcc inhibitory substances appear to be phenotypically 
unique. For example, standard bacteriocin assays are highly successful when applied to 
most species of Gram-negative bacteria (Pugsley & Oudega, 1987; Riley et al., 2003). 
And yet, these methods are far less effective when applied to Bcc. Most intriguing was 
the complete loss of all inhibitory activity in Bcc cell free extracts when extracts are 
concentrated 20-fold concentrations. Inhibitory activity was not recovered despite its 
presence on plate-based screens. In fact, the most successful protocols for obtaining Bcc 
inhibition involved concomitant growth of both the producer and sensitive strains on a 
solid surface. Perhaps inhibition production requires severely restricted resources and/or 
high levels of competition. An alternative explanation could be the presence of unstable 
phage particles in lysates from producer strains (Summer et al., 2004). We note that we 
were unable to propagate bacteriophage activity, only one Bcc strain was clearly shown 
to inhibit via phage (Figure 2-3). Recent studies on the bacteriophages of Bcc revealed 
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that bacteriophages are able to inhibit different Bcc genomovars. However, these phages 
had a relatively limited ability to inhibit Pa strains (Langley et al., 2003; Seed & Dennis, 
2005).  Clearly, this intriguing loss of inhibitory activity for the majority of Bcc 
producers requires further investigation. 
Pa strains are usually the persistent, resident bacterial species in the adult CF 
lung. A recent study revealed a clear example of how R-pyocins may play a role in 
mediating intra-specific competition and succession of Pa strains (Heo et al., 2007). 
Further, pyocin production has been shown to impact intra-specific interactions in mixed 
biofilms (Waite & Curtis, 2009). It is rare for a Bcc strain to be able to invade these 
established populations. In the relatively infrequent cases of co-existence, (i.e. the paired 
strains in this study), the Pa and Bcc strains are usually unable to inhibit each other. Only 
two Pa (via RF pyocins) and none of the Bcc strains in this study were able to inhibit 
their pair-mates (Table 2-1 and Figure 2-4). This observation may simply reflect the 
outcome of prior competition, if one or the other was able to inhibit the invader or 
resident strain, they would not now coexist. Clearly most unpaired Pa and Bcc strains can 
inhibit each other (75% vs. 62%, respectively) even while the pair mates cannot (Table 2-
1). 
Future efforts will focus on two significant features of bacteriocin biology 
revealed by this study. First, it is surprising that no molecular investigations of 
cepaciacins exist. Given the importance of Bcc in human disease, the presence of these 
potent toxins should have generated prior interest. In contrast, numerous studies have 
focused on the characterization of pyocins. Preliminary studies designed to provide a 
molecular characterization of cepaciacin identified here caution us that this may not be a 
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simple exercise. To date, our efforts have not yet resulted in a single cloned cepaciacins, 
or even a bacteriocin-like inhibitory function from these Bcc strains. Second, the 
suggestion that bacteriocin-like inhibition may play a role in mediating strain dynamics in 
the CF lung serves as inspiration for future studies designed to characterize the potential 
of these narrow spectrum antimicrobials to serve in future CF therapeutics. Clearly, such 
toxins are able to mediate inter-specific interactions of Pa and Bcc. Whether we can 
employ these toxins for our own purposes in a clinical setting remains to be seen. 
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 Table 2-1. Inhibitory activity of Pa and Bcc from the CF lung 
 
 
 
 
 
 
 
 
        
 
           *PI: Paired isolates; ‡UPI: Unpaired isolates. NA: Not applicable 
 
 
 
 
 
 
 
 
 Number of Pa isolates (%) Number of Bcc isolates (%) 
 
PI* 
n=14  
UPI‡ 
n=24  
Total 
N=38  
PI* 
n=7  
UPI‡ 
n=21  
Total 
N=28  
No inhibition 0 (0) 1 (4) 1 (3) 4 (57) 5 (24) 9 (32) 
Inhibits only Pa 1 (7) 5 (21) 6 (16) 0 (0) 4 (19) 4 (14) 
Inhibits only Bcc 1 (7) 1 (4) 2 (5) 0 (0) 3 (14) 3 (11) 
Inhibits both Pa and Bcc 12 (86) 17 (71) 29 (76) 3 (43) 9 (43) 12 (43) 
Total inhibition 14 (100) 23 (96) 37 (97) 3 (43) 16 (76) 19 (68) 
Paired inhibition 2 (14) NA 2 (5) 0 (0) NA 0 (0) 
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Table 2-2 Bacteriocin phenotypes of clinical Pa and Bcc strains 
 
 
  * Pa: Pseudomonas aeruginosa; Bcc: Burkholderia cepacia complex 
                  ‡ S type pyocins: S1, S2, S3, AP41; RF type pyocins: R2, R4, F2, F3 
 
 
 
 
  
 
 
Producer 
species* 
Phenotype 
designation 
 
Bacteriocin phenotype‡ Number of strains 
Average 
number of 
Pa inhibited  
Average  
number of 
Bcc inhibited  
Total number 
of strains 
inhibited 
Pa I S1, S2, S3, AP41, R2, R4, F2, F3 10 19 12 31 
Pa II S1, S2, AP41, R2, R4, F2, F3 12 16 7 23 
Pa III S1, R2, R4, F2 1 18 26 44 
Pa IV S1, R2, R4, F2, F3 2 5.5 1 6.5 
Pa V S1, S3, AP41, R2, R4, F2, F3 1 6 3 9 
Pa VI S1, S2, AP41 2 8.5 8.5 17 
 
 
 
Pa 
 
Pa VII - 9 1.8 0.6 2.4 
Bcc I S1, S2, AP41, F3 1 6 4 10 
Bcc II F3 1 4 2 6 
Bcc III R2, F2 1 1 2 3 
 
Bcc 
Bcc IV - 15 2.8 3 5.8 
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Table 2.3 S-pyocin sensitivity of clinical Pa and Bcc strains 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
‡ Phenotypes are according to sensitivity to S-pyocin producing clones, 
e.g. S1: only S1 sensitivity; S1, S2: S1 and S2 sensitivity
Source of pyocin Pyocin sensitivity phenotype‡ 
Number of Pa 
strains (%) 
       n=38  
Number of Bcc 
strains (%) 
 n=28  
S1 3 0 
S2 0 0 
S3 13 0 
AP41 5 0 
S1, S2 6 0 
S1, S3 0 0 
S1, AP41 1 0 
S2, S3 0 0 
S2, AP41 0 0 
S3, AP41 3 0 
S1, S2, AP41 1 0 
S1, S3, AP41 2 0 
S2, S3, AP41 0 0 
S1, S2, S3, AP41 0 0 
Cloned 
S-pyocins 
Total sensitivity 34 (89) 0 (0) 
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Figure 2-1 Genetic organization of exemplar pyocin genes 
 
adapted from Michel-Briand & Baysse, 2002 
a) S3 pyocin: P-box refers to the binding site for PrtN (not shown); The toxin 
gene is divided into four domains, labeled I-IV.  
b) R2F2-pyocin. Arrows indicate the direction of transcription. 
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Figure 2-2 Inhibition haplotypes of clinical Pa and Bcc strains 
Pa and Bcc strains inhibited multiple strains. For example, 12 Pa inhibit 1-10 strains.    
The Bcc isolates have a more limited inhibition range in comparison to Pa isolates. 
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Figure 2-3 Inhibition types produced by clinical Pa and Bcc strains 
Pa strains showed protease sensitive, phage-like, and/or both types of inhibition.         
Most of Bcc strains are nontypable. One Bcc strain showed phage activity. 
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Figure 2-4 Source of the intra- and inter-specific inhibitory activity of clinical Pa 
and Bcc strains 
Source of inhibitory activity of Pa and Bcc are different. In Pa, much of the intra- and 
inter-specific inhibitory activity was due to the activity of S- and RF-type pyocins, In 
Bcc, inhibitory activity is mostly novel or due to RF-like pyocins.  
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Figure 2-5 Pyocin gene distribution in the genomes of clinical Pa and Bcc 
PCR primers were used to screen genomes of clinical Pa for the known S-pyocins (S1, 
S2, S3, AP41) as well as RF pyocins (PRF10-, PRF31, PRF38). All Pa bacteriocin 
producers (100%) possessed one or multiple S- and RF pyocin genes in their genome.  
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CHAPTER 3 
 
CONSTRUCTION OF GENOMIC LIBRARIES TO IDENTIFY PUTATIVE 
GENES INVOLVED IN BACTERIOCIN-LIKE INHIBITORY ACTIVITY OF 
B. CEPACIA COMPLEX  
3. 1 Abstract  
A recent survey revealed a potential role for bacteriocins in mediating bacterial 
interaction in Cystic Fibrosis (CF) lungs. This study showed that 68% of Burkholderia 
cepacia complex (Bcc) strains isolated from lungs of CF patients possess potent 
inhibitory activity, which appears similar to the bacteriocin-like inhibition produced by 
many other bacterial species. Since most adult CF patients have pre-existing 
Pseudomonas aeruginosa (Pa) infections, Bcc strains must either compete with or act in 
synergy with the Pa already established in the lungs. Although this prior study made a 
compelling case for the potential role for these inhibitory substances in mediating 
bacterial interactions in the lungs, it could not identify the substances in question. In this 
study, genomic libraries of B. multivorans, B. dolosa, and B. cenocepacia were 
constructed to screen for genes responsible for the inhibitory activity previously 
described. ~10,000 clones/genome were screened, resulting in fifteen clones with the 
anticipated inhibitory activity. Of these fifteen, only five had stable inhibition activity, 
and were pursued further. These clones encoded proteins involved in various metabolic 
pathways including bacterial apoptosis, amino acid biosynthesis, sugar metabolism, and 
degradation of aromatic compounds. Surprisingly, none possessed typical bacteriocin-like 
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genes. These data suggest that Bcc may use novel inhibitory agents to mediate intra- and 
inter-specific interactions. 
3.2 Introduction 
B. cepacia complex species, most of which are temperate soil saprophytes and 
plant pathogens, are associated with severe, often fatal, pulmonary infections in persons 
with cystic fibrosis. 
                                                                            Summer et al., 2007 
3.2.1 B. cepacia complex (Bcc) 
In 1950, plant pathologist Walter Burkholder showed that Pseudomonas cepacia 
was different from other members of the Pseudomonas genus: they could grow on m-
hydroxy benzoate or tryptamine as carbon sources (Mahenthiralingam et al., 2005). 
Further, they are able to catabolize more than 200 organic carbon sources; demonstrating 
enormous metabolic versatility (Lessie et al., 1996). In 1992, Pseudomonas cepacia, 
Pseudomonas solanacearum, Pseudomonas pickettii, Pseudomonas glandioli, 
Pseudomonas mallei, Pseudomonas pseudomallei, and Pseudomonas caryophylli were 
incorporated into a new genus, Burkholderia, based on 16S rRNA sequences, DNA-DNA 
homology, lipid and fatty acid compositions, and phenotypic characteristics (Yabuuchi et 
al., 1992).   
In 1997, molecular and biochemical assays were performed on 128 tentatively 
classified B. cepacia strains. This study revealed five phenotypically similar, but 
genotypically distinct, Burkholderia species (genomovars), classified as the B. cepacia 
complex (Bcc). These species were named as B. cepacia (genomovar I), B. multivorans 
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(genomovar II), B. cenocepacia (genomovar III), B. stabilis (genomovar IV), and B. 
vietnamiensis (genomovar V) (Vandamme et al., 1997). Later, B. dolosa (genomovar VI), 
B. ambifaria (genomovar VII), B. anthina (genomovar VIII), and B. pyrrocinia 
(genomovar IX) were added to the Bcc (Coenye et al., 2001a; Coenye et al., 2001b; 
Vandamme et al., 2002). 
3.2.2 B. cepacia complex: Friend or Foe? 
Burkholderia species are opportunistic pathogens (Mahenthiralingam et al., 
2005). B. cepacia was the first pathogen identified in the genus. It is the causative agent 
of soft rot in onions (Sotokawa & Takikawa, 2004). Subsequently, B. glumae, B. 
plantarii, B. glandioli, and B. phytofirmans were shown to cause diseases in such 
economically important crops such as rice, maize, potato, and tomatoes (Coenye & 
Vandamme, 2003; Sessitsch et al., 2004). Members of the genus also engage in activities 
that are beneficial to humans, such as serving as bioremediation and biocontrol agents 
(Parke & Gurian-Sherman, 2001). Various species degrade aromatic compounds, crude 
oil, herbicides, and xenobiotics (Sousa et al., 2010). Further, they produce antibiotics and 
iron scavenging siderophores that repress fungal growth (Chiarini et al., 2006; Parke & 
Gurian-Sherman, 2001).  
Members of the genus are also associated with human disease and are responsible 
for numerous nosocomial infections in immunocompromised patients, such as those with 
cancer or HIV (Mann et al., 2010; Verghese et al., 1994). The focus of this study, 
however, is their role in Pa-Bcc interaction in lungs of patients with cystic fibrosis (CF) 
(Mahenthiralingam et al., 2005). Bcc infections in CF patients were first observed in the 
early 1980 (Tablan et al., 1985), and remain relatively rare, only 3% of CF patients are 
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infected with a member of this species complex (CFF, 2008). However, clinical outcomes 
of such infections are both unpredictable and potentially severe, ranging from 
asymptomatic, to chronic, and even fatal infections (Mahenthiralingam et al., 2002; 
Whiteford et al., 1995). Nearly 20% of Bcc infected CF patients develop cepacia 
syndrome, a fatal, rapid onset pneumonia, occurring within days or weeks of their 
introduction into the lung (Govan & Deretic, 1996).  The varied colonization outcomes 
may be due to strain, patient or treatment-based factors. Metabolic versatility, insertion 
sequences, genomic islands, bacteriophages, proteases, and exotoxins in Bcc are potential 
factors, which may serve to enhance their ability to invade and colonize the CF lung 
(Mahenthiralingam et al., 2001; Mahenthiralingam et al., 2005).  
Bcc species have large genomes, up to 6-9 Mb, which are organized as multiple 
chromosomes, with 67% GC content (Holden et al., 2009; Parke & Gurian-Sherman, 
2001).  The number of chromosomes and the total genome size varies among strains as 
well as within a genomovar (Table 3-1). Currently, the genomes of 38 Burkholderia 
strains have been sequenced, eleven of which are members of the Bcc species complex; 
including five strains of B. multivorans, two of B. cenocepacia, two B. ambifaria, one B. 
cepacia, and one B. vietnamiensis (NCBI, ; Pathema).  
Bcc genomes are rich in insertion sequence (IS) elements, which are transposable 
DNA sequences ranging between 700-2500 bp in length.  A recent study revealed one 
strain with 79 IS elements in its genome (Holden et al., 2009). IS elements are capable of 
inserting themselves at multiple sites in the genome, leading to a variety of genetic 
rearrangements such as duplications, deletions, and inversions. Studies have revealed that 
several IS elements in P. cepacia can activate gene expression (Wood et al., 1991) and 
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play a role in plasmid rearrangement (Byrne & Lessie, 1994). The presence of IS 
elements is proposed as one of the major driving forces of the versatility and adaptation 
of bacteria in different environmental niches (Mahillon & Chandler, 1998; Mira et al., 
2002). 
Genomic islands (GI), which are clusters of genes in bacterial genomes also 
involved in adaptation of bacteria in different environments as well as involved in 
virulence, antibiotic resistance, and other metabolic processes (Hacker & Carniel, 2001). 
GIs range in size from 10-100 kb in length and are often associated with horizontal gene 
transfer events (Hacker & Carniel, 2001). These islands are often called pathogenicity 
islands (PI), if the genes are associated with increased pathogenicity.  
Bcc genomes are rich in genomic islands. Fourteen GIs were identified in the 
recently published genome of B. cenocepacia J2315, distributed across all three 
chromosomes, some of which are unique to epidemic strain (Holden et al., 2009). One 
GI, cci, encodes virulence and metabolism genes, including arsenic and antibiotic 
resistance genes, quorum sensing genes, amino acid and fatty acid metabolism genes, and 
transcriptional regulator genes (Baldwin et al., 2004; Holden et al., 2009).  A second, 
BcenGI2 possesses genes that code for plasmid conjugation, while others, BcenGI9, 12, 
and 13, encode prophage genes (Baldwin et al., 2004; Holden et al., 2009). 
The presence of bacteriophages in pathogen genomes is frequently associated 
with enhanced virulence (Wagner & Waldor, 2002). Bacteriophages can be lytic or 
lysogenic. Lytic phages can multiply in host cells using the host’s transcription and 
translation machinery. The host cell is then lysed, disseminating phage progeny.  
Lysogenic phages integrate their DNA into the host chromosome; there is no subsequent 
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phage multiplication or host cell lysis. The phage DNA in this repressed state is called a 
prophage because it has the potential to produce phage progeny (Casjens, 2003; Synder & 
Champness, 2003). The host is not apparently adversely affected by the presence of 
prophage and the phage may persist in this state until induction by the presence of an 
inducing agent such as UV or oxidative stress (Barnhart et al., 1976; Los et al., 2010).  
 A number of bacteriophages have been isolated from members of Bcc strains. 
These include lysogenic (BcepMu, KS8, KS9, KS10, KS11, BcP15, DK4, CP1, CP75) 
and lytic (KS1, KS2, KS3, KS5, KS6) phages (Cihlar et al., 1978; Hens et al., 2005; 
Langley et al., 2005; Matsumoto et al., 1986; Summer et al., 2004; Summer et al., 2006).  
Seed et al., 2005 performed a study to determine the host range of these bacteriophages 
by infecting 24 strains from the Bcc complex with them. The study revealed that the lytic 
bacteriophages (KS1, KS5, and KS6) have broader host ranges, including B. cepacia, B. 
multivorans, B. cenocepacia, B. ambifaria. The lysogenic phages are restricted to a more 
limited number of host species, including B. cenocepacia and B. ambifaria (Seed & 
Dennis, 2005).  
Genomes of some bacteriophages in Bcc do encode putative proteins, which may 
be potential virulence factors involved in host cell lysis. Gene 53 from epidemic strain B. 
cenocepacia ET12 encodes acyltransferase, which modifies lipopolysaccaharides (LPS), 
resulting in strain serotype conversion. The gp8 gene from the same strain resembles the 
ExeA protein of Aeromonas hydrophilia, which is involved in the secretion of toxins such 
as aerolysin (Summer et al., 2007).  
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3.2.3 Burkholderia and Pseudomonas interaction 
P. aeruginosa (Pa) is the predominant infectious agent in the lungs of adult CF 
patients (Govan & Deretic, 1996), found in approximately 30% of infants and 80% of 
adult CF patients (CFF). Chronic Pa infection is one of the primary health concerns for 
adult CF patients, ultimately resulting in death of the patient (Lyczak et al., 2002).  
Secondary Bcc infections have become a major concern over the past 30 years 
(Tablan et al., 1985). Although all Bcc species can infect the lung, B. multivorans and B. 
cenocepacia are the species most frequently identified, with a prevalence of 38% and 
50%, respectively (LiPuma et al., 2001). In most cases, Bcc acquisition occurs in CF 
patients already colonized with Pa (Govan & Deretic, 1996). During this secondary 
infection it has been suggested that Bcc strains directly compete with the established Pa 
strains, although it is not known how such interactions occur. However, it is clear that 
Bcc-Pa co-infections are rare, suggesting that Bcc strains can successfully compete with 
and displace the resident Pa strains (Lambiase et al., 2006; McManus et al., 2004).  
Unfortunately, few studies have focused on these multi-species bacterial 
interactions in the CF lung. What we do know from the limited studies available is that 
strain replacement is only observed among members of Bcc (Govan et al., 1993; Ledson 
et al., 1998; Mahenthiralingam et al., 2001). A recent study revealed that in ~7% of CF 
patients examined, Bcc strains are replaced over time with other species of Bcc 
(Bernhardt et al., 2003). Further, Yang et al., 2006 revealed that co-infection with more 
than one Bcc strain may occur in the early phases, but is rare after the development of a 
chronic infection (Yang et al., 2006). None of these studies focused on the factors that 
mediate such interactions. 
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Bacterial antagonism is common due to competition for limiting resources. Iron is 
one of the main limiting factors, which bacteria utilize during colonization and invasion.  
Weaver and Kolter have shown that members of the Bcc species complex compete more 
effectively for iron than strains of Pa (Weaver & Kolter, 2004). They investigated the 
effect of Bcc presence on Pa gene expression by incubating the Pa strain in the presence 
and absence of a Bcc cell free extract. Pa virulence gene expression is enhanced by the 
presence of Bcc in iron-limited environments. Further, their data showed that the Bcc 
iron scavenging siderophore (ornibactin) limits available iron to Pa, leading the induction 
of Pa virulence genes (Weaver & Kolter, 2004).  
Bacteriocin production is another factor mediating bacterial antagonistic 
interactions. Aside from one recent study (Bakkal et al., 2010), there are no additional 
publications that focus on the effect of bacteriocin production on bacterial interactions in 
the CF lungs.  The Bakkal et al., 2010 study revealed bacteriocin production in 97% of 
Pa and 68% of Bcc strains isolated from CF lungs (Bakkal et al., 2010). In Pa, much of 
the inhibitory activity was shown to be due to S- and RF-type pyocins, bacteriocins of Pa. 
In Bcc, the source of inhibitory activity appears to be bacteriocin-like, but no bacteriocins 
of Bcc (cepaciacins) have been described (Bakkal et al., 2010).  
The goal of the present study is to identify the sources of the observed Bcc 
inhibitory activity. Three genome libraries were created from B. multivorans, B. dolosa, 
and B. cenocepacia and screened for inhibition against sensitive Pa and Bcc strains. Five 
clones from the B. multivorans library had inhibitory activity against the Pa strain. DNA 
sequences of these clones were determined and their putative functions were identified. 
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They include bacterial apoptosis, amino acid biosynthesis, sugar metabolism, and 
degradation of aromatic compounds.  
3.3 Materials and Methods 
3.3.1 Bacterial strains  
Genomic libraries were prepared from B. multivorans (ATCC 17616), B. dolosa 
(AUO158), B. cenocepacia (02-228-1429). Pseudomonas aeruginosa (327-6-1422), B. 
vietnamiensis (03-260-0635), and B. dolosa (04-053-0423) were used as sensitive lawns 
to detect inhibitory activity produced during the library screen (Bakkal et al., 2010). The 
genomes of Pseudomonas aeruginosa (PAO1), which encodes pyocin S2, and 
Pseudomonas aeruginosa (NIH3), which does not encode bacteriocins, served as positive 
and negative controls during the library screens (Bakkal et al., 2010, ; Matsui et al., 1993; 
Nakayama et al., 2000) PA01 produces a pyocin (S2). Escherichia coli XL1 Blue MRF’ 
(Stratagene, Agilent Technologies) was used as the recipient strain for the genomic 
libraries.  
3.3.2 Construction of genomic library 
Genomic libraries were constructed according to the method described in Ausubel 
et al., 2004 (Ausubel et al., 2004). Genomic DNA was produced using the Gentra 
Puregene kit (QIAGEN), with the gram-negative DNA isolation protocol and 5X109 cells 
from an overnight culture. Bam HI (10 U/µl; NEB) and/or Bfu CI (10 U/µl; NEB) were 
used to partially digest the genomic DNA at 37 0C for 30-50 minutes. The reaction was 
terminated by incubation at 65 0C and then run on a 0.6% SEAKEM® GTG agarose gel 
(FMC BioProducts) at 80 V for 5 hours. DNA fragments in the size range of 4-5 kb were 
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isolated from the gel using the QIAquick gel extraction kit (QIAGEN). These fragments 
were then ligated into a BamHI digested and dephosphorylated pUC19 plasmid vector 
(NEB) (Figure 3-1). The ligated DNA was chemically transformed into E. coli XL1 Blue 
MRF’ supercompetent cells (Stratagene, Agilent Technologies) (Figure 3-1). Blue/white 
colony screening was carried out on Luria Broth (LB) plates supplemented with 100 
µg/µl ampicillin (Sigma), 40 mM IPTG (Sigma), and 0.08% X-Gal (Sigma).  X-gal 
(bromo-chloro-indolyl-galactopyranoside) is a colorless substrate, which is metabolized 
by β-galactosidase to form an insoluble blue product (5-bromo-4 chloroindole). IPTG 
(Isopropyl β-D-1-thiogalactopyranoside) is used to induce transcription of the gene coding 
for β-galactosidase. If the ligation is successful, the insert DNA will interfere with the 
transcription of the β-galactosidase gene, resulting in white bacterial colonies; if the 
ligation is unsuccessful, the colonies will appear blue (Figure 3-1).  
3.3.3 Phenotypic screening of genomic clones 
The patch assay was used to identify Pa and Bcc inhibitory activity among the 
genomic clones. Strains were grown overnight in 10 ml LB at 37 0C, shaken at 250 rpm. 
Six ml of LB top agar (0.6%, w/v) mixed with 100 µl of 10 mM IPTG, and 100 µl of 
sensitive cells (108 cells) were plated as a lawn on an LB plate. All resulting white 
colonies from the genomic library were spotted on the sensitive Pa and/or Bcc lawn by 
toothpick. B. multivorans (ATCC17616) and XL1 Blue MRF’ transformed with pUC19 
plasmid were spotted on each lawn as positive and negative controls, respectively. After 
overnight incubation at 37 0C the plates were scored for the presence of inhibitory 
activity. More than 10,000 white colonies were screened per genomic library, resulting in 
2-fold coverage of each genome. Each positive clone was screened a second time. 
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Plasmids were isolated from overnight cultures of genomic clones with putative 
inhibitory activity, and digested with EcoRI (10 U/µl; NEB) to identify the presence or 
absence of the DNA insert. Finally, inhibition phenotypes of the genomic clones were 
visualized and photographed using a Leica MZ 16 FA fluorescent dissecting scope.  
3.3.4 Nucleotide sequencing 
Plasmid DNAs were isolated from overnight cultures of genomic clones using a 
plasmid isolation kit (QIAGEN). Plasmid DNAs were sequenced using Big Dye 
Terminator Cycle Sequencing mix with pUC19-forward (5’-AGC GGA TAA CAA TTT 
CAC ACA GGA-3’) and pUC 19- reverse (5’-CGC CAG GGT TTT CCC AGT CAC 
GAC-3’) primers (Applied Biosystems, Foster City, CA). The sequencing reaction was 
performed at 96 oC for 1 min, followed by 96 oC for 30 sec, 50 oC for 15 sec, and 60 oC 
for 4 min through 25 cycles. Homology searches were performed using the NCBI 
nucleotide–nucleotide Blast (blastn) algorithm on the combined GenBank/EMBL/DDBJ 
database. Further, gene annotations were performed via SEED, which is an annotation 
and analysis tool provided by the fellowship for interpretation of genomes (University of 
Chicago).  
3.4 Results 
3.4.1 Genomic Library Construction 
The Bcc species chosen for this study represent the most frequently isolated 
species from CF patients. B. multivorans and B. cenocepacia are isolated from 38% and 
50% of CF patients, respectively (LiPuma et al., 2001). The incidence of B. dolosa from 
CF patients is only 2% (Coenye et al., 2001a), but it is one of the most frequently isolated 
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species (39%) from our previous phenotypic bacteriocin screening study (Bakkal et al., 
2010). 
Partially digested genomic DNAs of B. multivorans (ATCC17616), B. dolosa 
(AUO158), and B. cenocepacia (02-228-1429) were ligated to BamHI digested and 
dephosphorylated pUC19 plasmids to construct genomic libraries of these strains. The 
genomes of B. multivorans (ATCC 17616) and B. dolosa (AUO158) have previously 
been sequenced and annotated in NCBI (NCBI, ; Pathema).  
The Pa strain, PAO1, was used as a positive control in the genomic library 
construction. Pa PAO1 produces pyocin S2, an S-type bacteriocin (Seo & Galloway, 
1990). It has been shown that PAO1 inhibits the growth of Pa NIH3 via the DNAse 
activity of pyocin S2. Thus, Pa NIH3 was used as a lawn to detect the pyocin S2 activity 
of the corresponding genomic clones of Pa PAO1.  
Approximately 10,000 white colonies/genome were screened on sensitive lawns 
of PA01 and Bcc strains. A total of fifteen clones with inhibitory activity were identified, 
twelve from B. multivorans (ATCC 17616), two from B. dolosa (AUO158), and one from 
B. cenocepacia (02-228-1429). Additionally, three clones were identified from the 
genomic library of PAO1, the positive control for screening. 
3.4.2 Phenotypic screening of genomic clones 
The phenotypic bacteriocin assay was repeated to verify inhibitory phenotypes of 
these fifteen genomic clones. Only six clones (Table 3-2) produced repeatable inhibitory 
activity (Figure 3-2a), five from B. multivorans (ATCC17616) and one from Pa (PAO1) 
(Figure 3-2a). B. multivorans (ATCC17616) showed an inhibition phenotype on a 
sensitive lawn of P. aeruginosa (327-6-1422), which consisted of the inhibition of growth 
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of the sensitive lawn under the producer Bcc colony (Figure 3-2b). Thus, the killing 
phenotype was defined as the loss of visible lawn growth under the putative producer 
clone. Genomic library clones (clones 2, 4, 6, 7, and 9) of B. multivorans (ATCC17616) 
possessed the described inhibitory phenotype (Figure 3-2a).   
Pa (PAO1) showed an inhibition phenotype on the sensitive lawn Pa (NIH3) 
(Figure 3-2b). This phenotype consists of a thin inhibition zone around the producer 
PAO1 colony. The PAO1 genomic colony also possessed the same phenotype as the 
pyocin S2 producer Pa (PAO1) (Figure 3-2a).  
3.4.3 Nucleotide sequencing 
Forward and reverse sequencing primers of the pUC19 plasmid were used to 
sequence the clones. The resulting DNA sequences were employed in BLAST screens 
against existing genome sequences of B. multivorans (ATCC17616) and Pa (PAO1) 
(Table 3-2).  
Genomic clone 2 had an insert of 714 nucleotides (nt), located on chromosome 1 
of B. multivorans (ATCC17616). The NCBI blast showed that the DNA sequence 
corresponded to the DNA sequence of a hypothetical protein (Bm 1615) with an 
unknown function (Figure 3-3a). The flanking DNA sequences of Bm1615 encode 
another hypothetical protein (Bm1614) and a membrane protein (seven transmembrane 
helix protein) (Bm1616) (Figure 3-3a). The DNA sequence alignment of Bm1615 and 
clone 2 has shown that DNA sequence of the clone 2 covered majority of the hypothetical 
protein (453 nt) including its start codon (Figure 3-3b). Finally, the last 22 nt of Bm1516 
are excluded in the clone 2.  
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Clone #4 had a DNA insert of 3,498 nt, containing genes encoding poly-beta-
hydroxyalkanoate depolymarase, glucoamylase, and 3-carboxymuconate cyclase proteins 
(Figure 3-4a). These genes are also located on chromosome 1 of B. multivorans 
(ATCC17616).  
Glucoamylase is an extracellular enzyme, common in fungus Aspergillus. This 
enzyme hydrolyzes starch into glucose via catalyzing hydrolysis of α-1,4 and α-1,6 
glycosidic bond (Sauer et al., 2000). Glucoamylase also induces biosynthesis of fungus 
toxin (aflatoxin), which causes infection in plant tissue (Mellon et al., 2007). Genomic 
clone 4 contained 1929 nt of DNA sequence, encoding full length glucoamylase enzyme 
(Figure 3-4b)  
The DNA insert of clone 4 also possessed partial DNA sequences, encoding poly-
beta-hydroxyalkolonate depolymerase and 3-carboxymuconate cyclase (1222 nt and 210 
nt, respectively)(Figure 3-4a and b). Both enzymes are involved degradation of aromatic 
hydrocarbons.  
Poly-beta-hydroxyalkolonate depolymerase is an enzyme involved in degradation 
of polyhydroxyalkanoates (PHAs) (Madison & Huisman, 1999). PHAs are biopolyesters, 
which are synthesized by Archea, Gram-positive, and Gram-negative bacteria in response 
to nutrient limitations. Bacteria accumulate PHAs into inclusion bodies and store them in 
their cytoplasm. The PHAs are then degraded via enzymatic reaction and used as carbon 
and energy resources (Madison & Huisman, 1999). 
3-carboxymuconate cyclase is also among the enzymes, responsible for 
degradation of aromatic hydrocarbons. It is one of the enzymes in the 3-oxodipate 
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pathway in fungi and bacteria. The 3-oxodipate pathway involves the conversion of 
hydroxybenzoate and catechol to succinate and acetyl-CoA (Cook & Cain, 1974). 
Clone # 6 consisted of a 677 nt insert, which corresponded to a partial DNA 
sequence of amidohydrose II and 4-hydroxybenzoate transporter (285 nt and 423 nt, 
respectively) (Figure 3-5a and b). These genes are located on chromosome 3 of B. 
multivorans (ATCC17616). 
Amidohydrolase II belongs to the functional category of enzymes with unknown 
specificity (Pathema). The protein belongs to the amidohyrolase superfamily consisting 
of hydrolase enzymes that catalyzes the cleavage of C-N, C-C, C-O, C-Cl, C-S, O-P 
bonds of organic substances. The group includes 771 enzymes, which are known to 
catalyse nonhydrolytic reactions including decarboxylation and hydration (Aimin et al., 
2007).  
4-hydroxybenzoate transporter is also involved degradation of aromatic benzoate. 
This enzyme belongs to beta-ketoadipate pathway, which degrades 4-hydrozybenzoate to 
succuniyl-CoA and Acetyl-CoA (Wright, 1993). 
The blast result of clone 7 contained a 3,956 nt long DNA sequence, 
corresponding to the DNA sequence encoding 3-isopropyl malate dehydrogenase (1066 
nt), 3-isopropyl malate dehydratase small subunit (651 nt), 3-isopropyl malate 
dehydratase large subunit (411 nt), aspartate semialdehyde dehydrogenase genes (1122 
nt), and entericidin AB (132 nt) (Figure 3-6a and b). These genes are possessed by 
chromosome 2 of B. multivorans (ATCC17616). 
3-isopropyl malate dehydrogenase, 3-isopropyl malate dehydratase small subunit, 
and 3-isopropylmalate dehydratase large subunit are among the enzymes responsible for 
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leucine biosynthesis. Leucine biosyntesis requires expression of four contigious genes- 
leuABCD as a single operon in E. coli. The leuA and leuB genes encode 2-
isopropylmalate synthetase and 3-isopropylmalate dehydrogenase, respectively. The leuC 
and leuD genes encode large and small subunits of isopropylmalate dehydratase 
(Tamakoshi et al., 1998). In some organisms, organization of these genes could be 
different. For example, leuB is located separately from leuACD in Leptospira interrogans 
(Ding & Yelton, 1993).  
3-Isopropylmalate dehydrogenase belongs to a family of metal dependent 
decarboxylating dehyrogenase enzymes. Thus, this enzyme requires divalent cations 
(Mg+2 or Mn+2) to become active. 3-Isopropylmalate dehydrogenase catalyzes the 
conversion of 3-isopropylmalate to 2-isopropyl-3-oxosuccinate (Hurley & Dean, 1994). 
3-isopropylmalate dehydratase (or isopropylmalate isomerase) is composed of 
large (Leu C) and small (LeuD) subunits, which catalyzes isomerisation of 2-
isopropylmalate and 3-isopropylmalate, via the formation of 2-isopropylmaleate. This 
enzyme performs the second step in the biosynthesis of leucine, and is present in most 
prokaryotes and many fungal species. 
Aspartate semialdehyde dehydrogenase is one of the enzymes in lysine 
biosythesis pathway. It catalyzes the conversion of beta-aspartly phosphate to L-aspartate 
beta-semialdehyde, which is ultimately converted to L-lysine (Tunca et al., 2004).  
Finally, this clone encodes for entericidin AB, which is a toxin-antitoxin gene pair 
involved in bacterial apoptosis in E. coli (Bishop et al., 1998). Entericidins are small, 
amphipathic alphahelical cationic lipoproteins, which bind to membrane 
phosphospholipids. The genes are induced in stationary phase, when cells are starved for 
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energy. The producing cell is lysed due to the resulting disruption in membrane stability 
(Bishop et al., 1998). 
Blast result of clone # 9 corresponded to 37 nt long sequence of the GGDEF 
domain, which is 1479 nt long (Figure 3-7a and b). The GGDEF is a conserved domain 
with unknown function, located on chromosome 1 of B. multivorans (ATCC17616) 
(Pathema). This domain is found in a diversity of bacteria (Pei & Grishin, 2001). It has 
been suggested that the domain is observed in multi-domain proteins such as those 
involved in signaling pathways. For example, diguanylate cyclase (DGC) is an enzyme 
involved in the synthesis of c-di-GMP, which is a secondary messenger involved in 
various cellular processes including cell-to-cell signaling, motility, virulence, biofilm 
formation, and antibiotic production (Tamayo et al., 2007). 
Finally, the genomic clone of Pa (PAO1) had an insert of 4089 nt, which encodes 
an hypothetical protein, pyocin S2 toxin, and immunity proteins (Figure 3-8 a and b). 
Pyocin S2 is one of the S-type pyocins found in Pa(Michel-Briand & Baysse, 2002). The 
genomic clone of PAO1 has DNA sequence, which covers the pyocin S2 toxin gene 
(Pa1152) and the pyocinS2 immunity gene (Pa1153), which provides immunity to pyocin 
S2 (Figure 3-8b).  
3.5 Discussion 
Patients with CF suffer from chronic lung infections that are associated with high 
mortality (Lyczak et al., 2002). During infancy, the patient’s airways and lungs are 
colonized intermittently with several species of bacteria, including Haemophilius 
influenzae (H. influenzae), Staphylococcus aureus (S. aureus), Pseudomonas aeruginosa 
(Pa), and B. cepacia complex (Bcc) (Hutchison & Govan, 1999). Infections may become 
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chronic, resulting in decreased lung capacity, continuous inflammation and ultimately 
result in the death of the patient (Govan & Deretic, 1996; Lyczak et al., 2002).  
CF patients’ susceptibility to particular pathogen species may be age-related 
(Govan & Deretic, 1996). H. influenzae and S. aureus colonize the lungs of infants 
primarily, but can be found in the lungs through early childhood (Gibson et al., 2003). Pa 
tends to colonize older patients, but can be found in up to 30% of young patients (2008). 
Early Pa colonizers are planktonic (free living) and these infections are relatively easily 
treated with broad-spectum antibiotics, usually a combination of beta-lactamases and 
aminoglycosides (Hansen et al., 2008). Over time, alginate-forming mucoid Pa variants 
emerge and dense biofilms develop in the lungs, resulting in chronic lung infections. 
These chronic, biofilm-based infections are difficult to eradicate since the biofilms 
enhance the innate antibiotic resistance of the strains (Hentzer et al., 2001).  
In the past thirty years, Bcc has emerged as a lung pathogen in CF patients 
(Govan & Deretic, 1996). Members of the species complex naturally reside in soil and on 
plants (Mahenthiralingam et al., 2005). Bcc is known for its metabolic versatility, which 
may contribute to its ability to survive, and even thrive, in numerous environments, 
including the human lung. Although the prevalence of Bcc lung infections is low (~3% of 
CF patients), the clinical outcomes are unpredictable and can be quite severe (Kalish et 
al., 2006). A small portion of those infected (20%) develop cepacia syndrome, which is a 
necrotizing pneumonia, leading to rapid lung failure and death (Jones et al., 2004; Kalish 
et al., 2006; Tablan et al., 1985).  
Bcc strains that invade the CF lung face numerous challenges, such as evading the 
host immune system, competing with the resident bacteria and colonizing the host tissue. 
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The focus of this study was an exploration of the virulence factors that play a role in one 
feature of Bcc invasion, the competition between Bcc and the bacteria already resident in 
the patient’s lungs. 
Bcc colonization usually involves competition with a resident strain of Pa (Govan 
& Deretic, 1996). In such a scenario, two kinds of species interactions may occur, 
synergism and antagonism, resulting in either co-infection or extinction of one species. 
The incidence of co-infection is quite low (Lambiase et al., 2006; McManus et al., 2004). 
In either case, the presence of Pa has been shown to have a detectable impact on Bcc, 
such as the promotion of virulence gene expression (Riedel et al., 2001). Riedel et al. 
2005 revealed that Bcc recognizes acylated homoserine lactones (AHLs) secreted by Pa, 
which are small molecules that induce expression of genes in Bcc involved in virulence 
and biofilm formation. The AHL recognition is unidirectional, Bcc recognizes AHL’s 
produced by Pa, while no recognition of Bcc AHLs by Pa is detected (Riedel et al., 
2001).  
 Another factor known to impact bacterial interactions is the production of 
bacteriocins, which are potent toxins produced by bacteria to kill the strains of the same 
or related species (Riley & Wertz, 2002a; Riley & Wertz, 2002b). Studies in which 
bacteria are competed in vitro (on petri plates) and in vivo (in the mouse colon) reveal 
that bacteriocins are highly effective in mediating intra- and inter-specific competition, 
(Bakkal et al., 2010; Michel-Briand & Baysse, 2002).  
Pa is a prolific producer of bacteriocins, with more than 90% of the strains 
assayed identified as producers (Fyfe et al., 1984). In contrast, far fewer strains of Bcc 
(~30%) produce bacteriocins (Govan & Harris, 1985). A survey of bacteriocin production 
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was undertaken with strains isolated from the lungs of CF patients. This study revealed 
that 97% of Pa and 68% of Bcc strains produce bacteriocin-like inhibitory activity 
(Bakkal et al., 2010).  
Detailed studies of Pa bacteriocin production have resulted in the identification of 
three pyocin types: S, R, and F (Michel-Briand & Baysse, 2002). S-pyocins are high 
molecular weight proteins, which possess DNAse activity to inhibit (Sano & Kageyama, 
1981; Sano & Kageyama, 1984; Sano et al., 1993a; Sano et al., 1993b). RF pyocins 
resemble phage tails, which depolarize the cell membrane (Nakayama et al., 2000). The 
bacteriocins of Bcc have not been studied extensively. In fact, there is no molecularly 
characterized Bcc bacteriocin. One available phenotypic study revealed that Bcc 
bacteriocins resemble phage tails (Govan & Harris, 1985) 
We employed genomic library screens of B. multivorans, B. dolosa, and B. 
cenocepacia to understand how Bcc mediates its interactions with Pa in the CF lung. The 
screening involved lawns of sensitive Pa and Bcc strains (Bakkal et al., 2010). Fifteen 
clones, from three Bcc genomic libraries, possessed a putative inhibitory activity as 
revealed by inhibition zones on the sensitive lawns. However, the activity was lost in ten 
of the clones in subsequent replications of the screen. We also lost the inhibitory activity 
of two Pa PAO1 genomic clones (three clones identified in total).  
The loss of inhibitory activity in ten Bcc and two Pa genomic clones can be 
explained simply by the absence of DNA sequence encoding immunity protein in 
genomic clones. In most bacteria, an immunity gene follows the bacteriocin gene (toxin), 
which are transcribed and translated together in bacteria. Immunity protein confers 
resistance to the toxin and thus, producer bacteria are immune to the produced bacteriocin 
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(Riley & Wertz, 2002a; Riley & Wertz, 2002b). Therefore, absence of immunity gene in 
genomic clones may result the lysis of E. coli recipient due to the toxicity of the cloned 
protein(s). Indeed, one Pa PAO1 genomic clone possessed DNA, encoding both pyocin 
S2 and corresponding immunity protein (Figure 3-8). In this clone, we observed clear 
inhibition of the sensitive lawn (Figure 3-2). Another reason of the loss of inhibitory 
activity might be the toxicity of Bcc and Pa bacteriocins (or novel toxins) to E. coli 
recipient. However, the bacteriocin producer Bcc and Pa strains were previously tested on 
E. coli XL1 Blue MRF’ recipient. E. coli XL1 Blue MRF’ recipient did not show 
sensitivity against these Pa and Bcc strains, which were used in genomic library 
construction.  
The DNA isolated from the remaining five clones of B. multivorans was 
sequenced. The genes identified correspond to four major functional categories: amino 
acid biosynthesis, sugar metabolism, degradation of aromatic compounds, and bacterial 
apoptosis (Table 3-2). 
3.5.1 Amino Acid and Sugar Metabolism 
An NCBI BLAST of the Bcc clones resulted in identification of genes for amino 
acid and sugar metabolisms. 3-isopropyl malate dehydrogenase, 3-isopropyl malate 
dehydratase small subunit, 3-isopropylmalate dehydratase large subunit, and aspartate 
semialdehyde dehydrogenase are involved in leucine and lysine biosynthesis (Black & 
Wright, 1954). The screen also revealed a sequence with homology to glucoamylase, a 
hydrolytic enzyme involved in sugar metabolism in fungus and bacteria, which converts 
starch into glucose (Sauer et al., 2000). Further, this enzyme is involved the induction of 
a fungal toxin (aflatoxin). Thus, glucoamylase might have similar function in Bcc and 
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causes induction of toxin genes. Partial aflatoxin gene (Genbank accession number: 
AY864289.1) was blasted against 38 sequenced Bcc genomes to identify if these 
genomes possess aflatoxin-like proteins. However, none of these genomes have proteins, 
which share homology with aflatoxin of fungus Aspergillus.  
3.5.2 Degradation of aromatic compounds 
The BLAST search of the genes (4-hydroxybenzoate transporters, poly-beta 
hydroxyalkonate) encoded in the Bcc genomic clones also revealed enzymes involved in 
degradation of aromatic compounds such as benzoate and polyhydroxyalkanoates 
(Nichols & Harwood, 1995). It is not clear how are these proteins can be involved in 
mediating Bcc competition in the CF lung? The primary reason of metabolizing toxic 
aromatic compounds is that they are used as energy sources where the nutrients are 
limited (Madison & Huisman, 1999). Thus, the presence of a competitor strain (Pa) in 
nature, as well as on solid LB agar medium, or even in a biofilm in the CF lung, may 
induce their expression, resulting in inhibition of Pa growth. It is also possible that the 
encoded proteins have secondary functions, which result in Pa inhibition.  
3.5.3 Bacterial apoptosis 
The BLAST search revealed the presence of a bacterial apoptosis gene 
(entericidinAB) (Bishop et al., 1998). Entericidins are produced at stationary phase, 
where nutrients are limited. These proteins bind to membrane phosphospholipids, and 
inhibit the cells via disruption of membrane stability (Bishop et al., 1998). No further 
functional information is known about entericidin AB in Bcc. 
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The gene organization of the locus is similar to that of the bacteriocins of 
numerous Gram-negative bacteria, including E. coli (colicin) and P. aeruginosa (pyocin). 
An immunity gene follows the toxin gene, which are transcribed and translated together 
(Figure 3-9). Entericidin AB locus also has toxin/antitoxin gene pair. Entericidin A 
provides immunity to the toxin entericidin B. However, no sequence similarity was 
detected between entericidin AB and colicins/pyocins. Finally, there is no information 
about the ability of entericidin AB to lyse strains other than the producer. Our study is the 
first report suggesting that entericidin AB might be responsible for Bcc inhibitory 
activity.  
3.5.4 Proteins with unknown functions 
BLAST searches of the remaining sequences obtained from the genomic clones 
also revealed the presence of genes with unknown functions, amidohydroyse II, GGDEF 
domain, and a hypothetical protein. Amidohydrolase II catalyzes the cleavage of C-N, C-
C, C-O, C-Cl, C-S, O-P bonds of organic substances (Aimin et al., 2007). Thus, it may be 
involved in hydrolysis of vital proteins in Pa. 
The GGDEF is a conserved domain, which is observed in multi-domain proteins 
such as those involved in signaling pathways including cell-to-cell signaling, motility, 
virulence, biofilm formation, and antibiotic production (Pei & Grishin, 2001; Tamayo et 
al., 2007). Thus, GGDEF domain could be present in any protein involved in virulence 
signaling pathways, and in that manner, may play a role in Bcc inhibitory activity. 
In summary, genomic screens for inhibitory activity in Bcc revealed a surprising 
absence of traditional bacteriocin genes. The five clones explored here possessed genes 
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involved in amino acid biosynthesis, energy metabolism, degradation of aromatic 
compounds, and bacterial apoptosis.  
Why does Bcc, in contrast with all Gram-negative species examined to date, not 
have any identifiable bacteriocin genes? One simple explanation might be genomes of 
Bcc possess bacteriocins, which we were unable to identify in this study due to technical 
challenges. As it was mentioned, we lost the inhibitory activity in ten Bcc and two Pa 
genomic clones, which might be due to either toxicity of the cloned protein or lack of the 
corresponding immunity gene in the genomic clone. Additionally, Bcc bacteriocins might 
be relatively big proteins or phage tails, which might not be possible to identify with our 
approach since we cloned 4-5 kb DNA sequences. Thus, cloning larger DNA inserts of 
Bcc genome might allow us to identify bacteriocins of Bcc.  
Another explanation is that Bcc has evolved a different solution to the challenge 
of bacterial competition. One solution may be found in the fact that Burkholderia has 
significantly more genes that encode proteins involved in such major metabolic pathways 
as energy metabolism, transport, and binding proteins are among these categories (Figure 
3-10). Bcc genomes have ability to gain additional genes via horizontal gene transfer 
(Mahillon & Chandler, 1998; Tyler et al., 1996; Wood et al., 1991). For example, the 
glucoamylase gene identified in the Bcc clone 4 is originally detected in Aspergillus, 
which uses this enzyme to become pathogenic to plants (Mellon et al., 2007). Perhaps 
these extra metabolic genes might provide a level of flexibility to Bcc, whose members 
has to adapt living in different environments (soil, plant, human tissue), where the level 
of bacterial competition is high.  
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This study revealed that members of Bcc might be using a different strategy to 
compete with Pa strains in our experimental conditions, where two species are in close 
contact. The genomic clones with inhibitory activity possess genes involved in major 
metabolic pathways, whose induction might provide Bcc strains a better growth 
advantage in the environment where competition is high and nutrients are limited. 
Revealing the exact roles of these genes is critical to our understanding the interaction 
between Pa and Bcc strains in CF lungs. Therefore, future efforts will focus on cloning of 
these genes identified in the genome library clones of Burkholderia multivorans 
(ATCC17616) to further characterize their potential roles in Bcc inhibitory activity.  
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Table 3-1 Chromosomes and genome size of members of B. cepacia complex 
The number of chromosomes and the total genome size varies among strains as well as 
within the same genomovar. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genomovar Strain ID 
Size of 
chromosomes 
(Mb) 
Overall 
genome size 
(Mb) 
Genomovar I  
(B. cepacia) 
ATCC 25416 
ATCC 17759 
3.5, 3.1, 1.1 
3.5, 3.3, 1.1 
7.7 
7.9 
Genomovar II  
(B. multivorans) 
ATCC17616 
C5274 
3.4, 2.5, 0.9 
3.3, 2.4, 1.3 
6.8 
7.0 
Genomovar III  
(B. cenocepacia) 
C4455 
CEP024 
3.9, 3.0, 1.0 
3.4, 2.7, 0.9 
7.9 
7.0 
Genomovar IV  
(B. stabilis) 
LMG14294 
LMG7000 
3.7, 2.3, 1.3 
3.9, 3.3, 1.4 
8.2 
8.6 
Genomovar V  
(B. vietnamiensis) 
ATCC53617 
LMG18836 
3.4, 3.2, 1.2, 1.1 
3.0, 1.8, 1.2 
8.9 
6.0 
Genomovar VII  
(B. ambifaria) 
ATCC17760 
BcF 
3.4, 1.3 
3.5, 2.6, 1.3 
4.7 
7.4 
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Table 3-2 Genomic library clones of B. multivorans (ATCC17616) and Pseudomonas aeruginosa (PAO1) 
Inhibitory activity has detected in five genomic clones of B. multivorans (ATCC 17616) and one genomic clone of P. aeruginosa 
(PAO1). Insert DNAs were sequenced from these genomic clones, which are involved in various metabolic pathways including 
degradation of aromatic hydrocarbons, sugar metabolism, amino acid biosynthesis, and apoptosis in Bcc, and pyocin S2 synthesis in 
Pa.  
 
 
Producer 
Strain 
Clone 
Number 
Length 
of the 
cloned 
DNA 
fragment 
(nt) 
Gene 
ID 
Corresponding genes in the 
cloned DNA fragment 
Functional 
Category 
2 714 Bm1615 Hypothetical protein Unknown function 
4 3498 Bm1065 Poly-beta-hydroxyalkanoate 
depolymerase 
Degradation of 
aromatic compounds 
  Bm1066 Glucoamylase Sugar metabolism 
  Bm1067 3-carboxymuconate cyclase Sugar metabolism 
6 677 Bm6110 Amidohydrolase 2 Unknown function 
  Bm6111 4-hydroxybenzoate 
transporter 
Degradation of 
aromatic compounds 
7 3956 Bm4756 Aspartate-semialdehyde 
dehydrogenase 
Amino acid 
biosynthesis 
  Bm4757 3-isopropylmalate 
dehydrogenase 
Amino acid 
biosynthesis 
  Bm4758 3-isopropylmalate 
dehydratase small subunit 
Amino acid 
biosynthesis 
  Bm4759 Entericidin AB Apoptosis 
  Bm4760 3-isopropylmalate 
dehydratase large subunit 
Amino acid 
biosynthesis 
B. multivorans 
ATCC17616 
9 37 Bm4824 GGDEF domain Unknown function 
Pseudomonas 
aeruginosa 
PAO1 
1 4089 
Pa1151 
Pa1152 
Pa1153 
Hypothetical protein 
Pyocin S2 
Pyocin immunity 
Bacteriocin 
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Figure 3-1 Genomic library construction 
Genomic DNA of bacteriocin producer strain was partially digested. DNA inserts were 
ligated into Bam HI digested and dephosphorylated pUC19 vector. Blue/white colony 
screening was performed on E. coli recipients transformed with pUC19 clones.  
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Figure 3-2 Inhibition phenotypes of genomic clones of B. multivorans (ATCC17616) 
and Pseudomonas aeruginosa (PAO1) 
a-Five B. multivorans (ATCC17616) clones (clone #2-9) and one P. aeruginosa (PAO1) 
clones (PAOI clone) were detected as genomic clones with inhibitory activity. These 
clones showed inhibitory activity on the sensitive Pa strains; b-Bm ATCC 17616 and Pa 
PAO1 producer strains were tested on corresponding sensitive Pa strains as positive 
control. E. coli with puC19 was used as negative control.  
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Figure 3-3 Blast result of the clone 2 of B. multivorans (ATCC17616) genome library 
 
 
 
a. Genomic organization of the clone 2 of B. multivorans (ATCC167616). Clone 2 
encoded for a hypothetical protein (Bm1615).  
 
 
 
 
 
 
 
 
 
 
 
Bm1614: hypothetical protein 
Bm1615: hypothetical protein 
Bm1616: YbbM seven transmembrane helix protein 
 
 
 
b. Alignment result of clone 2 and hypothetical protein of B. multivorans (ATCC17616) 
 
 
 
Bm1615          ------------------------------------------------------------ 
clone2          AGCGCTGAGCCGGCGCGTGGCCGGCATCGTCCGGTGCGCGCGCAACGAGTGGGCGGCCTG 60 
                                                                             
 
Bm1615          ------------------------------------------------------------ 
clone2          CGTTCGTACGCGTGGCGCCAGGCCGTATCCGCAGCCGGAGGCCATCGATACGAGCGCCAC 120 
                                                                             
 
Bm1615          ------------------------------------------------------------ 
clone2          GCGCGCGCGCTGCGGCCTCGCTTCACGCCGTTTCGCGCCGGGTCGATCCGCTGCGCCGCT 180 
                                                                             
 
Bm1615          ------------------------------------------------------------ 
clone2          CCATGGTTCGCGCGCCGCGTGACGCGATGCCGATGTCGCGCTATGCTCGCCGGCATCGTC 240 
                                                                             
                                            Bm1615 
Bm1615          ----------------------ATGAAACATCGAATGCGCGTGCTGCTGTCGGCCGTCGC 38 
clone2          CCTCTCCGCCAACGACCCTCCGATGAAACATCGAATGCGCGTGCTGCTGTCGGCCGTCGC 300 
                                      ************************************** 
 
Bm1615          GTTCGTCGCGGCCCATGCGCAGGCCGCCGACGACTGCAGCTTCGTGAAGAAAGTCGCGCT 98 
clone2          GTTCGTCGCGGCCCATGCGCAGGCCGCCGACGACTGCAGCTTCGTGAAGAAAGTCGCGCT 360 
                ************************************************************ 
 
Bm1615          GCCGGCGCGGCAGCAGACGATCGTCGTGTCGAGCGGCGCACTCGAGCCGTGCTCGACCGG 158 
clone2          GCCGGCGCGGCAGCAGACGATCGTCGTGTCGAGCGGCGCACTCGAGCCGTGCTCGACCGG 420 
                ************************************************************ 
 
Bm1615          CAGCTATGCGGTGCGCGTCTATTCGACCGCGAACACGGCGCCCGGCTTCGATACCGACGA 218 
clone2          CAGCTATGCGGTGCGCGTCTATTCGACCGCGAACACGGCGCCCGGCTTCGATACCGACGA 480 
                ************************************************************ 
 
Bm1615          CTACGTGAGCGGCGCGCTGCATGCGCGCGACGGCACCGTCACCGATGCGTTCGTCGCCGA 278 
clone2          CTACGTGAGCGGCGCGCTGCATGCGCGCGACGGCACCGTCACCGATGCGTTCGTCGCCGA 540 
                ************************************************************ 
 
Bm1615          TCTCGGCGCGCGTGCGCCGCATGCGCTGATCGTGACGACGCGTTCGGCCGGCAGCGGCGG 338 
clone2          TCTCGGCGCGCGTGCGCCGCATGCGCTGATCGTGACGACGCGTTCGGCCGGCAGCGGCGG 600 
                ************************************************************ 
Bm1614      Bm1615     Bm1616 
Clone2 
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Bm1615          CTACGTCGGCGCCCAGGCCTATCTGACGACGTCGCGCGCTGTGACGCTCGTCGCGTCGGT 398 
clone2          CTACGTCGGCGCCCAGGCCTATCTGACGACGTCGCGCGCTGTGACGCTCGTCGCGTCGGT 660 
                ************************************************************ 
 
Bm1615          CGACGGGCTCGCGCCCGATGCCGATGTCGCGGCGGCGCTGCGTCGCGCGCTCGGCGCACG 458 
clone2          CGACGGGCTCGCGCCCGATGCCGATGTCGCGGCGGCGCTGCGTCGCGCGCTCGG------ 714 
                ******************************************************       
 
Bm1615          TCGCGGCACGCACTGA 474 
clone2          ---------------- 
                                 
 
 
Figure 3-4 Blast result of the clone 4 of B. multivorans (ATCC17616) genome library 
 
a. Genomic organization of the clone 4 of B. multivorans (ATCC17616). ). Clone 4 
encoded partially for 3-carboxymuconate cyclase and poly-beta-hydroxyalkolonate 
depolymerase proteins. This clone also encoded for glucoamylase protein (full protein).  
 
 
 
 
 
 
 
 
 
 
Bm1065: Poly-beta-hydroxyalkolonate depolymerase 
Bm1066: Glucoamylase 
Bm1067: 3-carboxymuconate cyclase 
 
b. Alignment result of clone 4 and Bm1065-67 of B. multivorans (ATCC17616) 
 
                             Bm1067 
 
Bm1065-67       TTACTGCACCGGTACGAGCTTGAAATCGACCGGCTTGCCGACCGCCACCTTGCGCGGATT 60 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       CGCAGCGAGCTGCCCGCTGCCGACGTCGCGGCCGAACACGTAGAACGTGTCGCTGTCCTG 120 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       GTTGCCGACGATCAGCCACTTGCCGGTCGGATCGATCAGGAATTCGCGCGGCGTCCGGCC 180 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       GAGGCTCGACTGGCGGCCGACGGTCTTCAGCCGGCCGTCGGCCTGGTTCACCGCGTAGAT 240 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       CACGATCTCGTTCGCGTCGCCGCGGTTGCTCACGTACAGGAAGCGGCCGTCCGGCGACAG 300 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       GTGGATCGCGCCACCGCCGACCTTGCCCTTGAAGCCGGGCGCGATCATCGACACGGTCTC 360 
clone4          ------------------------------------------------------------ 
                                                                             
 
                   Bm1067       Bm1066    Bm1065          
Clone 4 
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Bm1065-67       GATCGGCGTGAGCTTCCCGTCGTGATAGCCGAACACCTCGACCGACGCGTTCAGCTCGCT 420 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       CGTCACATACGCGAACCGGCCGTCGGCACTGAACACGAGATGGCGCGGCCCCGCGCCGGC 480 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       CTTCACCGGCGTATAACGCGTGTCGGTCGGGCTGATCAGCCCGCGGCTGCCGTCGACCGT 540 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       GTAGCGATAGCCGTAGATCTTGTCGAGACCGAGATCCTGCACGAACAGATAGCGGCCGTC 600 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       GGGCGAGAACACCGTCGAGTGGACGTGCGCGTTGTCCTGTCGCCCTCTGACGGGCCCCTT 660 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       CCCTTCGTGGTGCACGCTGAGCACGGCCGGTGCGACGCCGCCGTCGTCGCGGACCGGAAA 720 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       CAGCGCGAAGCTGCCGCCCGGATCGGCCGCGACCGAATAGTTGGCCGTCACCAGATACTT 780 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       GCCGTCGGGCGACAGGCTCAAATAGCAAGGATCGTTCCCCTCTGACGATACGCGATCGAT 840 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       GAAGGTGAGCGCGCCCGTCTTCGCATCGAAACGGAACGCGCTGATGCCGCCGCGCTGCGT 900 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       CGCGGGCCCGTTGTCGCCGGGCAGTTCGTTGACCGCATACACGACGCGACCGTCGCGGCT 960 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       CGGCAACAGATACGACGGGTTCACCGTCTTCGCCGACGATACCGGTGCGACACTACCGGT 1020 
clone4          ---------------CGGGTTCACCGTCTTCGCCGACGATACCGGTGCGACACTACCGGT 45 
                               ********************************************* 
 
Bm1065-67       GCTCGTATCGAAGCGGTAAACGTAGATGCCGTCGCTGCCGGTGTCGGTATAGGTGCCGAC 1080 
clone4          GCTCGTATCGAAGCGGTAAACGTAGATGCCGTCGCTGCCGGTGTCGGTATAGGTGCCGAC 105 
                ************************************************************ 
 
Bm1065-67       GAGCAGGTTGTAGACGCCGTCGGCCGGTGCCGGCGATTGCTGCGCGAATGCATGGGTCGC 1140 
clone4          GAGCAGGTTGTAGACGCCGTCGGCCGGTGCCGGCGATTGCTGCGCGAATGCATGGGTCGC 165 
                ************************************************************ 
 
Bm1065-67       GGACAGGGAAAGCACGAACGCGAAACCTTTCATCCAGTGAGCGAGCCTAAGCGGGAACCC 1200 
clone4          GGACAGGGAAAGCACGAACGCGAAACCTTTCATCCAGTGAGCGAGCCTAAGCGGGAACCC 225 
                ************************************************************ 
 
Bm1065-67       TCGTGTCGAAGCGTGTGCGTCACGCTCGCGTAAACGGTTGGGCATTGAATCCTCCTTGCA 1260 
clone4          TCGTGTCGAAGCGTGTGCGTCACGCTCGCGTAAACGGTTGGGCATTGAATCCTCCTTGCA 285 
                ************************************************************ 
 
Bm1065-67       TCGAGTCGCTTCAAGTGTTGAGATAGGACGAAACGCCGGCCGTCATGCGCTCCGCCTTCG 1320 
clone4          TCGAGTCGCTTCAAGTGTTGAGATAGGACGAAACGCCGGCCGTCATGCGCTCCGCCTTCG 345 
                ************************************************************ 
 
Bm1065-67       ATCGAGTATACGGGGCGCGGCGCCAGCGCGTGAAGCTGTCCGTCCGCGGCCCGCATTGTG 1380 
clone4          ATCGAGTATACGGGGCGCGGCGCCAGCGCGTGAAGCTGTCCGTCCGCGGCCCGCATTGTG 405 
                ************************************************************ 
                                             Bm1066 
Bm1065-67       AACCCGAAACAAGGATTTGCCCGCCCATGCCCGCCTTGATCGAAGACTATGCCCTCGTCG 1440 
clone4          AACCCGAAACAAGGATTTGCCCGCCCATGCCCGCCTTGATCGAAGACTATGCCCTCGTCG 465 
                ************************************************************ 
 
 101 
Bm1065-67       GCGACGGCCACACGGCCGCGCTGATCGCAAAAGACGGCTCCGTCGACTGGCTGTGCTGGC 1500 
clone4          GCGACGGCCACACGGCCGCGCTGATCGCAAAAGACGGCTCCGTCGACTGGCTGTGCTGGC 525 
                ************************************************************ 
 
Bm1065-67       CCCGGTTCGACTCGGGCGCCTGCTTCGCGGCGCTCGTCGGCACACCCGAGCACGGTCGCT 1560 
clone4          CCCGGTTCGACTCGGGCGCCTGCTTCGCGGCGCTCGTCGGCACACCCGAGCACGGTCGCT 585 
                ************************************************************ 
 
Bm1065-67       GGCTGATCGCGCCGGCCGCCGACGTCGCGATTACGCATACGACACGCCGCTATCGCGGCG 1620 
clone4          GGCTGATCGCGCCGGCCGCCGACGTCGCGATTACGCATACGACACGCCGCTATCGCGGCG 645 
                ************************************************************ 
 
Bm1065-67       ACACGCTGATTCTCGAAACCGATTACGAAAGTGCCGACGGCGCCGTGACCGTCGTCGACT 1680 
clone4          ACACGCTGATTCTCGAAACCGATTACGAAAGTGCCGACGGCGCCGTGACCGTCGTCGACT 705 
                ************************************************************ 
 
Bm1065-67       TCATGCCGCCCGGCAACGGCTGGTCCGAGCTCGTGCGCATCGTCGTCGGCCGGCGCGGCA 1740 
clone4          TCATGCCGCCCGGCAACGGCTGGTCCGAGCTCGTGCGCATCGTCGTCGGCCGGCGCGGCA 765 
                ************************************************************ 
 
Bm1065-67       CGATGAAGATGCGGATGGAACTCGTGCTGCGCTTCGACTACGGCTTCTCAATCCCGTGGG 1800 
clone4          CGATGAAGATGCGGATGGAACTCGTGCTGCGCTTCGACTACGGCTTCTCAATCCCGTGGG 825 
                ************************************************************ 
 
Bm1065-67       TCACGCAGCTCACGCGCGAAGACGGGATGAAGGCGATCGCCGGCCCCGACACGGTCGTGC 1860 
clone4          TCACGCAGCTCACGCGCGAAGACGGGATGAAGGCGATCGCCGGCCCCGACACGGTCGTGC 885 
                ************************************************************ 
 
Bm1065-67       TGCGCACGCCGGTGCCGCTCACCGGCAAGAACCTGCATACGCTCGCGGAATTCACGGTCA 1920 
clone4          TGCGCACGCCGGTGCCGCTCACCGGCAAGAACCTGCATACGCTCGCGGAATTCACGGTCA 945 
                ************************************************************ 
 
Bm1065-67       GCGCCGACGAGCGCGTGCCGTTCTCGCTCGGCTATGCGCCCTCGCATCTGCGGCTGCCGC 1980 
clone4          GCGCCGACGAGCGCGTGCCGTTCTCGCTCGGCTATGCGCCCTCGCATCTGCGGCTGCCGC 1005 
                ************************************************************ 
 
Bm1065-67       CCGCGCGCGATCCGCTGTCGATGCTCGCGCGCACCGAGAACTACTGGCTCGAATGGTCGG 2040 
clone4          CCGCGCGCGATCCGCTGTCGATGCTCGCGCGCACCGAGAACTACTGGCTCGAATGGTCGG 1065 
                ************************************************************ 
 
Bm1065-67       GCCGCTGCCAGGTGCGCGGTCGCTATGCGGCCGCCGTGCGCCGTTCGCTGATCACGCTGA 2100 
clone4          GCCGCTGCCAGGTGCGCGGTCGCTATGCGGCCGCCGTGCGCCGTTCGCTGATCACGCTGA 1125 
                ************************************************************ 
 
Bm1065-67       AGGCGCTCGCCTACGAGCCGACCGGCGGGATCGTCGCCGCGCCCACCACGTCGCTGCCCG 2160 
clone4          AGGCGCTCGCCTACGAGCCGACCGGCGGGATCGTCGCCGCGCCCACCACGTCGCTGCCCG 1185 
                ************************************************************ 
 
Bm1065-67       AGAAGATCGGTGGCAACCGCAACTGGGACTACCGCTACTGCTGGCTGCGCGACGCGACGA 2220 
clone4          AGAAGATCGGTGGCAACCGCAACTGGGACTACCGCTACTGCTGGCTGCGCGACGCGACGA 1245 
                ************************************************************ 
 
Bm1065-67       TCACGCTGCTCGCGCTGATGCGCGGCGGCTACTACGACGAAGCGCGCGCGTGGCGCACGT 2280 
clone4          TCACGCTGCTCGCGCTGATGCGCGGCGGCTACTACGACGAAGCGCGCGCGTGGCGCACGT 1305 
                ************************************************************ 
 
Bm1065-67       GGCTCGGCCGCGTGATGGCCGGATCGCCCGAGCAGATTCAGATCATGTACGGGATCGCGG 2340 
clone4          GGCTCGGCCGCGTGATGGCCGGATCGCCCGAGCAGATTCAGATCATGTACGGGATCGCGG 1365 
                ************************************************************ 
 
Bm1065-67       GCGAGCGCCGCTTGCCCGAGATGGAGCTCGACTGGCTGCCCGGCTATCAGGACTCGAAGC 2400 
clone4          GCGAGCGCCGCTTGCCCGAGATGGAGCTCGACTGGCTGCCCGGCTATCAGGACTCGAAGC 1425 
                ************************************************************ 
 
Bm1065-67       CGGTGCGCGTCGGCAACGGCGCCGCGAACCAGCTGCAGCTCGACGTGTTCGGCGAAGTGA 2460 
clone4          CGGTGCGCGTCGGCAACGGCGCCGCGAACCAGCTGCAGCTCGACGTGTTCGGCGAAGTGA 1485 
                ************************************************************ 
 
Bm1065-67       TGGCCGCGCTGCATCTCGCGCGCGTCGGTGGTCTGCAGGCCGACGATACGGTGTGGTCGG 2520 
clone4          TGGCCGCGCTGCATCTCGCGCGCGTCGGTGGTCTGCAGGCCGACGATACGGTGTGGTCGG 1545 
                ************************************************************ 
 
Bm1065-67       TGCAGTGCGCGCTGCTCGATCACCTCGAGAAGATCTGGCAGGAGCCCGACGAAGGGATCT 2580 
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clone4          TGCAGTGCGCGCTGCTCGATCACCTCGAGAAGATCTGGCAGGAGCCCGACGAAGGGATCT 1605 
                ************************************************************ 
 
Bm1065-67       GGGAAACGCGCGGCGGCCGCCGCCATTTCACGTTCTCGAAGGTGATGGCATGGGTCGCGT 2640 
clone4          GGGAAACGCGCGGCGGCCGCCGCCATTTCACGTTCTCGAAGGTGATGGCATGGGTCGCGT 1665 
                ************************************************************ 
 
 
Bm1065-67       TCGACCGCGCGATCAAGTCCGCGGAGATGTTCCGCCTGCCGGGCTCGCTCGAGCGCTGGC 2700 
clone4          TCGACCGCGCGATCAAGTCCGCGGAGATGTTCCGCCTGCCGGGCTCGCTCGAGCGCTGGC 1725 
                ************************************************************ 
 
Bm1065-67       GCGCGCTGCGCGACCGCATCCATGCCGACGTCTGCGAGAAGGCGTGGCACGACGGCAAGC 2760 
clone4          GCGCGCTGCGCGACCGCATCCATGCCGACGTCTGCGAGAAGGCGTGGCACGACGGCAAGC 1785 
                ************************************************************ 
 
Bm1065-67       AGGCGTTCGCCCAAAGCTACGGCAGCGACGAGCTCGACGCGAGCGTGCTGCTGATGCCGC 2820 
clone4          AGGCGTTCGCCCAAAGCTACGGCAGCGACGAGCTCGACGCGAGCGTGCTGCTGATGCCGC 1845 
                ************************************************************ 
 
Bm1065-67       TGCTCGGCTTCCTGCCGCCCGAGGATCCGCGCATCGTCGGCACGGTGGAGGCGATCGAGC 2880 
clone4          TGCTCGGCTTCCTGCCGCCCGAGGATCCGCGCATCGTCGGCACGGTGGAGGCGATCGAGC 1905 
                ************************************************************ 
 
Bm1065-67       GGGAATTGCTGCACGACGGGCTCGTGATGCGCTACCGCACGACCGAGTACGACGACGGCC 2940 
clone4          GGGAATTGCTGCACGACGGGCTCGTGATGCGCTACCGCACGACCGAGTACGACGACGGCC 1965 
                ************************************************************ 
 
Bm1065-67       TGCCGCCCGGCGAAGGCACGTTTCTCGCGTGCAGTTTCTGGCTCGTCGACAACTACGCGC 3000 
clone4          TGCCGCCCGGCGAAGGCACGTTTCTCGCGTGCAGTTTCTGGCTCGTCGACAACTACGCGC 2025 
                ************************************************************ 
 
Bm1065-67       TGCTCGGCCGGATCGACGACGCGCATCGGCTGTTCAGTCGCCTGCTCGCGCTGTCGAACG 3060 
clone4          TGCTCGGCCGGATCGACGACGCGCATCGGCTGTTCAGTCGCCTGCTCGCGCTGTCGAACG 2085 
                ************************************************************ 
 
Bm1065-67       ACCTCGGGCTGCTCGCGGAGGAATACGACCCGGTCGAGGGGCGGCTCGTCGGCAATTTCC 3120 
clone4          ACCTCGGGCTGCTCGCGGAGGAATACGACCCGGTCGAGGGGCGGCTCGTCGGCAATTTCC 2145 
                ************************************************************ 
 
Bm1065-67       CGCAGGCGTTCTCGCACGTCGCGCTCGTGCATACCGCGATGAACCTGATGCACCACGAAG 3180 
clone4          CGCAGGCGTTCTCGCACGTCGCGCTCGTGCATACCGCGATGAACCTGATGCACCACGAAG 2205 
                ************************************************************ 
 
Bm1065-67       AGGCGATGGCGCGCGCGGCCGGACAGCCGGCGCCGGCGGCCGCGACGGGCCGCTGACCGC 3240 
clone4          AGGCGATGGCGCGCGCGGCCGGACAGCCGGCGCCGGCGGCCGCGACGGGCCGCTGACCGC 2265 
                ************************************************************ 
                                                       Bm1065 
Bm1065-67       GGCCGGTGCTATGGTAAGAGAACGTCAAATCGCAAAAATTTGATGAAAAATCCGGGAAAT 3300 
clone4          GGCCGGTGCTATGGTAAGAGAACGTCAAATCGCAAAAATTTGATGAAAAATCCGGGAAAT 2325 
                ************************************************************ 
 
Bm1065-67       GTTGCATTGCACCACGGATCGTTGTCCGATATGATCGACACGACTGTCCGGCTGCACTGC 3360 
clone4          GTTGCATTGCACCACGGATCGTTGTCCGATATGATCGACACGACTGTCCGGCTGCACTGC 2385 
                ************************************************************ 
 
Bm1065-67       AACATTGCCGGACGATGACCCACACGGCACGCCGCGACGCCCCACGCCGCCCTTGCGCAC 3420 
clone4          AACATTGCCGGACGATGACCCACACGGCACGCCGCGACGCCCCACGCCGCCCTTGCGCAC 2445 
                ************************************************************ 
 
Bm1065-67       CGTCCCCCACGCGGGAGTAGTCTGCATGCTTTACCAACTGCACGAATTCCAGCGGGCGAT 3480 
clone4          CGTCCCCCACGCGGGAGTAGTCTGCATGCTTTACCAACTGCACGAATTCCAGCGGGCGAT 2505 
                ************************************************************ 
 
Bm1065-67       GCTGAGCCCGCTCACGGCCTGGGCCCAGGCCGCGTCGAAGTCCTTCGCCAATCCGTCGAG 3540 
clone4          GCTGAGCCCGCTCACGGCCTGGGCCCAGGCCGCGTCGAAGTCCTTCGCCAATCCGTCGAG 2565 
                ************************************************************ 
 
Bm1065-67       CCCGTTTTCGCTGATCCCCGGCGCGCCGCGCATGGCGGCTGCGTACGAGCTGCTGTACCG 3600 
clone4          CCCGTTTTCGCTGATCCCCGGCGCGCCGCGCATGGCGGCTGCGTACGAGCTGCTGTACCG 2625 
                ************************************************************ 
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Bm1065-67       GCTCGGCAAGGATTACGAGAAGCCGGAGTTCAACATTCATCAGATCGTCAAGGACGGCCA 3660 
clone4          GCTCGGCAAGGATTACGAGAAGCCGGAGTTCAACATTCATCAGATCGTCAAGGACGGCCA 2685 
                ************************************************************ 
 
Bm1065-67       CAACATTCCGATCGTCGAGCAGACGATCGTCGAAAAGCCGTTCTGCCGGCTGCTGCGCTT 3720 
clone4          CAACATTCCGATCGTCGAGCAGACGATCGTCGAAAAGCCGTTCTGCCGGCTGCTGCGCTT 2745 
                ************************************************************ 
 
 
 
Bm1065-67       CAAGCGCTATTCGGACGATGCCGATGCGGTCACGCAGCTGAAGGACGAACCGGTCGTGCT 3780 
clone4          CAAGCGCTATTCGGACGATGCCGATGCGGTCACGCAGCTGAAGGACGAACCGGTCGTGCT 2805 
                ************************************************************ 
 
Bm1065-67       GGTCTGCGCGCCGCTGTCGGGCCACCACTCGACGCTGCTGCGCGACACCGTGCGCACGCT 3840 
clone4          GGTCTGCGCGCCGCTGTCGGGCCACCACTCGACGCTGCTGCGCGACACCGTGCGCACGCT 2865 
                ************************************************************ 
 
Bm1065-67       GCTGCAGGATCACAAGGTCTACATCACCGACTGGATCGACGCGCGGATGGTGCCGGTCGA 3900 
clone4          GCTGCAGGATCACAAGGTCTACATCACCGACTGGATCGACGCGCGGATGGTGCCGGTCGA 2925 
                ************************************************************ 
 
Bm1065-67       GGTCGGCCCGTTCCATCTGCACGACTACGTCGAGTACATCCAGGAATTCATCCGCCACAT 3960 
clone4          GGTCGGCCCGTTCCATCTGCACGACTACGTCGAGTACATCCAGGAATTCATCCGCCACAT 2985 
                ************************************************************ 
 
Bm1065-67       CGGTGCGCGCAATCTGCACGTCGTATCGGTGTGTCAGCCGACGGTGCCCGTGCTCGCGGC 4020 
clone4          CGGTGCGCGCAATCTGCACGTCGTATCGGTGTGTCAGCCGACGGTGCCCGTGCTCGCGGC 3045 
                ************************************************************ 
 
Bm1065-67       GATCTCGCTGATGGCGAGCCGCGGCGAGGACACGCCGCTCACGATGACGATGATGGGCGG 4080 
clone4          GATCTCGCTGATGGCGAGCCGCGGCGAGGACACGCCGCTCACGATGACGATGATGGGCGG 3105 
                ************************************************************ 
 
Bm1065-67       CCCGATCGACGCGCGCCGCAGCCCGACTTCGGTGAACTCGCTCGCGACGCAGCATTCGCT 4140 
clone4          CCCGATCGACGCGCGCCGCAGCCCGACTTCGGTGAACTCGCTCGCGACGCAGCATTCGCT 3165 
                ************************************************************ 
 
Bm1065-67       CGCGTGGTTCGAGAACAACGTGATCCACACGGTGCCGGCGAACTATCCGGGCGAAGGCCG 4200 
clone4          CGCGTGGTTCGAGAACAACGTGATCCACACGGTGCCGGCGAACTATCCGGGCGAAGGCCG 3225 
                ************************************************************ 
 
Bm1065-67       TCAGGTGTATCCGGGCTTCCTGCAGCACACGGGCTTCGTCGCGATGAATCCGGAGCGCCA 4260 
clone4          TCAGGTGTATCCGGGCTTCCTGCAGCACACGGGCTTCGTCGCGATGAATCCGGAGCGCCA 3285 
                ************************************************************ 
 
Bm1065-67       CGCGCAATCGCACTGGGACTTCTATCAGAGCCTGCTGCGGGGCGACGAGGAAGACGCCGA 4320 
clone4          CGCGCAATCGCACTGGGACTTCTATCAGAGCCTGCTGCGGGGCGACGAGGAAGACGCCGA 3345 
                ************************************************************ 
 
Bm1065-67       AGCGCACCGCCGCTTCTATGACGAATACAACGCGGTGCTCGACATGGCCGCCGAGTACTA 4380 
clone4          AGCGCACCGCCGCTTCTATGACGAATACAACGCGGTGCTCGACATGGCCGCCGAGTACTA 3405 
                ************************************************************ 
 
Bm1065-67       CCTCGAGACGATCCGCGTCGTGTTCCAGGAATTCCGCCTCGCGGAAGGCACGTGGGACGT 4440 
clone4          CCTCGAGACGATCCGCGTCGTGTTCCAGGAATTCCGCCTCGCGGAAGGCACGTGGGACGT 3465 
                ************************************************************ 
 
Bm1065-67       CAACGGCGAACGCGTACGCCCGCAGGACATCAAGCGCACCGCACTGATGACGATCGAAGG 4500 
clone4          CAACGGCGAACGCGTACGCCCGCAGGACATCAA--------------------------- 3498 
                *********************************                            
 
Bm1065-67       CGAGCTCGACGACATCTCGGGCAGCGGCCAGACGCACGTCGCGCACGAGCTGTGCACGGG 4560 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       CATTCCGCAGGATCAGCGCCGCAGCTTGACCGCCGAGAAGTGCGGCCATTACGGGATCTT 4620 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       CTCCGGCCGCCGCTGGCGCACGATCATCTACCCGCAACTGCGCGACTTCATCCGCGAGCA 4680 
clone4          ------------------------------------------------------------ 
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Bm1065-67       TGCGCCGGAGCCGAAGAACGGCAGCGCGAAGGATCGCCCGGACGCAACGGCCGGCACGTC 4740 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       CGACACGCCGGCCGCATCGGCGCCCGCGCTCGCGGCCGTCCCGGCCGGCCAGGCCCAGCG 4800 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       CGAAACCGCGAAGGCCCCGGCCACGCTCGCGAAACGCGCGCGCGCGAAATCGTCGGGCAC 4860 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       GCTGTCGCCGAAGGCCGCACCGGCCGCCAAGCGCGCGAGCGGCACACGCGCGAAGCCGGT 4920 
clone4          ------------------------------------------------------------ 
                                                                             
 
Bm1065-67       TCGCGCACGCAAGGCCGCCTGA 4942 
clone4          ---------------------- 
                                       
 
 
Figure 3-5 Blast result of clone 6 of B. multivorans (ATCC17616) genome library 
 
a. Genome organization of clone 6 of B. multivorans (ATCC17616). Clone 6 encoded for 
amidohydrolase II and 4-hydroxybenzoate transporter proteins. Both proteins were 
encoded partially.  
 
 
 
 
 
 
Bm6110: amidohydrolase II 
Bm6111:4-hydroxybenzoate transporter 
 
b. Alignment result of clone 6 and Bm6110-11 of B. multivorans (ATCC17616)                     
 
                                Bm6110 
Bm6110-11       ATGGCGAAGCGAAGCGCGGGTCGCCGCCAAGGAGACAGGAGAAACAGGATGGCAAGTGGA 60 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       AAGACAATCGACATCAAGTCGTTCATCGACGACCGGCCGGTGTCGCGCTACCAGTGGCTG 120 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       CTGGTCGCGCTGTGCTGCCTCGTCGTGATCGCGGACGGGATGGACGTCGCGATCATGGGG 180 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       TTCGTCGCACCGTCGGTGATTCGCGACTGGGCGATCTCGCGGCCGGAATTCGGGCTCGTG 240 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       ATGAGCGCGGCGCCGATCGGTCTCGTGATCGGTGCGCTCGTCGCCGGCCCGAGCGCGGAC 300 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       CGGTTCGGGCGCAAGCGCGTGCTGATCGCGTCGGTGTTGCTGTTCGGCCTCTTCACGATC 360 
clone6          ------------------------------------------------------------ 
                                                                             
                                         Bm6110    Bm6111 
Clone 6 
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Bm6110-11       GCGACCGCGTATGCGGGCTCGCCGGTTCAGATGGCCGTGCTGCGGCTGCTGACCGGCATC 420 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       GGGCTCGGCGCCGCGATGCCGAACACGACGACGCTGCTGTCGGAGTATGCGCCGCAGCGG 480 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       ATGCGGTCGCTGATGATCACGATCATGTTCACGGGCTTCAATCTCGGCTCGGCGCTGATC 540 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       GGCTTCGTCGCCGGCTGGCTGATTCCGCTGCACGGCTGGCGCGCGGTACTGCTGTTCGGC 600 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       GGCGCGCTGCCGCTGCTGCTGATTCCGCTGCAACTGTGGCTGCTGCCCGAATCGGCGCGG 660 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       CTGCTCGCCGTGCGCGGTGCGCCGTCGCAGCGCATCGGCGCGTTGCTGAACCGCGTCTGC 720 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       GGCGCACGCTTCGACGGCAACGAGACGTTCGTCTCGAACGAGCCGCCGCTGCCGACGCGC 780 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       AAGCCGATCGGCGTGCTGTTCTCGCAAGGCTACGGCGTCGTCACGGTATCGCTGTGGATC 840 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       ACGTACTTCATGGGACTGCTCGTGATCTATCTGCTGACCGGCTGGCTGCCGACACTGATC 900 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       AAGGATGCGGGCCTGTCGGTCAGCACGGCCGCGAACGTGACGGCGATGTTCCAGATCGGC 960 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       GGGACGATCGGCGCGATCGGCGTCGGCTGGCTGATGGACAAGGTGCGGCCGGCACCCGTG 1020 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       ATCGGCGCCGCGTATCTCGGTGGCGCACTGTGCGTGGCCGTGCTCGCGTGGGCCGGCGCG 1080 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       CTGTCGTCGTCGCTCGCGCTGCTCGTGTTTGCGGCGGGCTTCTGCATGAGCGGCGCGCAG 1140 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       ACGGGGCTGAACGCGTATGCGCCGGGCCGCTACCCGACCGTTGCGCGCGCAACCGGCGTG 1200 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       AGCTGGATGCTCGGCATGGGCCGCTTCGGCAGCATTTTCGGTTCGGCGATCGGCGGCGCG 1260 
clone6          -------------GCATGGGCCGCTTCGGCAGCATTTTCGGTTCGGCGATCGGCGGCGCG 47 
                             *********************************************** 
 
Bm6110-11       CTGCTCGGCCTCGGCTGGAAGTTCGACGCGATCCTGTCGATGCTCGCGGTGCCCGCCACG 1320 
clone6          CTGCTCGGCCTCGGCTGGAAGTTCGACGCGATCCTGTCGATGCTCGCGGTGCCCGCCACG 107 
                ************************************************************ 
 
Bm6110-11       CTTGCGGCGATCGCGATCGTCACGACGCAGCGCGCGGCCGCACCTGAACCGAAGGAAATG 1380 
clone6          CTTGCGGCGATCGCGATCGTCACGACGCAGCGCGCGGCCGCACCTGAACCGAAGGAAATG 167 
                ************************************************************ 
 
Bm6110-11       GAAAAACCGGCGCACTGACCGCGTCCGCACGATCGCGCGTCCCGCGTCGCGGGCCGGCGC 1440 
clone6          GAAAAACCGGCGCACTGACCGCGTCCGCACGATCGCGCGTCCCGCGTCGCGGGCCGGCGC 227 
                ************************************************************ 
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                                                     Bm6111 
Bm6110-11       CGACACGCGGCATCCGGCCAGCACGTCATGCAACAGGAGTGTCAATGATCATCGATATTC 1500 
clone6          CGACACGCGGCATCCGGCCAGCACGTCATGCAACAGGAGTGTCAATGATCATCGATATTC 287 
                ************************************************************ 
 
Bm6110-11       ACGGCCACTACACGACCGCGCCGAAGGCGCTCGAGACCTGGCGCAATCGCCAGATCGCGG 1560 
clone6          ACGGCCACTACACGACCGCGCCGAAGGCGCTCGAGACCTGGCGCAATCGCCAGATCGCGG 347 
                ************************************************************ 
 
Bm6110-11       CGATTCACAGCCCGTCCGAGCGGCCGAAGGTCGCGGAACTGAACATCAGCGACGACGAGC 1620 
clone6          CGATTCACAGCCCGTCCGAGCGGCCGAAGGTCGCGGAACTGAACATCAGCGACGACGAGC 407 
                ************************************************************ 
 
Bm6110-11       TGCGCGAGTCGCTCGAGCCCAACCAGTTGCGGCTGATGCGCGAGCGCGGCCTCGACCTGA 1680 
clone6          TGCGCGAGTCGCTCGAGCCCAACCAGTTGCGGCTGATGCGCGAGCGCGGCCTCGACCTGA 467 
                ************************************************************ 
 
Bm6110-11       CGATCTTCAGCCCGCGCGCGAGCTTCATGGCACACCACATCGGCGACTTCGACGTGTCGA 1740 
clone6          CGATCTTCAGCCCGCGCGCGAGCTTCATGGCACACCACATCGGCGACTTCGACGTGTCGA 527 
                ************************************************************ 
 
Bm6110-11       GCACCTGGGCCGCCGTCTGCAACGAGCTGTGCTACCGCGTGCACCGGCTGTACCCCGACC 1800 
clone6          GCACCTGGGCCGCCGTCTGCAACGAGCTGTGCTACCGCGTGCACCGGCTGTACCCCGACC 587 
                ************************************************************ 
 
Bm6110-11       GCTTCGTGCCGGCGGCGATGCTGCCGCAAAGCCCCGGCGTCGACGTGGCGACCTGCATTC 1860 
clone6          GCTTCGTGCCGGCGGCGATGCTGCCGCAAAGCCCCGGCGTCGACGTGGCGACCTGCATTC 647 
                ************************************************************ 
 
Bm6110-11       CGGAGCTCGTCCGGTGCGTCGAGGCGTACGGCAACGTCGCGGTCAACCTGAATCCCGATC 1920 
clone6          CGGAGCTCGTCCGGTGCGTCGAGGCGTACG------------------------------ 677 
                ******************************                               
 
Bm6110-11       CGTCCGGCGGCCACTGGACGAGCCCGCCGCTGTCGGACCGCTACTGGTATCCGCTGTACG 1980 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       AGAAGATGGTCGAGTACGACATCCCCGCGATGATCCACGTGAGCACGAGCTGCAACGCGT 2040 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       GCTTTCACACGACCGGCGCGCACTACCTGAACGCGGACACGACCGCGTTCATGCAGTGCC 2100 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       TGACGTCGGATCTGTTCAAGGACTTTCCGACGCTGCGCTTCGTGATTCCGCACGGCGGCG 2160 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       GCGCGGTGCCGTATCACTGGGGGCGCTTTCGCGGCCTCGCACAGGAACTGAAGAAGCCGC 2220 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       TCCTGACCGAGCATCTACTCAACAACGTGTTCTTCGATACGTGCGTCTATCACCAGCCGG 2280 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       GCATCGATCTGCTGACCGGCGTGATTCCGGTCGACAACATCCTGTTCGCGAGCGAGATGA 2340 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       TCGGCGCGGTTCGCGGCATCGATCCGGAGACCGGGCACTACTACGACGACACGAAGCGCT 2400 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       ACATCGAAGCGTCGGCACTCGACGCGCAGGCGCGCTACAAGATTTACGAAGGCAATGCGC 2460 
clone6          ------------------------------------------------------------ 
                                                                             
 
Bm6110-11       GCCGCGTGTATCCGCGCCTGGATGCGCAACTGAAAGCGAAGGGGAAGTGA 2510 
clone6          -------------------------------------------------- 
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Figure 3-6 Blast result of clone 7 of B. multivorans (ATCC17616) genome library 
 
a. Genomic organization of clone 7 of B. multivorans (ATCC17616). Clone 7 encoded 
for 3-isopropylmalate dehydratase large subunit, entericidinAB, 3-isopropylmalate 
dehydratase small subunit, 3-isopropylmalate dehydrogenase, and Aspartate-
semialdehyde dehydrogenase proteins. 3-isopropylmalate dehydratase large subunit (Bm 
4760) was partially encoded. Remainder genes were encoded as full length proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bm4756: Aspartate-semialdehyde dehydrogenase  
Bm4757: 3-isopropylmalate dehydrogenase 
Bm4758: 3-isopropylmalate dehydratase small subunit 
Bm4759: entericidinAB 
Bm4760: 3-isopropylmalate dehydratase large subunit 
 
 
b. Alignment of genome 7 and Bm4756-60 of B. multivorans (ATCC17616) 
         
                              Bm4760 
 
Bm4756-60       TTGATGTCACAACGACCCCGCATACCCATGGCACAGACTCTCTACGACAAACTGTGGAAT 60 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       TCCCACGTCGTCCACACCGAGGAAGACGGCACGGCATTGCTGTATATCGACCGTCAACTG 120 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       CTGCATGAAGTCACGAGCCCGCAGGCGTTCGAAGGGCTGAAGATCGCGCAGCGTCCGGTG 180 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       TGGCGCATCAGCGCGAACCTGGCCGTGTCCGACCACAACGTGCCGACCACCGATCGCAGC 240 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       CACGGCATCGCCGATCCCGTCTCGAAGCTGCAGGTCGACACGCTCGACGCGAACTGCGAT 300 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       GCGTTCGGCATCACGCAGTTCAAGATGAACGACGTGCGTCAGGGCATCGTGCACATCATC 360 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       GGGCCGGAGCAGGGCGCGACGCTGCCGGGCATGACGATCGTGTGCGGCGATTCGCACACG 420 
clone7          ------------------------------------------------------------ 
                                                                             
Clone 7 
Bm4760    Bm4759 Bm4758   Bm4757   Bm4756 
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Bm4756-60       TCGACGCACGGCGCGTTCGGCGCGCTCGCGCACGGCATCGGCACGTCGGAAGTCGAGCAC 480 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       GTGCTCGCGACGCAGACTTTGCTGCAGAAGAAGAGCAAGAACATGCTCGTGAAGGTCGAG 540 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       GGCGCACTGCCGCGCGGCTGCACCGCGAAGGACATCGTGCTCGCGATCATCGGCAAGATC 600 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       GGCACGGCAGGCGGCACCGGCTATGCGATCGAATTCGGCGGCTCGACGATCCGCGCGCTG 660 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       TCGATGGAAGGCCGGATGACGGTCTGCAACATGGCGATCGAAGCCGGCGCGCGCGCGGGC 720 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       ATGGTCGCCGTCGACGACACGACGATCGACTACCTGAAGGGCCGTCCGTTCGTGCCGACC 780 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       GGCGCGGAATGGGATCAGGCCGTCGAATACTGGCGCCAGTTCAAGTCGGACGAAGGCGCG 840 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       CATTTCGATCGCGTCGTCGAGCTGAACGCGGCCGAGATCGTCCCGCAGGTCACGTGGGGC 900 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       ACGTCGCCGGAAATGGTCACGTCGATCGACGGTCGCGTGCCCGATCCCGAGCGCGAGAAG 960 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       GATCCGGTCAAGCGCGACGCGATGGAGCGCGCGCTCGCCTACATGGCGCTCGAACCGAAC 1020 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       ACGCCGATCGAATCGATCAAGGTCGACAAGATCTTCATCGGCTCGTGCACGAACGCGCGC 1080 
clone7          ------ATCGAATCGATCAAGGTCGACAAGATCTTCATCGGCTCGTGCACGAACGCGCGC 54 
                      ****************************************************** 
 
Bm4756-60       ATCGAGGACATCCGCGCGGCCGCGTACGTCGTGAAGAAGCTGAACCGTCGCGTCGCCTCG 1140 
clone7          ATCGAGGACATCCGCGCGGCCGCGTACGTCGTGAAGAAGCTGAACCGTCGCGTCGCCTCG 114 
                ************************************************************ 
 
Bm4756-60       AACGTGCGGCTCGCGATGGTCGTGCCGGGCTCGGGCCTCGTGAAGGCGCAGGCCGAGCGC 1200 
clone7          AACGTGCGGCTCGCGATGGTCGTGCCGGGCTCGGGCCTCGTGAAGGCGCAGGCCGAGCGC 174 
                ************************************************************ 
 
Bm4756-60       GAAGGCCTCGACAAGGTGTTTACCGATGCGGGCTTCGAATGGCGCGAGCCGGGCTGCTCG 1260 
clone7          GAAGGCCTCGACAAGGTGTTTACCGATGCGGGCTTCGAATGGCGCGAGCCGGGCTGCTCG 234 
                ************************************************************ 
 
Bm4756-60       ATGTGTCTCGCGATGAACGCCGACCGCCTCGAGCCGGGCGAGCGCTGCGCCTCGACGTCG 1320 
clone7          ATGTGTCTCGCGATGAACGCCGACCGCCTCGAGCCGGGCGAGCGCTGCGCCTCGACGTCG 294 
                ************************************************************ 
 
Bm4756-60       AACCGCAACTTCGAAGGCCGGCAGGGCGCGGGCGGCCGCACGCACCTCGTCAGCCCCGCG 1380 
clone7          AACCGCAACTTCGAAGGCCGGCAGGGCGCGGGCGGCCGCACGCACCTCGTCAGCCCCGCG 354 
                ************************************************************ 
 
Bm4756-60       ATGGCGGCGGCCGCGGCGATCGAAGGCCATTTCGTCGACATTCGCAAGCTGGGGTAACGC 1440 
clone7          ATGGCGGCGGCCGCGGCGATCGAAGGCCATTTCGTCGACATTCGCAAGCTGGGGTAACGC 414 
                ************************************************************ 
                                                  Bm4759 
Bm4756-60       GTGACGGCATCGAAATGGGTTGCGCGGCTCGCCGCCGCGCTGGCGCTCGCGGGGCTCGGC 1500 
clone7          GTGACGGCATCGAAATGGGTTGCGCGGCTCGCCGCCGCGCTGGCGCTCGCGGGGCTCGGC 474 
                ************************************************************ 
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Bm4756-60       TTCGGTCTCGCGGGCTGCAACACCGTCCGAGGCTTCGGCGAGGACGTCAATGCCGCCGGC 1560 
clone7          TTCGGTCTCGCGGGCTGCAACACCGTCCGAGGCTTCGGCGAGGACGTCAATGCCGCCGGC 534 
                ************************************************************ 
 
Bm4756-60       AGCGCACTGAAGCGCGCCGCGGAGTGACCCCGCCGAGAATTTGTCGATGTGCGCCGGCCG 1620 
clone7          AGCGCACTGAAGCGCGCCGCGGAGTGACCCCGCCGAGAATTTGTCGATGTGCGCCGGCCG 594 
                ************************************************************ 
                                                
                                                Bm4758   
Bm4756-60       CGGGCCGGCCCTTCAACCGGATAGACGGATCATGGAAAAATTCACAGTGCATACCGGCGT 1680 
clone7          CGGGCCGGCCCTTCAACCGGATAGACGGATCATGGAAAAATTCACAGTGCATACCGGCGT 654 
                ************************************************************ 
 
Bm4756-60       CGTGGCGCCGCTCGATCGCGAGAACGTCGACACCGACGCGATCATTCCGAAGCAGTTCCT 1740 
clone7          CGTGGCGCCGCTCGATCGCGAGAACGTCGACACCGACGCGATCATTCCGAAGCAGTTCCT 714 
                ************************************************************ 
 
Bm4756-60       GAAGTCGATCAAGCGCACGGGCTTCGGTCCGAACGCGTTCGACGAGTGGCGCTATCTTGA 1800 
clone7          GAAGTCGATCAAGCGCACGGGCTTCGGTCCGAACGCGTTCGACGAGTGGCGCTATCTTGA 774 
                ************************************************************ 
 
Bm4756-60       CCACGGCGAGCCGGGCCAGGACAACTCGAAGCGTCCGCTGAACCCGGACTTCGTGCTGAA 1860 
clone7          CCACGGCGAGCCGGGCCAGGACAACTCGAAGCGTCCGCTGAACCCGGACTTCGTGCTGAA 834 
                ************************************************************ 
 
Bm4756-60       CCAGCCGCGCTACCAGGGCGCGTCGATTCTCGTCACGCGCAAGAACTTCGGCTGCGGCAG 1920 
clone7          CCAGCCGCGCTACCAGGGCGCGTCGATTCTCGTCACGCGCAAGAACTTCGGCTGCGGCAG 894 
                ************************************************************ 
 
Bm4756-60       CTCGCGCGAGCACGCGCCGTGGGCGCTGCAGCAGTACGGCTTCCGCGCGATCATCGCGCC 1980 
clone7          CTCGCGCGAGCACGCGCCGTGGGCGCTGCAGCAGTACGGCTTCCGCGCGATCATCGCGCC 954 
                ************************************************************ 
 
Bm4756-60       GAGCTTCGCGGACATCTTCTTCAACAACTGCTTCAAGAACGGGCTGCTGCCGATCGTGCT 2040 
clone7          GAGCTTCGCGGACATCTTCTTCAACAACTGCTTCAAGAACGGGCTGCTGCCGATCGTGCT 1014 
                ************************************************************ 
 
Bm4756-60       GACCGAGCAGCAGGTCGATCATCTGATCAACGAGACGGTCGCGTTCAACGGCTATCAGCT 2100 
clone7          GACCGAGCAGCAGGTCGATCATCTGATCAACGAGACGGTCGCGTTCAACGGCTATCAGCT 1074 
                ************************************************************ 
 
Bm4756-60       GACGATCGATCTCGAGGCGCAGGTCGTGCGCACGCCGGACGGCCGCGACTATCCGTTCGA 2160 
clone7          GACGATCGATCTCGAGGCGCAGGTCGTGCGCACGCCGGACGGCCGCGACTATCCGTTCGA 1134 
                ************************************************************ 
 
Bm4756-60       GATCACCGCGTTCCGCAAGTACTGCCTGCTGAACGGTTTCGACGACATCGGCCTCACGCT 2220 
clone7          GATCACCGCGTTCCGCAAGTACTGCCTGCTGAACGGTTTCGACGACATCGGCCTCACGCT 1194 
                ************************************************************ 
 
Bm4756-60       GCGTCACGCGGACAAGATCCGCCAGTTCGAAGCGGAGCGGCTCGCGAAGCAGCCGTGGCT 2280 
clone7          GCGTCACGCGGACAAGATCCGCCAGTTCGAAGCGGAGCGGCTCGCGAAGCAGCCGTGGCT 1254 
                ************************************************************ 
 
Bm4756-60       CAACAACAAGCTGGTCGGCTGAAGTCGTCCTTCGGGCGGGCGCGCACGCCGCGCGTTCGC 2340 
clone7          CAACAACAAGCTGGTCGGCTGAAGTCGTCCTTCGGGCGGGCGCGCACGCCGCGCGTTCGC 1314 
                ************************************************************ 
                                                                      Bm4757 
Bm4756-60       CCGCCAGCCATCACCCCTTATTCAGTCAGGAACAACGCATGAAGATTGCAGTGCTGCCGG 2400 
clone7          CCGCCAGCCATCACCCCTTATTCAGTCAGGAACAACGCATGAAGATTGCAGTGCTGCCGG 1374 
                ************************************************************ 
 
Bm4756-60       GCGACGGCATCGGTCCGGAAATCGTCACCGAAGCGGTGAAGGTGCTGAACGCACTCGACG 2460 
clone7          GCGACGGCATCGGTCCGGAAATCGTCACCGAAGCGGTGAAGGTGCTGAACGCACTCGACG 1434 
                ************************************************************ 
 
Bm4756-60       AGAAGTTCGAACTCGAACAGGCGCCGGTCGGCGGCGCGGGCTACGAGGCGAGGGGTCATC 2520 
clone7          AGAAGTTCGAACTCGAACAGGCGCCGGTCGGCGGCGCGGGCTACGAGGCGAGGGGTCATC 1494 
                ************************************************************ 
 
Bm4756-60       CGCTGCCGGACGCGACGCTGAAGCTCGCGAAGGAAGCCGACGCGATCCTGTTCGGCGCGG 2580 
clone7          CGCTGCCGGACGCGACGCTGAAGCTCGCGAAGGAAGCCGACGCGATCCTGTTCGGCGCGG 1554 
 110 
                ************************************************************ 
 
Bm4756-60       TCGGCGACTGGAAGTACGACTCGCTCGAACGCGCGCTGCGTCCCGAGCAGGCGATTCTCG 2640 
clone7          TCGGCGACTGGAAGTACGACTCGCTCGAACGCGCGCTGCGTCCCGAGCAGGCGATTCTCG 1614 
                ************************************************************ 
 
Bm4756-60       GCCTGCGCAAGCACCTCGAGCTGTTCGCGAACTTCCGTCCGGCGATCTGCTATCCGCAGC 2700 
clone7          GCCTGCGCAAGCACCTCGAGCTGTTCGCGAACTTCCGTCCGGCGATCTGCTATCCGCAGC 1674 
                ************************************************************ 
 
Bm4756-60       TCGTCGACGCGTCGCCGCTGAAGCCCGAACTTGTCGCGGGCCTCGACATCCTGATCGTGC 2760 
clone7          TCGTCGACGCGTCGCCGCTGAAGCCCGAACTTGTCGCGGGCCTCGACATCCTGATCGTGC 1734 
                ************************************************************ 
 
Bm4756-60       GCGAACTGAACGGCGACATCTATTTCGGCCAGCCGCGCGGCGTGCGCGCGGCACCGGACG 2820 
clone7          GCGAACTGAACGGCGACATCTATTTCGGCCAGCCGCGCGGCGTGCGCGCGGCACCGGACG 1794 
                ************************************************************ 
 
Bm4756-60       GCCCGTTCGCGGGCGAGCGCGAAGGCTTCGACACGATGCGCTATTCGGAGCCGGAAGTGC 2880 
clone7          GCCCGTTCGCGGGCGAGCGCGAAGGCTTCGACACGATGCGCTATTCGGAGCCGGAAGTGC 1854 
                ************************************************************ 
 
Bm4756-60       GCCGCATCGCGCACGTCGCGTTCCAGGCCGCGCAAAAGCGCGCGAAGAAGCTGCTGTCGG 2940 
clone7          GCCGCATCGCGCACGTCGCGTTCCAGGCCGCGCAAAAGCGCGCGAAGAAGCTGCTGTCGG 1914 
                ************************************************************ 
 
Bm4756-60       TCGACAAGTCGAACGTGCTCGAGACGTCGCAGTTCTGGCGCGACATCATGATCGACGTGT 3000 
clone7          TCGACAAGTCGAACGTGCTCGAGACGTCGCAGTTCTGGCGCGACATCATGATCGACGTGT 1974 
                ************************************************************ 
 
Bm4756-60       CGAAGGAATATGCGGACGTCGAGCTGTCGCACATGTACGTCGACAACGCGGCGATGCAGC 3060 
clone7          CGAAGGAATATGCGGACGTCGAGCTGTCGCACATGTACGTCGACAACGCGGCGATGCAGC 2034 
                ************************************************************ 
 
Bm4756-60       TCGCGAAGGCGCCGAAGCAGTTCGACGTGATCGTGACCGGCAACATGTTCGGCGACATCC 3120 
clone7          TCGCGAAGGCGCCGAAGCAGTTCGACGTGATCGTGACCGGCAACATGTTCGGCGACATCC 2094 
                ************************************************************ 
 
Bm4756-60       TGTCGGATGAAGCGTCGATGCTGACGGGCTCGATCGGCATGCTGCCGTCGGCGTCGCTCG 3180 
clone7          TGTCGGATGAAGCGTCGATGCTGACGGGCTCGATCGGCATGCTGCCGTCGGCGTCGCTCG 2154 
                ************************************************************ 
 
Bm4756-60       ACAAGAACAACAAGGGTCTGTACGAGCCGTCGCACGGTTCGGCGCCGGACATCGCGGGCA 3240 
clone7          ACAAGAACAACAAGGGTCTGTACGAGCCGTCGCACGGTTCGGCGCCGGACATCGCGGGCA 2214 
                ************************************************************ 
 
Bm4756-60       AGGGCATCGCGAATCCGCTCGCGACGATCCTGTCGGCCGCGATGCTGCTGCGCTATTCGC 3300 
clone7          AGGGCATCGCGAATCCGCTCGCGACGATCCTGTCGGCCGCGATGCTGCTGCGCTATTCGC 2274 
                ************************************************************ 
 
Bm4756-60       TGAACCGCGCCGAGCAGGCCGACCGCATCGAGCGCGCGGTCAAAACGGTGCTCGAACAGG 3360 
clone7          TGAACCGCGCCGAGCAGGCCGACCGCATCGAGCGCGCGGTCAAAACGGTGCTCGAACAGG 2334 
                ************************************************************ 
 
Bm4756-60       GCTACCGCACCGGCGACATCGCGACGCCGGGCTGCAAGCAGGTCGGCACGGCGGCGATGG 3420 
clone7          GCTACCGCACCGGCGACATCGCGACGCCGGGCTGCAAGCAGGTCGGCACGGCGGCGATGG 2394 
                ************************************************************ 
 
Bm4756-60       GCGACGCGGTGGTCGCGGCCCTCTGAGCGGCCGGCAAGTCACGATGTAGAAAGGGCGCGA 3480 
clone7          GCGACGCGGTGGTCGCGGCCCTCTGAGCGGCCGGCAAGTCACGATGTAGAAAGGGCGCGA 2454 
                ************************************************************ 
 
Bm4756-60       ACGGGCCGAAAAAAATCGGTTCGTTCGCGCACGGTTGGCCGTTGTGCGGGCAACCGGCTT 3540 
clone7          ACGGGCCGAAAAAAATCGGTTCGTTCGCGCACGGTTGGCCGTTGTGCGGGCAACCGGCTT 2514 
                ************************************************************ 
 
Bm4756-60       TGTGTAGACTCGAACGATGGCGCTGATTTCCCTGATCTCCCCGGTCCTGAAACTCCACGG 3600 
clone7          TGTGTAGACTCGAACGATGGCGCTGATTTCCCTGATCTCCCCGGTCCTGAAACTCCACGG 2574 
                ************************************************************ 
 
Bm4756-60       CAACACTGCCCGTGCGGGTGCGCGCGCCATCGTCATCACGAAAACCATTACCACGAAAAC 3660 
clone7          CAACACTGCCCGTGCGGGTGCGCGCGCCATCGTCATCACGAAAACCATTACCACGAAAAC 2634 
                ************************************************************ 
 111 
 
Bm4756-60       GATCATTAAACGCTGATCGTCCGTCGTGCCCGCCTGTTTCCCCGCGCGGTCACGCCGGGG 3720 
clone7          GATCATTAAACGCTGATCGTCCGTCGTGCCCGCCTGTTTCCCCGCGCGGTCACGCCGGGG 2694 
                ************************************************************ 
                   
                                                     Bm4756 
Bm4756-60       GCGGAAATGGCGGGGAAGCTCCATTCAAAGGGTTAGTCATGAACGTAGGTCTCGTAGGTT 3780 
clone7          GCGGAAATGGCGGGGAAGCTCCATTCAAAGGGTTAGTCATGAACGTAGGTCTCGTAGGTT 2754 
                ************************************************************ 
 
Bm4756-60       GGCGCGGCATGGTCGGCAGCGTCCTGATGCAGCGCATGCAGGAAGAGGGCGATTTCGACC 3840 
clone7          GGCGCGGCATGGTCGGCAGCGTCCTGATGCAGCGCATGCAGGAAGAGGGCGATTTCGACC 2814 
                ************************************************************ 
 
Bm4756-60       TGATCGAACCGGTGTTTTTCAGCACCAGCAACTCGGGCGGCAAGGCACCGTCGTTCGCGA 3900 
clone7          TGATCGAACCGGTGTTTTTCAGCACCAGCAACTCGGGCGGCAAGGCACCGTCGTTCGCGA 2874 
                ************************************************************ 
 
Bm4756-60       AAAACGAGACCACGCTGAAGGACGCGACCAACGTCGACGAACTGAAGAAGTGCGACGTCA 3960 
clone7          AAAACGAGACCACGCTGAAGGACGCGACCAACGTCGACGAACTGAAGAAGTGCGACGTCA 2934 
                ************************************************************ 
 
Bm4756-60       TCATCACGTGCCAGGGCGGCGACTACACGAATGACGTGTTCCCGAAGCTGCGCGCGGCGG 4020 
clone7          TCATCACGTGCCAGGGCGGCGACTACACGAATGACGTGTTCCCGAAGCTGCGCGCGGCGG 2994 
                ************************************************************ 
 
Bm4756-60       GCTGGAACGGCTACTGGATCGATGCGGCGTCGTCGCTGCGGATGAAGGACGACGCGGTCA 4080 
clone7          GCTGGAACGGCTACTGGATCGATGCGGCGTCGTCGCTGCGGATGAAGGACGACGCGGTCA 3054 
                ************************************************************ 
 
Bm4756-60       TCATCCTCGATCCGGTGAACCTCGACGTCATCAAGGACGCGCTCGTCAAGGGCACGAAGA 4140 
clone7          TCATCCTCGATCCGGTGAACCTCGACGTCATCAAGGACGCGCTCGTCAAGGGCACGAAGA 3114 
                ************************************************************ 
 
Bm4756-60       ACTTCATCGGCGGCAACTGCACGGTCAGCCTGATGCTGATGGCGCTCGGCGGCCTGTTCC 4200 
clone7          ACTTCATCGGCGGCAACTGCACGGTCAGCCTGATGCTGATGGCGCTCGGCGGCCTGTTCC 3174 
                ************************************************************ 
 
Bm4756-60       GCGAGAACCTCGTCGATTGGATGACGGCCATGACGTATCAGGCCGCGTCGGGCGCGGGCG 4260 
clone7          GCGAGAACCTCGTCGATTGGATGACGGCCATGACGTATCAGGCCGCGTCGGGCGCGGGCG 3234 
                ************************************************************ 
 
Bm4756-60       CGCAGAACATGCGTGAACTGCTGTCGCAGATGGGCGCGCTGCACGGCGCGGTGCAGCAGC 4320 
clone7          CGCAGAACATGCGTGAACTGCTGTCGCAGATGGGCGCGCTGCACGGCGCGGTGCAGCAGC 3294 
                ************************************************************ 
 
Bm4756-60       AGCTCGCCGATCCGGCATCGGCGATCCTCGACATCGATCGCCGCGTGCTCGCCACGATGA 4380 
clone7          AGCTCGCCGATCCGGCATCGGCGATCCTCGACATCGATCGCCGCGTGCTCGCCACGATGA 3354 
                ************************************************************ 
 
Bm4756-60       ACAGCGACGCGATGCCGACGAGCCACTTCGGCGTGCCGCTCGCGGGTTCGCTGATTCCGT 4440 
clone7          ACAGCGACGCGATGCCGACGAGCCACTTCGGCGTGCCGCTCGCGGGTTCGCTGATTCCGT 3414 
                ************************************************************ 
 
Bm4756-60       GGATCGACAAGGATCTCGGCAACGGCATGTCGAAGGAAGAATGGAAGGGCGGCGCGGAAA 4500 
clone7          GGATCGACAAGGATCTCGGCAACGGCATGTCGAAGGAAGAATGGAAGGGCGGCGCGGAAA 3474 
                ************************************************************ 
 
Bm4756-60       CGAACAAGATCCTCGGCAAGCCGGCGATGGGCGAGCCGGGCTCGATTCCGGTCGACGGGC 4560 
clone7          CGAACAAGATCCTCGGCAAGCCGGCGATGGGCGAGCCGGGCTCGATTCCGGTCGACGGGC 3534 
                ************************************************************ 
 
Bm4756-60       TGTGCGTGCGGATCGGCGCGATGCGCTGCCACTCGCAGGCGCTGACGATCAAGCTGAAGA 4620 
clone7          TGTGCGTGCGGATCGGCGCGATGCGCTGCCACTCGCAGGCGCTGACGATCAAGCTGAAGA 3594 
                ************************************************************ 
 
Bm4756-60       AGGACGTGCCGCTCGACGAGATCAACGGCATTCTCGCGTCGGCGAACGACTGGGTGAAGG 4680 
clone7          AGGACGTGCCGCTCGACGAGATCAACGGCATTCTCGCGTCGGCGAACGACTGGGTGAAGG 3654 
                ************************************************************ 
 
Bm4756-60       TCGTGCCGAACGAGCGCGAAGCGTCGATGCACGATCTGTCGCCGGCGAAGGTCACCGGCA 4740 
clone7          TCGTGCCGAACGAGCGCGAAGCGTCGATGCACGATCTGTCGCCGGCGAAGGTCACCGGCA 3714 
 112 
                ************************************************************ 
 
Bm4756-60       CGCTGACCGTGCCGGTCGGCCGTCTGCGCAAGCTCGCGATGGGCGGCGAATACCTGTCGG 4800 
clone7          CGCTGACCGTGCCGGTCGGCCGTCTGCGCAAGCTCGCGATGGGCGGCGAATACCTGTCGG 3774 
                ************************************************************ 
 
Bm4756-60       CGTTCACGGTCGGCGATCAGTTGCTGTGGGGCGCGGCCGAACCGCTGCGCCGCATGCTGC 4860 
clone7          CGTTCACGGTCGGCGATCAGTTGCTGTGGGGCGCGGCCGAACCGCTGCGCCGCATGCTGC 3834 
                ************************************************************ 
 
Bm4756-60       GCATCCTGCTCGACAAGTAAGACGAGATCGTGCGCCGGCCGGCGCGCGATGCGACGCGCC 4920 
clone7          GCATCCTGCTCGACAAGTAAGACGAGATCGTGCGCCGGCCGGCGCGCGATGCGACGCGCC 3894 
                ************************************************************ 
 
Bm4756-60       TGCGTGCCTTCAACGGGCCGCAGGCGCGTTTTTTATCGGCGGGCGCCGTGCCCGAAAATG 4980 
clone7          TGCGTGCCTTCAACGGGCCGCAGGCGCGTTTTTTATCGGCGGGCGCCGTGCCCGAAAATG 3954 
                ************************************************************ 
 
Bm4756-60       CGAAAGCCCCGAACCGCTCTCCCGGCCGGGGCTTTCTTGCATCGATTCCTTTGGCACGAG 5040 
clone7          CG---------------------------------------------------------- 3956 
                **                                                           
 
Bm4756-60       GAAGTGACGCGGTGCGCAGTATAAGGCACGCAGTTCGTCGGCATGTTGATAATGTTGTCG 5100 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       GGATTTACATCAATTGATGCTCGATTTTTGATAATGGCGTGCGGCGCGCAGTGGCGCATC 5160 
clone7          ------------------------------------------------------------ 
                                                                             
 
Bm4756-60       GGCCGCCTGTTCCCGGTCGTGCGCGCCGACGAATTCGGCCCGAACGCGATCGTGTGA 5217 
clone7          --------------------------------------------------------- 
                                                                          
 
Figure 3-7  Blast result of clone 9 of B. multivorans (ATCC17616) genome library 
 
 
a. Genome organization of the clone 9 of B. multivorans (ATCC17616). Clone 9 
encoded for GGDEF domain. This domain was partially encoded in clone 9.  
 
 
 
 
 
 
 
 
Bm4824: GGDEF domain 
 
b. Alignment of the clone 9 and Bm4824 of B. multivorans (ATCC17616) 
 
                                          Bm4824 
Bm4825          TCAGGCAGTCGGTTCGAATTGCGTGACCTTGTTGCGTCCCGTCGCTTTCGCGTAATAAAG 60 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          CGCTTCGTCGGCAGCCTTGATGATCGCGTCGGGTTCGACGTCCTGATCGGGTTTCCAGCT 120 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          CGCCAGGCCGATGCTCGCGGTGACGCGTCCGAACTCGCTGCCGACATGTTCGAGGCCCAG 180 
clone9          ------------------------------------------------------------ 
                                      
Bm4824 
Clone 9 
 113 
                                                                             
 
Bm4825          TTCGTTGATGGCGATTCGAATCCGTTCGGCAATCTGCGCGGCGCCGTTCTCCGCCGTATC 240 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          GGGCAGCAGGACGACGAACTCTTCGCCGCCGTAGCGGGCGGCGACGTCCGCGGGCCGGCG 300 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          AATGTTCTCGCCGATGCAGCGCGCGACTGCAGCGAGCGCATCGTCGCCGGCCTGGTGGCC 360 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          GTACGTGTCGTTGTAGGCCTTGAAGCGGTCGACGTCGACGAAGAGCAGCGAAAAGACCGA 420 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          TCGTACCCGGCGTGCGCGGCGCCATTCGCGATCGAGCACCTCGCCGAAGCTGCGGCGGTT 480 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          GTTGAGACCCGTGAGCCCGTCGGTGCGCGCGAGCAGGATCAGCTCCGATTCGGCTCGCAT 540 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          CCTGCGCCGCAGCTGCGCGCCGAGCAATACGGAAAGCGCGATGAACGCAGCGCCGAACGT 600 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          CGCGACCAGCGCGCCGATCGTGAGCGCGCGACGATGCCATGCCGCGTAAATGTCCTGTTC 660 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          GGCCTCGGCGACCATCACGATCAGCGGCAGGTTCGGCAATGTCTTGAAGTAATACAGGCG 720 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          GCGCACGCCGTCGATGGACGAGCGCTCGAGAAACGATCCTTCGGGTGCGCTTCGGAAGCG 780 
clone9          ------------------------------------TCCTTCGGGTGCGCTTCGGAAGCG 24 
                                                    ************************ 
 
Bm4825          GCGGAACGTGGCGGCCTGGCTGATGTCCCGTCCGATCGTATTCAGTTCGTAAGGCTGGCG 840 
clone9          GCGGAACGTGGCG----------------------------------------------- 37 
                *************                                                
 
Bm4825          CATGACCATGATGCCGTCGGTGCCGATTAGGGAAATCGATCCGTGCGGACCCAGCGCGAG 900 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          CCCGGCAAACAACTTGTGGAAATACTCGAGGTTGATCGCGATCAATGCGACGCCGGCGAA 960 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          GGAGCCGTCCGGGTTCGATACGCGACGGCTCAGCACGATGCTTGGTGTACCGCCGCGCAG 1020 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          CCGCGATGCGAATGGATCGCTGACGTAAAGCCCCACGTCGGCGCGGTCGCGGTGGACGGT 1080 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          GAAATATTTTCGATCCGAGAAGTTGCCGTGGCGCGGCACGTCGTTCTGCGAGTCGAGAAC 1140 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          GATATTGCCCTGCGCATCGAGGACCAGCATCGAACCGAGATATTGGGCCGTCATCGCGTG 1200 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          GTCGAACAGCACGCCGCGGCGAAGCGCAGGCGAAGCCGCCATCACGTCGGGGCGCCGAAG 1260 
clone9          ------------------------------------------------------------ 
                                                                             
 114 
 
Bm4825          CCCCTGGAGGACGGCCTCGAGCGACAGATTGTAGAGCTCGACGTTGCGCGTGATGTCGCG 1320 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          TTCGGCGACGAGCGCGAGATTGCGCGAAGTCTCGCGTGCCCTGTCCAGCGCATCCTGGCG 1380 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          GCTCTGGAACAGCTGGAGTATGCAAAGCCCCATCAGCGCGAAGGCGATCAGCACGCCGAC 1440 
clone9          ------------------------------------------------------------ 
                                                                             
 
Bm4825          GGCGACGACATAGTGAGGCGCTGATGAGCGCGGTTGCAT 1479 
clone9          --------------------------------------- 
                                                        
Figure 3-8 Blast result of clone 1 of Pa PAO1 genome library 
 
 
 
a. Genome organization of clone 1 of Pa PAO1. Clone 1 of Pa PAO1 encoded pyocin S2 
(Pa 1152) and corresponding immunity protein (Pa1153).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b. Alignment of clone 1 and Pa PAO1  
 
Pa1151-53       GTCGGGCGAGCCGGCGGAGAGCGGCGGGGCGTCTAGGGTGCGGGTTGCGGGGAGGCTGGC 60 
clone1          GTCGGGCGAGCCGGCGGAGAGCGGCGGGGCGTCTAGGGTGCGGGTTGCGGGGAGGCTGGC 60 
                ************************************************************ 
 
Pa1151-53       GGGGAGCGGAAGAGAGCTTTTATGGGATTTATGAACTGGATTGCAGAGTGGTGAATGTGC 120 
clone1          GGGGAGCGGAAGAGAGCTTTTATGGGATTTATGAACTGGATTGCAGAGTGGTGAATGTGC 120 
                ************************************************************ 
 
Pa1151-53       GAACGGGAGGCTTGCCGATCGGAGGATACATGCAGGGCGTCCATCTCGGCCTGGTGGTGG 180 
clone1          GAACGGGAGGCTTGCCGATCGGAGGATACATGCAGGGCGTCCATCTCGGCCTGGTGGTGG 180 
                ************************************************************ 
                                     Pa1151 
Pa1151-53       CAGCCCGGCCTGTCAGTCAGGCGCCTGACAACCCAGGGTGACGACCAGTTCGCGGCCGCT 240 
clone1          CAGCCCGGCCTGTCAGTCAGGCGCCTGACAACCCAGGGTGACGACCAGTTCGCGGCCGCT 240 
                ************************************************************ 
 
Pa1151-53       CGCCAAGCCGGCGTCCGCCGCCAGGGTCAGCGTGCGCGGCGTGTCCTGGCGACTATCGAG 300 
clone1          CGCCAAGCCGGCGTCCGCCGCCAGGGTCAGCGTGCGCGGCGTGTCCTGGCGACTATCGAG 300 
                ************************************************************ 
 
Pa1151-53       CAGCCCCTCTTGAAGCACGAGGCTGTCGGCGCTGGCGCCCCTGGCCAGCAGCCGATATCG 360 
clone1          CAGCCCCTCTTGAAGCACGAGGCTGTCGGCGCTGGCGCCCCTGGCCAGCAGCCGATATCG 360 
                ************************************************************ 
 
Pa1151-53       CACCAGCGCCGAGGTACAGCCGCATTCGCCGGTGGAGCGCCGGGCCTCAAGGGTGAGTGG 420 
clone1          CACCAGCGCCGAGGTACAGCCGCATTCGCCGGTGGAGCGCCGGGCCTCAAGGGTGAGTGG 420 
                ************************************************************ 
 
Pa1151-53       CAGGTGCAACTGGCCCTCCGCCGTGTGCGGTGCACCGAGCCGGGCGGCGAGGCAGGCGGA 480 
clone1          CAGGTGCAACTGGCCCTCCGCCGTGTGCGGTGCACCGAGCCGGGCGGCGAGGCAGGCGGA 480 
                       Pa1150    Pa1152          Pa1153 
Clone 1 
 115 
                ************************************************************ 
 
Pa1151-53       GAGAGCATTGTCGAGCGTCGCCGCGTCGGCGAATGGGGCGGCCAGGCAGAGGCTGCCGAG 540 
clone1          GAGAGCATTGTCGAGCGTCGCCGCGTCGGCGAATGGGGCGGCCAGGCAGAGGCTGCCGAG 540 
                ************************************************************ 
 
Pa1151-53       GAGCAGGGCTTTGGCGTCCATGTCGGGGTTCCGCTGGGGATGGAAAGGGCATCATGGCTG 600 
clone1          GAGCAGGGCTTTGGCGTCCATGTCGGGGTTCCGCTGGGGATGGAAAGGGCATCATGGCTG 600 
                ************************************************************ 
 
Pa1151-53       AGGTGGCTTTATTCGTCGAACAATGGCTGGCCCTGCCGGTATATCGGCCAGGACTTCAAG 660 
clone1          AGGTGGCTTTATTCGTCGAACAATGGCTGGCCCTGCCGGTATATCGGCCAGGACTTCAAG 660 
                ************************************************************ 
 
Pa1151-53       CGTTGCGGAAACGGCCTGACCAGCTGCAGCGGCTTGCAATCAAAAACGCTGGGCTCGCAA 720 
clone1          CGTTGCGGAAACGGCCTGACCAGCTGCAGCGGCTTGCAATCAAAAACGCTGGGCTCGCAA 720 
                ************************************************************ 
 
Pa1151-53       TCAGCGTGGCTTTGTCCGGAAGCTCGCGAAGGGGCGGCATGGATGAATTTTGAAAGTGGG 780 
clone1          TCAGCGTGGCTTTGTCCGGAAGCTCGCGAAGGGGCGGCATGGATGAATTTTGAAAGTGGG 780 
                ************************************************************ 
 
Pa1151-53       AGTTCGTTAATGAACCGAAGGTATGCGGCTTCCGTGACTGGCCGGGGTAGATGAGGTGTG 840 
clone1          AGTTCGTTAATGAACCGAAGGTATGCGGCTTCCGTGACTGGCCGGGGTAGATGAGGTGTG 840 
                ************************************************************ 
 
Pa1151-53       CGTTAAGGAAATGACCGTTTGACGCAGGCGCGATTATAAGAGGCGAGAGAGCGCACCTTC 900 
clone1          CGTTAAGGAAATGACCGTTTGACGCAGGCGCGATTATAAGAGGCGAGAGAGCGCACCTTC 900 
                ************************************************************ 
 
Pa1151-53       TGGATCATCTAAACACGGGATATTGAAGTTGATTGCAGTGTATTGCCGATGCATTGGGGC 960 
clone1          TGGATCATCTAAACACGGGATATTGAAGTTGATTGCAGTGTATTGCCGATGCATTGGGGC 960 
                ************************************************************ 
 
Pa1151-53       TTATTGACTGGGAGAGGGTTCTCTAGGTGGGAGTCGCTCAATACATTACACTTTCAAATT 1020 
clone1          TTATTGACTGGGAGAGGGTTCTCTAGGTGGGAGTCGCTCAATACATTACACTTTCAAATT 1020 
                ************************************************************ 
                                         Pa1152 
Pa1151-53       AATGTAGGGGCGATCTATGGCTGTCAATGATTACGAACCTGGTTCGATGGTTATTACACA 1080 
clone1          AATGTAGGGGCGATCTATGGCTGTCAATGATTACGAACCTGGTTCGATGGTTATTACACA 1080 
                ************************************************************ 
 
Pa1151-53       TGTGCAGGGTGGTGGGCGTGACATAATCCAGTATATTCCTGCTCGATCAAGCTACGGTAC 1140 
clone1          TGTGCAGGGTGGTGGGCGTGACATAATCCAGTATATTCCTGCTCGATCAAGCTACGGTAC 1140 
                ************************************************************ 
 
Pa1151-53       TCCACCATTTGTCCCACCAGGACCAAGTCCGTATGTCGGTACTGGAATGCAGGAGTACAG 1200 
clone1          TCCACCATTTGTCCCACCAGGACCAAGTCCGTATGTCGGTACTGGAATGCAGGAGTACAG 1200 
                ************************************************************ 
 
Pa1151-53       GAAGCTAAGAAGTACGCTTGATAAGTCCCATTCAGAACTCAAGAAAAACCTGAAAAATGA 1260 
clone1          GAAGCTAAGAAGTACGCTTGATAAGTCCCATTCAGAACTCAAGAAAAACCTGAAAAATGA 1260 
                ************************************************************ 
 
Pa1151-53       AACCCTGAAGGAGGTTGATGAACTCAAGAGTGAAGCGGGGTTGCCAGGTAAAGCGGTCAG 1320 
clone1          AACCCTGAAGGAGGTTGATGAACTCAAGAGTGAAGCGGGGTTGCCAGGTAAAGCGGTCAG 1320 
                ************************************************************ 
 
Pa1151-53       TGCCAATGACATCCGCGATGAAAAGAGTATCGTTGATGCACTCATGGATGCCAAAGCAAA 1380 
clone1          TGCCAATGACATCCGCGATGAAAAGAGTATCGTTGATGCACTCATGGATGCCAAAGCAAA 1380 
                ************************************************************ 
 
Pa1151-53       ATCGCTAAAGGCCATTGAGGATCGCCCGGCCAATCTTTATACGGCTTCAGACTTTCCTCA 1440 
clone1          ATCGCTAAAGGCCATTGAGGATCGCCCGGCCAATCTTTATACGGCTTCAGACTTTCCTCA 1440 
                ************************************************************ 
 
Pa1151-53       GAAGTCAGAGTCGATGTACCAGAGTCAGTTGCTGGCCAGCCGAAAATTCTATGGAGAGTT 1500 
clone1          GAAGTCAGAGTCGATGTACCAGAGTCAGTTGCTGGCCAGCCGAAAATTCTATGGAGAGTT 1500 
                ************************************************************ 
 
Pa1151-53       CCTGGATCGCCATATGAGTGAGCTGGCCAAAGCGTACAGCGCCGATATCTATAAGGCGCA 1560 
clone1          CCTGGATCGCCATATGAGTGAGCTGGCCAAAGCGTACAGCGCCGATATCTATAAGGCGCA 1560 
 116 
                ************************************************************ 
 
Pa1151-53       AATCGCTATCTTGAAACAAACGTCTCAAGAGCTGGAGAATAAAGCCCGGTCATTGGAAGC 1620 
clone1          AATCGCTATCTTGAAACAAACGTCTCAAGAGCTGGAGAATAAAGCCCGGTCATTGGAAGC 1620 
                ************************************************************ 
 
Pa1151-53       AGAAGCCCAGCGAGCCGCTGCTGAGGTGGAGGCGGACTACAAGGCCAGGAAGGCAAATGT 1680 
clone1          AGAAGCCCAGCGAGCCGCTGCTGAGGTGGAGGCGGACTACAAGGCCAGGAAGGCAAATGT 1680 
                ************************************************************ 
 
Pa1151-53       CGAGAAAAAAGTGCAGTCCGAGCTTGACCAGGCTGGGAATGCTTTGCCTCAACTGACCAA 1740 
clone1          CGAGAAAAAAGTGCAGTCCGAGCTTGACCAGGCTGGGAATGCTTTGCCTCAACTGACCAA 1740 
                ************************************************************ 
 
Pa1151-53       TCCAACGCCAGAGCAGTGGCTTGAACGCGCTACTCAACTGGTTACGCAGGCGATCGCCAA 1800 
clone1          TCCAACGCCAGAGCAGTGGCTTGAACGCGCTACTCAACTGGTTACGCAGGCGATCGCCAA 1800 
                ************************************************************ 
 
Pa1151-53       TAAGAAGAAATTGCAGACTGCAAACAATGCCTTGATTGCCAAGGCACCCAATGCACTGGA 1860 
clone1          TAAGAAGAAATTGCAGACTGCAAACAATGCCTTGATTGCCAAGGCACCCAATGCACTGGA 1860 
                ************************************************************ 
 
Pa1151-53       GAAACAAAAGGCAACCTACAACGCCGATCTCCTAGTGGATGAAATCGCCAGCCTGCAAGC 1920 
clone1          GAAACAAAAGGCAACCTACAACGCCGATCTCCTAGTGGATGAAATCGCCAGCCTGCAAGC 1920 
                ************************************************************ 
 
Pa1151-53       ACGGCTGGACAAGCTGAACGCCGAAACGGCAAGGCGCAAGGAAATCGCTCGTCAAGCGGC 1980 
clone1          ACGGCTGGACAAGCTGAACGCCGAAACGGCAAGGCGCAAGGAAATCGCTCGTCAAGCGGC 1980 
                ************************************************************ 
 
Pa1151-53       GATCAGGGCTGCCAATACTTATGCCATGCCAGCCAATGGCAGCGTTGTCGCCACCGCCGC 2040 
clone1          GATCAGGGCTGCCAATACTTATGCCATGCCAGCCAATGGCAGCGTTGTCGCCACCGCCGC 2040 
                ************************************************************ 
 
Pa1151-53       AGGCCGGGGTCTGATCCAGGTCGCACAAGGCGCCGCATCCCTTGCTCAAGCGATCTCCGA 2100 
clone1          AGGCCGGGGTCTGATCCAGGTCGCACAAGGCGCCGCATCCCTTGCTCAAGCGATCTCCGA 2100 
                ************************************************************ 
 
Pa1151-53       TGCGATTGCCGTCCTGGGCCGGGTCCTGGCTTCAGCACCCTCGGTGATGGCCGTGGGCTT 2160 
clone1          TGCGATTGCCGTCCTGGGCCGGGTCCTGGCTTCAGCACCCTCGGTGATGGCCGTGGGCTT 2160 
                ************************************************************ 
 
Pa1151-53       TGCCAGTCTGACCTACTCCTCCCGGACTGCCGAGCAATGGCAGGACCAAACGCCCGATAG 2220 
clone1          TGCCAGTCTGACCTACTCCTCCCGGACTGCCGAGCAATGGCAGGACCAAACGCCCGATAG 2220 
                ************************************************************ 
 
Pa1151-53       CGTTCGTTACGCCCTGGGCATGGATGCCGCTAAATTGGGGCTTCCCCCAAGCGTAAACCT 2280 
clone1          CGTTCGTTACGCCCTGGGCATGGATGCCGCTAAATTGGGGCTTCCCCCAAGCGTAAACCT 2280 
                ************************************************************ 
 
Pa1151-53       GAACGCGGTTGCAAAAGCCAGCGGTACCGTCGATCTGCCGATGCGCCTGACCAACGAGGC 2340 
clone1          GAACGCGGTTGCAAAAGCCAGCGGTACCGTCGATCTGCCGATGCGCCTGACCAACGAGGC 2340 
                ************************************************************ 
 
Pa1151-53       ACGAGGCAACACGACGACCCTTTCGGTGGTCAGCACCGATGGTGTGAGCGTTCCGAAAGC 2400 
clone1          ACGAGGCAACACGACGACCCTTTCGGTGGTCAGCACCGATGGTGTGAGCGTTCCGAAAGC 2400 
                ************************************************************ 
 
Pa1151-53       CGTTCCGGTCCGGATGGCGGCCTACAATGCCACGACAGGCCTGTACGAGGTTACGGTTCC 2460 
clone1          CGTTCCGGTCCGGATGGCGGCCTACAATGCCACGACAGGCCTGTACGAGGTTACGGTTCC 2460 
                ************************************************************ 
 
Pa1151-53       CTCTACGACCGCAGAAGCGCCGCCACTGATCCTGACCTGGACGCCGGCGAGTCCTCCAGG 2520 
clone1          CTCTACGACCGCAGAAGCGCCGCCACTGATCCTGACCTGGACGCCGGCGAGTCCTCCAGG 2520 
                ************************************************************ 
 
Pa1151-53       AAACCAGAACCCTTCGAGTACCACTCCGGTCGTACCGAAGCCGGTGCCGGTATATGAGGG 2580 
clone1          AAACCAGAACCCTTCGAGTACCACTCCGGTCGTACCGAAGCCGGTGCCGGTATATGAGGG 2580 
                ************************************************************ 
 
Pa1151-53       AGCGACCCTTACACCGGTGAAGGCTACCCCGGAAACCTATCCTGGGGTGATTACACTACC 2640 
clone1          AGCGACCCTTACACCGGTGAAGGCTACCCCGGAAACCTATCCTGGGGTGATTACACTACC 2640 
                ************************************************************ 
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Pa1151-53       GGAAGACCTGATCATCGGCTTCCCGGCCGACTCGGGGATCAAGCCGATCTATGTGATGTT 2700 
clone1          GGAAGACCTGATCATCGGCTTCCCGGCCGACTCGGGGATCAAGCCGATCTATGTGATGTT 2700 
                ************************************************************ 
 
Pa1151-53       CAGGGATCCGCGGGATGTACCTGGTGCTGCGACTGGCAAGGGACAGCCCGTCAGCGGTAA 2760 
clone1          CAGGGATCCGCGGGATGTACCTGGTGCTGCGACTGGCAAGGGACAGCCCGTCAGCGGTAA 2760 
                ************************************************************ 
 
Pa1151-53       TTGGCTCGGCGCCGCCTCTCAAGGTGAGGGGGCTCCAATTCCAAGCCAGATTGCGGATAA 2820 
clone1          TTGGCTCGGCGCCGCCTCTCAAGGTGAGGGGGCTCCAATTCCAAGCCAGATTGCGGATAA 2820 
                ************************************************************ 
 
Pa1151-53       ACTACGTGGTAAGACATTCAAAAACTGGCGGGACTTTCGGGAACAATTCTGGATAGCTGT 2880 
clone1          ACTACGTGGTAAGACATTCAAAAACTGGCGGGACTTTCGGGAACAATTCTGGATAGCTGT 2880 
                ************************************************************ 
 
Pa1151-53       GGCTAATGATCCTGAGTTAAGTAAACAGTTTAATCCTGGTAGTTTAGCTGTAATGAGAGA 2940 
clone1          GGCTAATGATCCTGAGTTAAGTAAACAGTTTAATCCTGGTAGTTTAGCTGTAATGAGAGA 2940 
                ************************************************************ 
 
Pa1151-53       TGGAGGGGCTCCTTATGTCAGAGAGTCAGAACAGGCTGGCGGGAGAATAAAGATCGAAAT 3000 
clone1          TGGAGGGGCTCCTTATGTCAGAGAGTCAGAACAGGCTGGCGGGAGAATAAAGATCGAAAT 3000 
                ************************************************************ 
 
Pa1151-53       CCACCACAAGGTTCGAATAGCAGATGGAGGCGGCGTTTACAATATGGGGAACCTTGTTGC 3060 
clone1          CCACCACAAGGTTCGAATAGCAGATGGAGGCGGCGTTTACAATATGGGGAACCTTGTTGC 3060 
                ************************************************************ 
                                                                                                   Pa1153 
Pa1151-53       AGTAACGCCAAAACGTCATATAGAAATCCACAAGGGAGGGAAGTGATATGAAGTCCAAGA 3120 
clone1          AGTAACGCCAAAACGTCATATAGAAATCCACAAGGGAGGGAAGTGATATGAAGTCCAAGA 3120 
                ************************************************************ 
 
Pa1151-53       TTTCCGAATATACGGAAAAAGAGTTTCTTGAGTTTGTTAAAGACATATACACAAACAATA 3180 
clone1          TTTCCGAATATACGGAAAAAGAGTTTCTTGAGTTTGTTAAAGACATATACACAAACAATA 3180 
                ************************************************************ 
 
Pa1151-53       AGAAAAAGTTCCCTACCGAGGAGTCTCATATTCAAGCCGTGCTTGAATTTAAAAAACTAA 3240 
clone1          AGAAAAAGTTCCCTACCGAGGAGTCTCATATTCAAGCCGTGCTTGAATTTAAAAAACTAA 3240 
                ************************************************************ 
 
Pa1151-53       CGGAACACCCAAGCGGCTCAGACCTTCTTTACTACCCCAACGAAAATAGAGAAGATAGCC 3300 
clone1          CGGAACACCCAAGCGGCTCAGACCTTCTTTACTACCCCAACGAAAATAGAGAAGATAGCC 3300 
                ************************************************************ 
 
Pa1151-53       CAGCTGGAGTTGTAAAGGAAGTTAAAGAATGGCGTGCTTCCAAGGGGCTTCCTGGCTTTA 3360 
clone1          CAGCTGGAGTTGTAAAGGAAGTTAAAGAATGGCGTGCTTCCAAGGGGCTTCCTGGCTTTA 3360 
                ************************************************************ 
 
Pa1151-53       AGGCCGGTTAGTTGGCCATCAACAAGCCCCGTTTCGACGGGGCTTGTTCCATGTTGACGC 3420 
clone1          AGGCCGGTTAGTTGGCCATCAACAAGCCCCGTTTCGACGGGGCTTGTTCCATGTTGACGC 3420 
                ************************************************************ 
 
Pa1151-53       TGCTCTATCTTGACAGTCTGTCCTGAATATTCTTGAAGACAATCACATTATGAGCCGCAA 3480 
clone1          TGCTCTATCTTGACAGTCTGTCCTGAATATTCTTGAAGACAATCACATTATGAGCCGCAA 3480 
                ************************************************************ 
 
Pa1151-53       CCACCGCAAAACACCCATCGTCGGGCGCACGAGCTGCCGTAGCGAGCTCTCCACGTTGGC 3540 
clone1          CCACCGCAAAACACCCATCGTCGGGCGCACGAGCTGCCGTAGCGAGCTCTCCACGTTGGC 3540 
                ************************************************************ 
 
Pa1151-53       CAGCAGCCCACCTCTCCCTACTGGAAAGTCAGGTCAATAACACTGGTGCCACGTAAGGAT 3600 
clone1          CAGCAGCCCACCTCTCCCTACTGGAAAGTCAGGTCAATAACACTGGTGCCACGTAAGGAT 3600 
                ************************************************************ 
 
Pa1151-53       GGGCGTTCCTACTGGCCCCTCATACGCCAGGCTGCTACGGCAGATCGTGTCGCTAACCTC 3660 
clone1          GGGCGTTCCTACTGGCCCCTCATACGCCAGGCTGCTACGGCAGATCGTGTCGCTAACCTC 3660 
                ************************************************************ 
 
Pa1151-53       AAGGGACACAACCCGCAAGAACGCGCGTCCCTGAAAAAGCGCCTGCTGCGCAAGTGGATG 3720 
clone1          AAGGGACACAACCCGCAAGAACGCGCGTCCCTGAAAAAGCGCCTGCTGCGCAAGTGGATG 3720 
                ************************************************************ 
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Pa1151-53       AGCAAATGAGTACATCCAACATCCAGGCATTGGCCAGCACTGGGCACAGCTCGCCAAAGA 3780 
clone1          AGCAAATGAGTACATCCAACATCCAGGCATTGGCCAGCACTGGGCACAGCTCGCCAAAGA 3780 
                ************************************************************ 
 
Pa1151-53       AGCGGGATTCCGAGCCGACTATGACAGCACATCAACGCCAGAAACACATCTGGTCTGCGG 3840 
clone1          AGCGGGATTCCGAGCCGACTATGACAGCACATCAACGCCAGAAACACATCTGGTCTGCGG 3840 
                ************************************************************ 
 
Pa1151-53       AGTAACCCAAGAGTGGATTCGAGAACACATCGTTGCCACCAACGATATGCGCCCGTTCGG 3900 
clone1          AGTAACCCAAGAGTGGATTCGAGAACACATCGTTGCCACCAACGATATGCGCCCGTTCGG 3900 
                ************************************************************ 
 
Pa1151-53       CCTGCTGCATTTGCTGGGTCAGGCATCGTTGCGCATGGAGCAAGCGTTGTGGCCGGAAGA 3960 
clone1          CCTGCTGCATTTGCTGGGTCAGGCATCGTTGCGCATGGAGCAAGCGTTGTGGCCGGAAGA 3960 
                ************************************************************ 
 
Pa1151-53       TTACGAGCGGATGACTCGTAAGGTCAAGGGAGTCCAGCGGGAAGCTGAAGGCGACAACGC 4020 
clone1          TTACGAGCGGATGACTCGTAAGGTCAAGGGAGTCCAGCGGGAAGCTGAAGGCGACAACGC 4020 
                ************************************************************ 
 
Pa1151-53       CAAATCATACATTTATGAAGAAGTCATGCAGATAAGGCAGGAGCGCTTCGATAAAGCACG 4080 
clone1          CAAATCATACATTTATGAAGAAGTCATGCAGATAAGGCAGGAGCGCTTCGATAAAGCACG 4080 
                ************************************************************ 
 
Pa1151-53       ACATAATTTGCAAGGGGTTTGTCATAGGTATCAAGGATCCAATTATTTTACAGTCCTGAT 4140 
clone1          ACA--------------------------------------------------------- 4083 
                ***                                                          
 
Pa1151-53       ACTAGTATTGTGGTTGTTCTCAAAGAGGATGGAATGTTTTTGTCAGGGTGGTATCTTGAG 4200 
clone1          ------------------------------------------------------------ 
                                                                             
 
Pa1151-53       CCAGGAAGCAGACAGGAAAAAACTATTTTGA 4231 
clone1          ------------------------------- 
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Figure 3-9 Open reading frame organization of colicin E2, pyocin S3, and 
entericidinAB 
The genes encoding bacteriocins of enteric bacteria (i.e. colicin E2), Pa (i.e. pyocin S3), 
and entericidin AB are organized in a similar way. These proteins are toxin/antitoxin 
(immunity) complexes. An immunity gene (i.e. ceiB, pyoS3A entA) follows the toxin 
gene (i.e ceaB, pyoS3I, entB).  
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Figure 3-10 Genome comparison of B. multivorans (Bm) ATCC17616 and 
Pseudomonas aeruginosa (Pa) PAO1 
Genes of Pa and Bcc were classified into 21 functional classes. Bm ATCC17616 genome 
possessed additional genes in majority of these functional classes in comparison to Pa 
PAO1 genome (Pathema). 
 
 
 
1 Amino acid biosynthesis 
2 Biosynthesis of cofactors, prosthetic groups, and carriers 
3 Cell envelope 
4 Cellular processes 
5 Central intermediary metabolism 
6 DNA metabolism 
7 Energy metabolism 
8 Fatty acid and phospholipids metabolism 
9 Mobile and extrachromosomal element functions 
10 Protein fate 
11 Protein synthesis 
12 Purines, pyrimidines, nucleosides, and nucleotides 
13 Regulatory functions 
14 Signal transduction 
15 Transcription 
16 Transport and binding proteins 
17 Viral functions 
18 Hypothetical proteins 
19 Hypothetical proteins-conserved 
20 Unclassified 
21 Unknown function 
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CHAPTER 4 
 
                                                    CONCLUSION 
 
 “Two nebulisers in the morning with breathing exercises that take about half an 
hour. Then oral antibiotics, vitamins and occasionally steroids. I used to do chest 
physiotherapy but they gave me a PEP mask because (pause) well I just wanted to get on 
(with life) really rather than spend too long on treatment” by a CF patient 
                                                                            Kathryn Badlan, 2006 
4.1 The Life of a CF patient 
Cystic Fibrosis (CF) is a rare genetic disorder that occurs in 1 in every 3,000 
Americans, 1 in every 2-3,000 Europeans, and 1 in every 7,056 Africans (WHO, 2004). 
CF patients have a defective cystic fibrosis transmembrane regulator (CFTR) protein, 
which is a chloride ion channel on the apical surface of epithelial cells (Matthay et al., 
2005). The defective CFTR channel leads to decreased chloride secretion and increased 
sodium absorption across the cytoplasmic membrane. Imbalanced sodium and chloride 
transport leads to dehydration of the mucous across the epithelia, which results in failure 
of multiple organ systems including the digestive, reproductive, and respiratory systems 
(Gibson et al., 2003).   
CF patients suffer from vitamin-A deficiency, poor growth, persistent coughing, 
wheezing, shortness of breath, digestive complications, and fertility problems (Darling et 
al., 1953; Freedman et al., 2000a; Freedman et al., 2000b). The most severe health 
 122 
challenge, however, is the presence of chronic lung infections, which are associated with 
high mortality and shortened lifespans (George et al., 2009).   
The life of a CF patient is physically and emotionally challenging. Their daily 
routine includes repeated sessions of chest physiotherapy (to clear mucus from lungs), a 
high energy supplemented diet, digestive enzymes (taken with all meals to improve 
digestion), and finally oral and nebulized antibiotics (to treat lung infections) (Foster et 
al., 2001).  None of these treatments represent a cure, but significantly improve the 
quality of life, as well as increase the lifespan, of CF patients. The estimated median 
survival age of CF patients in the US was 37 years in 2008 . Even with aggressive 
therapies, CF patients ultimately die in their mid-30s (Gibson et al., 2003; Govan & 
Deretic, 1996). 
4.2 The battle with bacterial infections: Pseudomonas aeruginosa and Burkholderia 
cepacia complex 
More than eighty percent of CF patients die due to respiratory failure (Lyczak et 
al., 2002). Bacterial infections and the resulting lung tissue destruction are the major 
causes of respiratory failure (Gibson et al., 2003; Govan & Deretic, 1996). Bacteria are 
trapped in the dehydrated mucus covering the epithelial cells of the airway, and thus 
escape from phagocytosis by the immune system, and are able to colonize in the airway 
and lungs (Gibson et al., 2003). The presence of pathogens in the airway induces 
inflammation. Secretory cells release antibacterial proteins and neutrophils, which are 
attracted to the site of the infection (Konstan & Berger, 1997). However, rather than 
killing the invading bacteria, this process results in tissue destruction due to the degraded 
neutrophils releasing proteases which damage the lung tissue. The damaged tissue 
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provides food for the bacterial infection. Thus, inflammation leads to more bacterial 
colonization, which leads to more inflammation, resulting in a vicious cycle of 
host/pathogen interaction (Gibson et al., 2003). 
Most research on CF-based lung infections is focused on Staphylococcus aureus, 
Haemophilus influenzae, Stenotrophomonas maltophilia, Pseudomonas aeruginosa (Pa), 
and Burkholderia cepacia complex (Bcc) since these are the primary colonizers of the CF 
lung (Hutchison & Govan, 1999). It has been suggested that the prevalence of these 
species is age-related. S. aureus and H. influenzae are isolated in early years and are 
replaced with Pa and Bcc during adolescence (Govan & Deretic, 1996).  
This thesis focused on the interaction between one pair of species, Pa and Bcc, 
which are associated with chronic lung infections in adult CF patients (Govan & Deretic, 
1996). Once a chronic infection is established, eradication of Pa and Bcc is virtually 
impossible (Hentzer et al., 2001) and the patients experience progressive lung failure and 
premature death (Jones et al., 2004; Lyczak et al., 2002; Tummler et al., 1997).  
Pa is the most persistent bacterial species in the CF lung. Approximately 30% of 
infants and 80% of adult CF patients are colonized with Pa. During infancy and 
childhood Pa is isolated only intermittently (Hansen et al., 2008). At this stage, the Pa 
strains are usually in a planktonic form, which respond well to antibiotic treatment. As 
the disease progresses, alginate forming variants overtake the resident strain, resulting in 
mucoid production and biofilms formation (Govan & Deretic, 1996). Mucoid Pa form 
biofilms, which are associated with chronic lung infections and lead to progressive lung 
failure and death of CF patients (Hentzer et al., 2001).  
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Bcc secondary infections have become a major concern in the last 30 years. 
Although the incidence of colonization is low (~3%), clinical outcomes are unpredictable 
and various - ranging from asymptomatic to severe chronic lung infections (Whiteford et 
al., 1995). A small portion of CF patients succumbs to cepacia syndrome, which is fatal 
necrotizing pneumonia (Govan & Deretic, 1996). The prevalence of Bcc in infants is very 
low (less than one percent), most cases are reported after 5 years of age .  
Combinatorial antibiotic therapy is the only treatment option for chronic lung 
infections in CF. Pa infections are usually treated with a combination of beta-lactamases 
and aminoglycosides (Aaron et al., 2000; Hoiby et al., 2001). However, the success of 
antibiotic treatments is limited by several factors. 
The most critical factor is that both species are multi-drug resistant. One form of 
resistance is conferred by actively pumping the drugs through the cytoplasmic membrane. 
Five pump mechanisms have been described: resistance - nodulation - cell division 
(RND), major facilitator superfamily (MFS), small multi-drug resistance family (SMR), 
multidrug and toxic compound extrusion family (MATE), and ATP binding cassette 
family (ABC)(Paulsen, 2003). These pumps provide intrinsic antibiotic resistance to 
various classes of antibiotics including fluoroquinolones, beta-lactams, tetracycline, 
macrolides, chloramphenicol, trimethoprim, and sulfonamides (Poole & Srikumar, 2001). 
Genomes of Pa and Bcc encode all five mechanisms (Holden et al., 2009; Stover et al., 
2000).  
Biofilm formation is another factor contributing to antibiotic resistance. Bacteria 
in a biofilm are 10-1000 fold more resistant to antibiotic treatment than their planktonic 
counterparts (Mah & O'Toole, 2001). Both species form biofilms in CF lungs (Conway et 
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al., 2002; Singh et al., 2000), in fact, alginate-forming mucoid Pa variants are a signature 
of chronic Pa infections (Hentzer et al., 2001). Antibiotic resistance in the biofilms may 
result from reduced growth rate, the anaerobic environment, and the presence of 
negatively charged alginate surrounding the biofilm structure, which traps the antibiotics 
(Hoiby et al., 2001).  
The situation is more complex with strains of Bcc. In vitro studies have shown 
that strains in both planktonic and biofilm form have similar levels of resistance to 
ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin, and 
trimethoprim/sulfamethoxazole (Peeters et al., 2009). However, Caraher et al., 2007 
found elevated levels of resistance to meropenem and piperacillin-tazobactam in biofilm-
based strains in comparison to planktonic forms, whereas the both showed similar levels 
of resistance to tobramycin and amikacin (Caraher et al., 2007). These contradictory 
results may be due to differences in the alginates produced by the species. Alginate 
produced by Pa is an acetylated copolymer of beta-D-mannuronic acid and alpha-L-
glucoronic acid, whereas Bcc produces a branched acetylated heptasaccharide composed 
of D-glucose, D-rhamnose, D-mannose, D-galactose, and D-glucoronic acid (Bylund et 
al., 2006). Structural differences between these exopolysaccharides may explain the 
differential accessibility of various antibiotics in the biofilm structure. 
The presence of hypermutable strains is another factor resulting in high levels of 
antibiotic resistance in CF strains. The emergence of hypermutable strains is thought to 
emerge due to the adaptation of bacteria to the continuously changing lung environment. 
Oliver et al., 2000 compared the levels of antibiotic resistance of hypermutable (or 
mutator) and nonmutator Pa isolates from CF patients against ticarcillin, ceftazidime, 
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imipenem, gentamycin, tobramycin, amikacin, norfloxacin, and fosfomycin. The 
hypermutable Pa strains showed elevated resistance to all of the antibiotics (Oliver et al., 
2000).  
In summary, CF patients experience long-term exposure to antibiotic treatment, 
which selects for multi-drug resistant strains. In addition, the bacterial strains in residence 
in their lungs encode several factors that ensure high levels of intrinsic resistance. Not 
surprising, nearly half of adult CF patients are chronically infected with multi-drug 
resistant Pa, which is associated with a more rapid decline in lung function (Lechtzin et 
al., 2006).  
New antibiotics are in the drug development pipeline, such as MP-376, a new 
formulation of levofloxacin; GS9310/11, an inhaled combination of the antibiotics 
fosfomycin and tobramycin; BAY Q3939, an inhaled version of ciprofloxacin; 
ArikaceTM, a liposomal formulation of amikacin (CF Foundation). We can anticipate 
that repeated exposure of these drugs will also result in the emergence of resistant strains. 
One goal of the present study is to better understand the nature of bacterial interactions in 
the CF lung, in order to identify new targets for therapeutic intervention. 
Most adult CF patients are infected with Pa (Govan & Deretic, 1996). When a 
secondary Bcc infection occurs, the infecting strain must compete against the resident Pa 
strain(s). These competitive interactions are mediated by a variety of factors. A better 
understanding of these factors and the role they play in mediating Pa and Bcc interactions 
may provide novel insights into the development of alternative therapeutic approaches.  
In my thesis, I specifically focused on one such factor, the bacteriocins produced 
by both species, and the role that these toxins play in mediating interactions between 
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these species. Bacteriocins are potent toxins produced by bacteria and are implicated in 
intra- and inter-specific competition of bacteria in various environments (Riley & 
Gordon, 1999; Riley et al., 2003). Although the bacteriocins of Pa have been studied in 
great detail, far less is known about the corresponding toxins produced by Bcc species 
and even less is know about if or how they might contribute to bacterial interactions in 
the CF lung.  
In my thesis, I focused on answering the following questions: 
• Do clinical strains of Pa and Bcc isolated from CF lungs produce 
bacteriocins? 
• If so, what types of bacteriocins are produced and how specific or broad 
are their killing activities? 
• What roles do these bacteriocins serve in mediating intra- and inter-
specific interactions of Pa and Bcc isolated from CF patients? 
4.3 Do clinical strains of Pa and Bcc isolated from CF lungs produce bacteriocins? 
To address this question, a bacteriocin assay was performed. The first step was to 
obtain a collection of isolates from CF lungs. This proved to be one of the most difficult 
challenges I encountered; it is extremely challenging to obtain access to such strain 
collections. However, I owe a great debt to Dr. Claudia Ordonez for providing me with a 
set of 66 clinical Pa (38) and Bcc (28) strains isolated from CF patients.  The strain 
collection can be divided into two groups. The first is composed of 14 Pa and 7 Bcc 
paired isolates procured from 7 CF patients, each pair isolated from the same patient at 
the same time. The second group is composed of 24 Pa and 21 Bcc isolates procured 
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independently from 33 CF patients.  The bacteriocin-screening assay employed each Pa 
and Bcc strain as a sensitive lawn and potential bacteriocin producer. 
Previous studies of bacteriocin production in Pa and Bcc focused on bacteriocin 
typing and the use of such types to rapidly screen clinical isolates. These studies revealed 
that Pa is one of the most prolific Gram-negative producers of bacteriocins. Indeed, more 
than 90% of the strains tested produce bacteriocins, known as pyocins (B.Bouhaddioui, 
2002; Bruun et al., 1976; Edmonds et al., 1972a; Farmer & Herman, 1969; Jones et al., 
1974b; Zabransky & Day, 1969). In contrast, prior typing of a much smaller number of 
Bcc strains from clinical sources revealed that only 30% produce bacteriocins, known as 
cepaciacins (Govan & Harris, 1985).  
Our phenotypic assay revealed that 97% of Pa strains (37 strains) and 68% of Bcc 
strains (19 strains) possess bacteriocin-like inhibitory activity (Table 2-1). The frequency 
of production in Pa isolated from CF lungs is indistinguishable from strains isolated from 
other clinical sources. In contrast, the frequency of production in Bcc is far higher in 
strains isolated from CF lungs than from strains isolated from other clinical sources 
(Govan & Harris, 1985). The higher frequency of Bcc inhibitory activity in our study 
could be due to the fact that certain Bcc isolates (i.e. those which produce bacteriocins) 
are so successful in invading the CF lung, which requires interacting and/or competing 
with resident Pa strains. Further, the strains used to assay for inhibition activity were 
different in the prior study. The survey described here involved 28 strains of Bcc, 
representing 4 genomovars (B. multivorans, B. dolosa, B. vietnamiensis, and B. 
cenocepacia) and identified 19 bacteriocin-producing strains, of which ten are B. 
multivorans, six B. dolosa, two B. cenocepacia, and one B. vietnamiensis. B. multivorans 
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and B. cenocepacia are the most frequently isolated species from CF patients (LiPuma et 
al., 2001). The previous study typed only B. cepacia (Govan & Harris, 1985). 
4.4 What types of bacteriocins are produced and how specific or broad are their 
killing activities? 
A set of reference strains was used in the bacteriocin screen identification of 
bacteriocin types. This collection included strains producing S and RF type pyocins and 
those sensitive to pyocins, as well as strains carrying plasmids with cloned S-type 
pyocins (pyocin S1, S2, S3, and AP41) (de Chial et al., 2003; Duport et al., 1995; 
Kageyama et al., 1979; Kuroda & Kagiyama, 1983; Sano & Kageyama, 1981; Sano et 
al., 1993a; Sano et al., 1993b; Williams et al., 2008). Unfortunately, no cepaciacins have 
been fully characterized and there are no corresponding reference strains.  
The Pa strains produced seven distinct bacteriocin phenotypes (based upon 
patterns of sensitivity to the reference collection), while the Bcc strains produced four 
phenotypes. Further, each Pa phenotype resulted from a combination of S and RF 
pyocins. In contrast to the bacteriocins of enteric bacteria, Pa is unique in producing 
numerous different pyocins per strain. However, there is no correlation between the 
number of bacteriocins produced and the number of strains inhibited. For example the Pa 
I bacteriocin phenotype produced at least eight pyocins (S1, S2, S3, AP41, R2, R4, F2, 
and F3) and inhibited 31 strains, of which 19 are Pa and 12 strains are Bcc (Table 2.2). Pa 
III pyocin phenotype III produces only 4 pyocins (S1, R2, R4, and F2), yet inhibited 44 
strains of which, 18 were Pa and 26 Bcc (Table 2-2). The enhanced inhibition by strains 
with fewer pyocins could be due to the fact that particular combinations of pyocins may 
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be more inhibitory, or the fact that these strains may have also produced additional 
virulence factors, or novel bacteriocins.  
Bacteriocin typing of Bcc strains was relatively challenging since there is no 
indicator strain collection including bacteriocin producer and sensitive Bcc strains. 
Burkholderia and Pseudomonas are closely related. They do co-exist in the same natural 
environment, and interact with each other. Further, their genome organization allows 
these bacteria to swap genes via horizontal gene transfer (Holden et al., 2009; Stover et 
al., 2000). In fact, Burkholderia species were formerly included within the genus 
Pseudomonas (for example, as Pseudomonas cepacia) (Yabuuchi et al., 1992). Thus, I 
decided to use the same Pa reference strains to characterize bacteriocin phenotype of 
clinical Bcc strains. Indeed, this study revealed that 3 Bcc strains possessed bacteriocin 
phenotypes similar to those found in Pa. Bcc I phenotype produces 4 pyocins (S1, S2, 
AP41, F3), Bcc II phenotype produces F3 pyocin, and finally Bcc III phenotype produces 
R2 and F2 pyocins (Table 2-2). The bacteriocin phenotype of the remaining 15 Bcc 
strains could not be characterized, which suggests that they possessed novel toxins that 
provided inhibitory activity (Table 2-2).  
4.5 What roles do these bacteriocins serve in mediating intra- and inter-specific 
interactions of Pa and Bcc strains isolated from CF lung patients? 
The screening study revealed Pa and Bcc strains produced significantly different 
levels of intra- and inter-specific inhibition. The Pa strains showed similar levels of intra- 
and inter-specific inhibition (92 % and 81%, respectively) (Table 2-1). Bcc strains also 
showed similar levels of intra- and inter-specific inhibition, but at a much lower level 
(54% and 57%, respectively) (Table 2-1).  
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This study also revealed that the source(s) of the inhibitory activity is different for 
the two species. The intra-specific inhibitory activity for Pa strains was due primarily to 
S- and RF-pyocins, while inter-specific inhibition appeared to due to only RF pyocins 
(Figure 2-3). Not enough is known yet about cepaciacins to determine what types of 
toxins (i.e protease sensitive or phage-tail like) are acting. 
4.6 Further characterization of Bcc inhibitory activity 
Phenotypic and molecular studies revealed that the source of Bcc inhibitory 
activity is novel. Thus, genome libraries of three Bcc strains were constructed and 
screened against sensitive Pa and Bcc lawns to identify the source of the inhibition 
observed (Bakkal et al., 2010). Fifteen genomic clones with putative inhibitory activity 
were identified from three Bcc genomes. Ten of the clones (B. dolosa and B. 
cenocepacia) did not have replicable inhibitory activity. The five remaining clones, 
which consistently maintained their inhibitory activity, were all from B. multivorans. The 
loss of inhibition in some of the clones is not surprising. The proteins produced could be 
toxic to the recipient E. coli due to the lack of cloned immunity gene, which confer 
resistance to the toxin.  
The DNA inserts from the remaining five genomic clones were sequenced and 
compared to the genome sequence of B. multivorans. Instead, the Bcc genes identified are 
involved in amino acid biosynthesis, sugar metabolism, degradation of aromatic 
compounds, and bacterial apoptosis (Table 3-2). One explanation could be failure to 
detect Bcc bacteriocin genes due to technical challenges (Chapter 3.5). Another 
explanation could be Bcc strains use different strategies when it comes to bacterial 
competition. The genomes of Bcc strains possess numerous additional genes (Figure 3-
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10), including the genes involved in primary metabolic pathways. Perhaps, instead of 
killing their competitors with highly costly bacteriocins, Bcc they used the advantage of 
their gene potential to grow and to adapt faster to any environment, where they are in 
competition with other species.  
4.7 The lessons learned from phenotypic bacteriocin screening and genome library 
of Pa and Bcc 
My thesis research has revealed that Bcc inhibitory agents appear to be 
phenotypically and genotypically different from that observed in the majority of Gram-
negative bacteria. Most bacterial strains surveyed for an inhibition or killing activity are 
found, under further characterization, to encode one or more bacteriocin proteins. Riley 
(Riley & Gordon, 1999; Riley & Wertz, 2002a; Riley & Wertz, 2002b; Riley et al., 2003) 
has gone so far as to label bacteriocins as the “weapon of choice” in bacteria. Even 
among the strains surveyed here, half of which were isolates of Pa, a plethora of 
bacteriocins were identified – all of which were encoded in the Pa genomes. In sharp 
contrast, none of the functions identified in the genome screens of Bcc bore any 
detectable similarity to the diversity of bacteriocins characterized in the literature. 
(Hardy, 1987; Riley et al., 2003).  
 A further frustration was encountered when the standard bacteriocin assays were 
employed with Bcc. Inhibition phenotypes were constantly disappearing. A clear 
inhibition zone on a plate might disappear upon replication of that strain. Most of the 
inhibition zones observed in the standard plate assays also disappeared when subjected to 
the usual methods of concentration, such as is done with the crude lysate procedure 
(Bakkal et al.). Even with 20-fold concentrations during crude lysate preparation, 
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inhibition was lost in all of the Bcc strains. Further, only three of the 19 Bcc strains 
examined showed inhibition against the Pa indicator strain collection. These three Bcc 
strains were predicted to possess RF-like pyocins. Unfortunately, the PCR-based 
molecular screening methods employed here were unable to confirm the presence of any 
known RF-pyocin genes. Whether this absence is due to the fact that the pyocin-like 
genes are present but too divergent to amplify or they represent entirely novel 
bacteriocins remains unclear. BLAST-based examination of the 38 available Bcc 
genomes has also failed to detect the presence of any previously characterized 
bacteriocins.  
The genome library of one of the Bcc strains surveyed was screened to identify 
the source of Bcc inhibitory activity. More than 10,000 genomic clones were screened on 
an appropriate sensitive lawn. As a positive control for the library construction and 
screening methods, a Pa strain, whose genome has been sequenced and is known to 
encode pyocin S2, was screened in an identical manner. It is surprising that no 
bacteriocin gene was identified from Bcc genome, while the first and the only gene 
detected from Pa PAO1 library was pyocin S2 as the source of inhibitory activity. Five 
inhibitory clones were identified from the Bcc strain. Sequence analysis determined that 
the Bcc clones are responsible for primary metabolic pathways including amino acid 
metabolism, carbohydrate metabolism, degradation of aromatic compounds, and bacterial 
apoptosis. Surprisingly, no bacteriocin-like genes were detected.  
This library screen outcome was quite surprising. To our knowledge, no other 
Gram negative bacterial species examined at this level of detail has failed to reveal the 
presence of one or more recognizable bacteriocins. This result suggests that we should 
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not extrapolate from the existing surveys of bacteriocin-based inhibition. It is possible 
that some, or even much, of the inhibitory activities of Gram-negative bacteria are not 
bacteriocin-based. Until further molecular characterizations are carried out; it is 
premature to conclude the presence of bacteriocins, as was done even in the Bcc literature 
(Govan & Harris, 1985).  
How then does Bcc produce inhibitory activity with the genes identified in the 
library screen? It is difficult to answer this question. First, we identified a number of 
primary metabolism genes, which are involved at specific steps of amino acid, 
carbohydrate metabolisms, and degradation of aromatic compounds. The remaining 
genes involved in these pathways are not isolated from our genomic clones. One 
explanation would be the proteins expressed in E. coli could be involved the very same 
metabolic pathways used in E. coli, and thus provided E. coli a growth advantage over 
the Pa lawn. Second, some of these genes are represented partially in E. coli, so the 
genomic clones do not express some of these genes (such as GGDEF domain, 
amidohydrolyse II) as functional proteins. Thus, the complete DNA sequence of these 
genes needs to be cloned to prove the Bcc inhibitory phenotype observed in genomic 
clones. Third, one apoptosis gene (Entericidin AB) was identified in clone 7. Like 
bacteriocins, entericidinAB is a toxin-antitoxin complex, whose open reading frame is 
organized similar to colicins of enteric bacteria and pyocins of Pa (Figure 3-11). A toxin 
gene and immunity gene are organized consecutively and transcribed together. Both pore 
former colicins and entericidin distrupt membrane stability and lyse the bacterial 
cells(Bishop et al., 1998; Michel-Briand & Baysse, 2002; Riley & Wertz, 2002a). 
However, there is no sequence similarity between entericidin AB and pore former 
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colicins. Further, there is no literature suggesting that E. coli use entericin to inhibit 
bacterial growth. Instead, it has suggested that entericidins are produced by in a 
population, which is exposed to nutrient limitation (stationary phase). Thus, bacteria lyse 
themselves to provide nutrients to the remaining members of the population (Bishop et 
al., 1998). Another interesting gene was glucoamylase from clone 4 of B. multivorans 
(ATCC17616). Glucoamylase is an extracellular enzyme, common in fungus Aspergillus. 
This enzyme hydrolyzes starch into glucose (Sauer et al., 2000). More importantly, 
glucoamylase has a second function, which is induction of a fungal toxin (aflatoxin) 
biosynthesis (Mellon et al., 2007). Bcc may be using this secondary function to induce 
similar toxin genes in its genome to inhibit other species. Finally, the inhibitory activity 
of the clones detected might be artifacts of the genomic library construction. Cloning and 
expression of identified Bcc genes is required to further verification and characterization 
of inhibitory activity in Bcc.  
One goal of the present study is to better understand the nature of bacterial 
interactions in the CF lung in order to identify new targets for therapeutic intervention. In 
recent years, bacteriocins have been considered for therapeutic use in human health 
(Gillor et al., 2005; Gillor & Ghazaryan, 2007). For example, bacteriocins from 
Staphylococcus aureus are used to treat skin infections. Bacteriocins from Bacillus 
subtilis are employed to treat vancomycin-resistant bacterial infections, while bacteriocin 
from Lactococus lactis are effective in the treatment of peptic ulcers and bacteriocin from 
enteric bacteria are used to treat urinary tract infections (Gillor et al., 2004; Gillor et al., 
2005). Future studies should focus on the efficacy of S and RF type pyocins on in vitro 
and in vivo single and mixed species biofilms of Pa and Bcc strains.  
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Finally, this study showed that Bcc strains might use primary metabolism to 
become more competent against Pa strains. We isolated five clones of B. multivorans 
(ATCC17616), which possessed inhibitory activity on a Pa lawn. Additional study needs 
to be done on these genomic clones to further prove this conclusion. First, genes 
possessed by these five clones should be cloned separately and the effect of protein 
expression on the Pa lawn should be investigated. Second approach could be creation of 
deletion mutants of Bcc for the genes detected in the genome library study. Finally, 
genome libraries of Bcc clones should be tested on Bcc lawns to observe the differences 
between within and between inhibitory activities.  
One final study could be suggested on Pa inhibitory activity. It has been revealed 
that majority of Pa inhibitory activity is due to the presence of S- and RF pyocins. Indeed, 
we identified pyocin S2 in one genomic clone of Pa PAO1, which inhibits a Pa lawn. 
However, there are other pyocin-like genes annotated in Pa PAO1 genome. Interestingly, 
we only detected one S-pyocin (pyocin S2) in one Pa PAO1 genomic clone. This result 
may be due to sensitivity phenotype of the lawn. The lawn used to screen Pa PAO1 
genomic library might be resistant to the other pyocin-like genes possessed in Pa PAO1 
genome. Various lawns might be used to screen genomic clones to identify other pyocins 
in Pa PAO1 genome as well as in clinical Pa strains.  
The treatment of Pa and Bcc chronic lung infections is a problem faced in the 
treatment of chronic CF lung infections. These species will survive and infect CF lungs 
as long as CF patients have defective CFTR on their epithelial cells. Antibiotics are the 
only available treatment option, but the multiple drug resistant nature of these species and 
emerging drug resistance to current antibiotics will make this option obsolete in the near 
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future. This study revealed sources of inhibitory agents, which are responsible for within 
and between species inhibitory activities of Pa and Bcc strains. Nature of bacterial 
interactions in the CF lung may reveal new targets for therapeutic intervention.  
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APPENDIX A 
CLINICAL PSEUDOMONAS AND BURKHOLDERIA STRAIN 
COLLECTION 
 
Paired isolates1 
Study 
ID 
Strain 
 ID 
 
Species 
Study 
ID 
Strain 
ID 
 
Species 
1 03-195-0952 B. cenocepacia 19 181-0-63 P. aeruginosa                       
2 03-104-0962 B. multivorans 8 015-4-1076 P. aeruginosa                       
3 03-303-0655 B. dolosa 12 159-4-1077 P. aeruginosa                       
3 03-303-0655 B. dolosa 13 159-4-1078 P. aeruginosa                       
3 03-303-0655 B. dolosa 14 159-4-1178 P. aeruginosa                       
3 03-303-0655 B. dolosa 15 159-4-1606 P. aeruginosa                       
3 03-303-0655 B. dolosa 16 159-4-1607 P. aeruginosay 
3 03-303-0655 B. dolosa 17 159-4-1674 P. aeruginosa                       
3 03-303-0655 B. dolosa 18 159-4-1675 P. aeruginosa                       
4 03-287-0857 B. multivorans 10 080-4-34 P. aeruginosa                       
4 03-287-0857 B. multivorans 11 080-4-1247 P. aeruginosa                       
5 03-350-1649 B. dolosa 20 203-1-1394 P. aeruginosa                      
6 03-318-1184 B. dolosa 9 030-7-33 P. aeruginosa                       
7 03-219-0968 B. multivorans 21 228-0-1396 P. aeruginosa                       
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Unpaired isolates 
Study 
ID 
Strain ID Species Study 
ID 
Strain ID Species                                    
22 085-3-1211 P. aeruginosa 46 95-258-0446 B. cenocepacia                      
23 093-8-1498 P. aeruginosa 47 02-228-1429 B. cenocepacia                      
24 180-8-72 P. aeruginosa 48 03-342-1396 B. cenocepacia                      
25 180-8-75 P. aeruginosa 49 03-281-1317 B. dolosa                               
26 195-1-271 P. aeruginosa 50 03-277-0282 B. dolosa                               
27 195-1-272 P. aeruginosa 51 03-303-1206 B. dolosa                               
28 202-3-1393 P. aeruginosa 52 03-338-1539 B. dolosa                               
29 202-3-1504 P. aeruginosa 53 03-339-1377 B. dolosa                               
30 217-7-1505 P. aeruginosa 54 03-336-0575 B. multivorans                      
31 217-7-1506 P. aeruginosa 55 04-021-0261 B. dolosa                               
32 217-7-1507 P. aeruginosa 56 04-032-0605 B. dolosa                               
33 239-7-1215 P. aeruginosa 57 04-053-0423 B. dolosa                               
34 276-6-1714 P. aeruginosa 58 03-255-0518 B. multivorans                      
35 276-6-1715 P. aeruginosa 59 03-289-0554 B. multivorans                      
36 283-1-88 P. aeruginosa 60 03-338-0277 B. multivorans                      
37 283-1-89 P. aeruginosa 61 03-350-0955 B. multivorans                      
38 325-5-1421 P. aeruginosa 62 03-364-0829 B. multivorans                      
39 325-5-1428 P. aeruginosa 63 03-365-0241 B. multivorans                      
40 325-5-1533 P. aeruginosa 64 04-050-0866 B. multivorans                      
41 327-6-1422 P. aeruginosa 65 04-065-1420 B. multivorans                      
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Paired isolate1: Seven Bcc strains are isolated as pairs with 14 Pa strains. Two Bcc strains 
(Study ID # 3 and #4) have multiple corresponding Pa isolates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 327-6-1423 P. aeruginosa 66 03-260-0635 B. vietnamiensis                    
43 327-6-1424 P. aeruginosa      
44 327-6-1518 P. aeruginosa      
45 327-6-1519 P. aeruginosa      
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APPENDIX B 
 
 
RESULT OF PHENOTYPIC BACTERIOCIN ASSAY OF CLINICAL 
PSEUDOMONAS AND BURKHOLDERIA STRAINS 
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APPENDIX C 
PRIMER PAIRS USED TO SCREEN PYOCIN GENES 
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